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Abstract 
 
Aims and scope 
The Royal College of Pathologists recommend at least 12 lymph nodes should 
be harvested for adequate staging of colorectal cancer.  Just one nodal tumour 
deposit upstages the malignancy.  This is important as node-positive patients 
are considered for adjuvant chemotherapy whereas node negative patients may 
not be.  It is not always easy to harvest the required number, especially in 
patients with rectal cancer receiving neoadjuvant therapy which further 
decreases the number and size of nodes. 
  
Lymph node revealing solutions, e.g. GEWF have been investigated to help 
improve nodal retrieval.  GEWF is safe, cheap and easy to use, improving nodal 
retrieval and possibly cause upstaging, triggering adjuvant 
chemotherapy.  However, existing evidence to support this argument is limited. 
 
Methods 
A controlled trial was designed, comparing further formalin fixation (n=101) to 
GEWF (n=99).  Colorectal resections were placed in formalin or GEWF for 24 
hours before performing a secondary dissection.  The number, size and any 
tumour in nodes was compared between groups. 
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Results 
The use of formalin further fixation and GEWF detected more nodes at 
secondary dissection.  The mean number of additional nodes harvested was 
greater with formalin (8.3) in comparison to GEWF (7.3). When compared to 
formalin, GEWF does not cause a statistically significant increase in node 
numbers in the entire sample (p=0.218), non-neoadjuvant group (p=0.226) or 
neoadjuvant group (p=0.569). 
 
When compared to formalin, GEWF does not find statistically significant smaller 
nodes in the entire sample (p=0.093), non-neoadjuvant group (p=0.053), or 
neoadjuvant group (p=0.730).  Upstaging triggering adjunct chemotherapy was 
identified in 2/200 cases. 
 
Conclusions 
The routine use of adjunct techniques is unnecessary with underlying high 
quality dissection practice.  Emphasis should be placed upon educating and 
training staff, spending appropriate time dissecting, and ensuring specimens are 
sufficiently fixed beforehand. 
 
Contribution 
This research is the first to provide robust statistical analysis regarding the 
efficacy of adjunct techniques in colorectal cancer.  Further research could be 
performed to assess their use in other cancers where nodes are difficult to 
detect.  
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1. INTRODUCTION AND BACKGROUND 
This chapter outlines the introduction and background to this research.  It will 
introduce the subject of colorectal cancer, the role of histopathology and the 
evolving role of healthcare scientists within this field.  
 
1.1 BACKGROUND 
This section describes the background to this research. Describing the 
epidemiology of cancer, cancer statistics, the role of healthcare organisations 
and the cancer strategies in place to deal with the disease. 
  
1.1.1 THE EPIDEMIOLOGY OF CANCER 
The World Health Organization (WHO) define cancer as the “rapid creation of 
abnormal cells that grow beyond their usual boundaries, and which can then 
invade adjoining parts of the body and spread to other organs.” (World Health 
Organization, 2014).  The spread of cancer to other organs via blood vessels, 
lymphatic vessels or transcoelomic spread, is known as metastasis, and it is 
usually this feature which leads to death.  Cancer can arise from any cell when 
it loses its molecular mechanisms of control.  Numerous risk factors are known 
to contribute to this; including smoking, infection, radiation, diet, weight and 
exercise.  Table 1.1 demonstrates the international, national and local incidence 
and mortality of common cancers, whilst Table 1.2 shows the known risk factors 
for developing the same common cancers. 
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Table 1.1.  Summary statistics table - international, national and local incidence and mortality of common cancers. 
 
Cancer International 
incidence 
by cases 
(2012)a 
 
International 
mortality by 
cases 
(2012)b 
National 
incidence 
by cases 
(2011)c 
National 
mortality by 
cases (2011)c 
National 
incidence per 
100,000 
(2008-2010)d 
National 
mortality 
per 100,000 
(2008-2010)d 
Local 
incidence per 
100,000 
(2008-2010)d 
Local mortality 
per 100,000 
(2008-2010)d 
Lung 1.82 million 
 
1.59 million 43,463 
 
35,184 47.7 38.3 59.6 48.4 
(Female) 
breast 
1.68 million 521,817 49,936 11,684 125.7 24.8 127.4 25.4 
Colorectum 
 
1.36 million 693,881 41,581 15,659 46.5 16.4 47.3 16.3 
Prostate 1.11 million 
 
307,471 41,736 10,793 105.8 24 81.1 17.3 
Stomach 
 
951,594 723,027 7,089 4,830 - - - - 
Liver 
 
782,451 745,517 4,348 4,106 - - - - 
aCancer Research UK (2014a); bCancer Research UK (2014b); cCancer Research UK (2014c); dCancer Research UK (n.d.). 
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Table 1.2.  Known risk factors for developing common cancers. 
 
Cancer 
 
Known risk factors 
Lung Tobacco smokinga 
Occupationb 
  
(Female) breast Endogenous hormonesc 
Exogenous hormonesc 
Exercised 
Bodyweighte 
Alcoholf 
Genetic susceptibilityg 
Colorectum Dieth 
Tobacco smokinga 
Alcoholf 
Bodyweighte 
Exercised 
Genetic susceptibilityg 
Prostate Genetic susceptibilityg 
 
  
Stomach 
 
Helicobacter pylori infectioni 
Tobacco smokinga 
Bodyweighte 
Occupationb 
Genetic susceptibilityg 
Liver 
 
Hepatitis B and C infectionj 
Tobacco smokinga   
Alcoholf 
Occupationb 
 
aCancer Research UK (2014d); bCancer Research UK (2014e); cCancer Research UK (2013a); 
dCancer Research UK (2014f); eCancer Research UK (2014g); fCancer Research UK (2014h); 
gCancer Research UK (2013b); hCancer Research UK (2014i); iCancer Research UK (2012); 
jCancer Research UK (2014j).      
 
1.1.2 CANCER STATISTICS 
The latest available international cancer statistics are for 2012.  During this 
period there were 14.1 million cases of cancer (incidence), with 8.2 million 
deaths worldwide (International Agency for Research on Cancer, 2014a).  The 
four most common cancers are lung, female breast, colorectum and prostate, 
accounting for 42% of all cancers diagnosed (Cancer Research UK, 2014k).  
Nearly 50% of all deaths are caused by lung, liver, stomach and colorectal 
cancers, with lung cancer accounting for almost 20% due to its direct 
association with tobacco smoking (Cancer Research UK, 2014l).   
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The latest available national cancer statistics are for 2012.  During this period 
there were 281,118 newly diagnosed cases of cancer in England (Office for 
National Statistics, 2014a), with 133,131 deaths (Cancer Research UK, 2014m).  
The most common sites for cancer in England are prostate (25.9%), lung 
(13.6%) and colorectum (13.4%) in men and breast (30.9%), lung (11.9%) and 
colorectum (10.9%) in women (Office for National Statistics, 2014a).  Within the 
UK, these cancers accounted for almost half (46%) of all cancer deaths (Cancer 
Research UK, 2014n).  
 
The latest available local cancer statistics are for 2008 to 2010.  During this 
period there were 402.3 cases per 100,000 people in the NHS Southampton 
Clinical Commissioning Group (CCG) area (Cancer Research UK, n.d.). This 
was similar to the national average of 398.1 cases per 100,000 people (Cancer 
Research UK, n.d.).  Between 2008 and 2010 the mortality rate was 181.1 per 
100,000 in Southampton, which was only slightly above the national rate of 172 
per 100,000 people (Cancer Research UK, n.d.).  Table 1.1 summarises 
international, national and local cancer incidence and mortality statistics for six 
of the most common cancers worldwide (Cancer Research UK, 2014a; Cancer 
Research UK, 2014b; Cancer Research UK, 2014c; Cancer Research UK, n.d.). 
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1.1.3 THE NATIONAL HEALTH SERVICE AND CANCER 
The National Health Service (NHS) is the world’s largest publicly funded health 
service, remaining free at the point of use for any of the 63.2 million people 
resident in the United Kingdom (NHS Choices, 2013a).  The NHS in England 
serves a population of 53 million people, and employs more than 1.35 million 
staff (NHS Choices, 2013a).   
 
In a 2014 audit the NHS was found to be the most overall impressive healthcare 
system in comparison to ten other westernised countries, however in the 
category of healthy lives the NHS was tenth (NHS Confederation, 2014), 
signifying a deficiency within this area. 
 
In England, over 250,000 people are diagnosed with cancer each year, with 
130,000 deaths (NHS Choices, 2013a).  Annual NHS costs for cancer services 
are £5 billion, but the cost to society is thought to be as high as £18.3 billion 
(NHS Choices, 2013a).   
 
1.1.4 CANCER STRATEGY 
 
Worldwide cancer strategy 
According to the WHO publication ‘Fight against cancer: strategies that prevent, 
cure and care’, cancer deaths are expected to rise to 9 million and 11.5 million 
by 2015 and 2030 respectively (World Health Organization, 2007).  Of the 7.6 
million deaths caused by cancer in 2005, 75 percent were in low and middle 
income countries (World Health Organization, 2007).  Cancer is one of a 
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number of non-communicable diseases that is well understood and partly 
preventable (World Health Organization, 2013).  WHO believe that 40 percent 
of cancers can be prevented by “reducing tobacco use, improving diets and 
physical activity, lowering alcohol consumption, eliminating workplace 
carcinogens and immunizing against hepatitis B virus and the human 
papillomavirus” (World Health Organization, 2007).   
 
National Cancer Strategy 
Recent data from a large Europe-wide retrospective observational study, 
represented in Figure 1.1, has shown that survival rates from various cancers in 
England are lower than those in other European countries (De Angelis et al., 
2014).  It is thought that this is due to diagnostic delays, underuse of successful 
treatments and unequal access to treatments, particularly among the elderly 
(NHS Choices, 2013b).  However, smoking, alcohol and poor diet may also be 
important factors in England (NHS Choices, 2013b).    
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Figure 1.1.  Comparison of age standardised relative % survival rates for 
the most common cancers in England vs other European countries (De 
Angelis et al., 2014). 
  
 
In a policy entitled ‘Helping more people survive cancer’, the Department of 
Health conceded that although more people are surviving cancer in England, 
rates are still worse than for other countries with similar wealth (Great Britain. 
Department of Health, 2013a), declaring that “by 2014, we want to match the 
average cancer survival rate in Europe and to save an extra 5,000 lives every 
year” (Great Britain. Department of Health, 2013a).  However, an October 2014 
report by the Office for National Statistics showed that although cancer survival 
in England was improving, it was still generally lower than countries with a 
comparable wealth such as Denmark, Norway or Sweden (Office for National 
Statistics, 2014b).  Some media outlets reported the updated figures as 
demonstration of falling survival rates, suggesting a link to coalition government 
healthcare strategies (Borland, 2014; Donnelly, 2014; Gregory, 2014).  Focus 
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has now moved to lifestyle factors associated with cancers, with national plans 
in place to reduce smoking, obesity and harmful drinking (Great Britain. 
Department of Health, 2013b; Great Britain. Department of Health, 2013c) and 
to improve diet (Great Britain. Department of Health, 2013d). 
 
To help achieve its goals NHS England implemented a strategy for cancer 
called ‘Improving Outcomes: a Strategy for Cancer’, originally outlined in 2011 
(Great Britain. Department of Health, 2011a).  The third annual report of 
‘Improving Outcomes: a Strategy for Cancer’ (Great Britain. Department of 
Health, 2013e) published in December 2013, demonstrated progress in the 
following areas: 
 
 
 
 
 
 
 
  
(Great Britain. Department of Health, 2013e) 
 
 
 
 
 
 
 Significant developments in cancer screening, particularly introducing 
Bowel Scope Screening. 
 
 Promoting earlier diagnosis of symptomatic cancers, e.g. via the ‘Be 
Clear on Cancer’ campaign. 
 
 Ensuring better access for all to the best possible treatment. 
 
 Significant developments in collection and reporting of new datasets 
and analysis of information, to drive improvements and inform 
patients. 
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Whilst the following priority areas were identified:  
 
 
 
 
 
 
 (Great Britain. Department of Health, 2013e) 
 
The next section will describe the pathogenesis of colorectal cancer. 
 
1.2 COLORECTAL CANCER 
 
1.2.1 PATHOGENESIS 
 
Anatomical variation 
The overarching term colorectal cancer refers to adenocarcinoma arising within 
the large bowel, anywhere from the caecum, on the right side, to the rectum on 
the left side.  Figure 1.2 shows the anatomical distribution of tumours resected 
in Southampton in 2013 (Horne, Carr, Green & Walker, 2014a).  
 
 
 
 
 
 
 Tackling lifestyle factors, particularly smoking. 
 
 Improving uptake of screening amongst disadvantaged groups. 
 
 Building on the ‘Be Clear on Cancer’ awareness raising campaigns. 
 
 Ensuring sufficient endoscopy capacity to deliver Bowel Scope 
Screening. 
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Figure 1.2.  The anatomical distribution of colorectal cancers resected in 
Southampton in 2013 (Horne et al., 2014a). 
 
 
 
Figure 1.2 demonstrates an uneven distribution in the anatomical occurrence of 
tumours in the colon.  More than 60% of tumours occur in the left side, most 
notably in either the sigmoid colon or the rectum (Horne et al., 2014a).  Thirty-
six point six percent of tumours occur in the right side, with most of these 
(26.7%) occurring in either the caecum or the ascending colon.  In a recent 
study by the University of Glasgow, Powell et al. (2012) showed similar 
anatomical variation to that found locally.  Of the 411 patients entered into their 
study, 33% had a right sided tumour, 30% had a left sided tumour and 37% had 
a rectal tumour.   
 
The reason for this variety in the anatomical location of colorectal tumours is 
poorly understood, but it is linked to the different pathogeneses behind the 
disease.  It has been suggested that colorectal cancers of the right and left side 
are in fact different entities, with different aetiologies, behaviours, treatments 
Caecum 
17.8% 
Sigmoid colon 
28.7% 
Descending 
colon 2.5% 
Splenic flexure 
4.4% 
Transverse 
colon 4% 
Hepatic flexure 
1.5% 
Ascending 
colon 8.9% 
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36.6% 
Left sided:  
63.4% 
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and prognoses (Syam, 2013; Benedix et al., 2010; Nawa et al., 2007; Iacopetta, 
2002; Bufill, 1990).  These differences are summarised below in Table 1.3.   
 
Table 1.3.  Differences between right and left sided colorectal cancers. 
 
Theme 
 
Characteristic Right sided  Left sided  
Dietary Red meat consumptiona Lower incidence Higher incidence 
 Alcohol consumptiona Lower incidence Higher incidence 
 High body mass indexa Lower incidence Higher incidence 
General Age at diagnosisb,c Higher incidence in 
older people 
Higher incidence in 
younger people 
 Genderb,c Higher incidence in 
females 
Higher incidence in 
males 
 Hepatic / pulmonary 
metastasesc 
Lower incidence Higher incidence 
 Peritoneal carcinomatosisc Higher incidence Lower incidence 
 5 year survival ratec Lower incidence Higher incidence 
 Early detectiona Lower incidence Higher incidence 
 Anaemiad Higher incidence Lower incidence 
Genetic Hereditary non-polyposis 
colorectal cancerb 
Higher incidence Lower incidence 
 Familial adenomatous 
polyposisb 
Lower incidence Higher incidence 
 Ploidyb Mostly diploid Mostly aneuploid 
 Loss of heterozygosityb Lower incidence Higher incidence 
 TP53 mutationb Lower incidence Higher incidence 
 Microsatellite instabilityb Higher incidence Lower incidence 
 CpG island methylator 
phenotypeb 
Higher incidence Lower incidence 
Histopathology Mucinousb,c Higher incidence Lower incidence 
 Undifferentiatedc Higher incidence Lower incidence 
 Poorly differentiated / signet 
ring cellc 
Higher incidence Lower incidence 
 Appearance of tumoura Higher incidence of 
sessile lesions 
Higher incidence of 
polypoid lesions 
Treatment 5FU chemotherapyb Beneficial Minimal benefit 
 Intraoperative complicationsc Lower incidence Higher incidence 
 Multivisceral resectionc Lower incidence Higher incidence 
aNawa et al. (2007); bIacopetta (2002; cBenedix et al. (2010); dKnight, Wade & Balducci (2004). 
 
Pathways of carcinogenesis 
Colorectal cancer arises through one of two major pathways.  Approximately 
70% develop via chromosomal instability (Bettington et al., 2013), whilst others 
may develop by other pathways including microsatellite instability (Boland & 
Goel, 2010), and various polyposes (Tomlinson, 2014; Galiatsatos & Foulkes, 
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2006).  The chromosomal instability pathway of colorectal tumorigenesis 
involves a sequence of molecular events including mutation accumulation, loss 
of heterozygosity and hypermethylation, which leads to the activation of 
oncogenes and suppression of tumour suppressor genes (Fearnhead, Wilding 
& Bodmer, 2002).  These initially cause adenomatous polyps, which are known 
dysplastic precursor lesions.  A specific sequence of molecular events is known 
to cause the transformation from adenoma to adenocarcinoma.  This sequence 
of events is shown in Figure 1.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.  The adenoma – adenocarcinoma sequence (Pathology 
Outlines, 2012; Fearnhead et al., 2002). 
 
The next section will look at worldwide and UK colorectal cancer statistics.  
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1.2.2 COLORECTAL CANCER STATISTICS 
According to the World Cancer Research Fund (WCRF) International (2013) 
there were 1.36 million new cases of colorectal cancer diagnosed in 2012.  It is 
also estimated that by 2035 there will be 2.4 million cases of colorectal cancer 
diagnosed worldwide each year (World Cancer Research Fund International, 
2013) 
 
The Republic of Korea has the highest rate of colorectal cancer, with 45.0 cases 
per 100,000 people in 2012 (World Cancer Research Fund International, 2013).  
In comparison, the UK has the 26th highest rate, with 30.2 cases per 100,000 
people during the same period (International Agency for Research on Cancer, 
2014b). 
 
Figure 1.4 demonstrates trends in UK colorectal cancer incidence and mortality 
trends between 2003 and 2011.  
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Figure 1.4.  UK colorectal cancer incidence and mortality trends 2003 – 2011 
(Cancer Research UK, 2014o; Cancer Research UK, 2014p). 
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Between 2003 and 2010 there was a slight rise in the number of cases of 
colorectal cancer diagnosed annually until 2008, which saw a peak of 46.9 
cases per 100,000 (Cancer Research UK, 2014o).  The two subsequent years 
showed a small decrease in the number of new cases (Cancer Research UK, 
2014o).  Data from 2011 showed a continual decrease in the annual number of 
deaths due to colorectal cancer, from 18.6 per 100,000 people in 2003 to 16 per 
100,000 (Cancer Research UK, 2014p).  The decrease in new cases and 
reduced mortality may be due to implementation of the Bowel Cancer Screening 
Programme (BCSP) in 2006 (NHS Cancer Screening Programmes, 2014a), 
which by October 2008 had performed colonoscopy on 98% of the 17,518 
people detected to have an abnormal screening test (Logan et al., 2012).  Out 
of these, 1772 cancers and 6543 high risk adenomas were diagnosed (Logan et 
al., 2012).  Seventy-one percent of the cancers were classed as ‘early’, being 
either a polyp cancer or Dukes A or B (node negative) (Logan et al., 2012).  
Removal of these cancers before metastatic spread via lymph nodes would 
explain the decrease in number of new cases and the reduction in mortality.  
The BCSP are aiming for a 16 percent reduction in mortality as a result of the 
programme (Logan et al., 2012).  The role of the BCSP will be further explored 
in section 1.2.6. 
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1.2.3 AETIOLOGY OF COLORECTAL CANCER 
Numerous factors are either known or suspected to be associated with an 
increased or reduced risk of developing colorectal cancer (Cancer Research 
UK, 2014q).  
 
Factors known to be associated with an increased risk  
There is a substantial body of evidence for factors known to be associated with 
an increased risk of developing colorectal cancer.  These include a high red and 
processed meat intake (Chan et al., 2011), a high body mass index (Ma et al., 
2013; Robsahm et al., 2013), a high waist circumference (Li et al., 2013), 
moderate to high alcohol intake (Parkin, 2011), and cigarette smoking (Tsoi et 
al., 2009).  Co-morbidities associated with a known increased risk include 
inflammatory bowel disease (Lutgens et al., 2013), diabetes mellitus (Jiang et 
al., 2011), human papillomavirus infection (Damin, Ziegelmann & Damin, 2013) 
and Helicobacter pylori infection (Wu, Yang, Xu, Gao & Fan, 2013).  Further to 
this, radiation exposure (Parkin & Darby, 2011), having a familial syndrome 
(Fearnhead et al., 2002) or a first degree relative with colorectal cancer (Johns 
& Houlston, 2001) are all known to increase the risk of colorectal cancer 
development. 
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Factors suspected to be associated with an increased risk  
Factors suspected to be associated with an increased risk of developing 
colorectal cancer are a high cheese and egg intake (Tse & Eslick, 2014) and 
being of increased height (Wirén et al., 2014).  The evidence for the association 
with high cheese and egg intake and height is strong, based upon meta-
analyses of a number of studies (Tse & Eslick, 2014; Wirén et al., 2014).  The 
evidence for an increased risk relating to high cheese intake and height is also 
supported by systematic reviews of the literature by a WCRF and American 
Institute for Cancer Research (AICR) expert panel (World Cancer Research 
Fund International/American Institute for Cancer Research, 2011). 
 
Decreased melatonin production in night shift workers is also thought to be 
associated with an increased risk (Schernhammer et al., 2003).  The evidence 
for this association is weaker than for cheese and egg intake and height 
because it is based on a single cohort study.  There is a potential that the 
development of colorectal cancer may be due to other causes with the authors 
saying that the findings are only ‘suggestive’ of an association (Schernhammer 
et al., 2003). 
 
 
Factors known to be associated with a reduced risk 
In contrast, in their systematic review and meta-analysis of 25 prospective 
observational studies, Aune et al. (2011a) found that a high fibre diet is known 
to reduce the risk of developing colorectal cancer (Aune et al., 2011a) whilst 
being physically active is known to reduce the risk of developing colonic cancer 
(Robsahm et al., 2013). 
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Factors suspected to be associated with a reduced risk 
Numerous other studies have suggested factors which might also lower the risk 
of developing colorectal cancer, however the strength of the supporting 
evidence is variable. 
   
Higher dietary intakes of fish (Wu et al., 2012), fruit and vegetables (Aune et al., 
2011b), milk (Cho et al., 2004), folate (Gibson et al., 2011), zinc (Li et al., 2014), 
calcium and vitamin D (World Cancer Research Fund International/American 
Institute for Cancer Research, 2011) and garlic (McCullough, Jacobs, Shah, 
Campbell & Gapstur, 2012) are all linked to a decreased risk of developing 
colorectal cancer.   
 
The evidence supporting the association of higher dietary intake of fish, fruit and 
vegetables and milk is good, based upon meta-analyses of multiple studies (Wu 
et al., 2012; Aune et al., 2011b; Cho et al., 2004).  In a 2011 report the WCRF 
stated that the strongest evidence, based upon systematic literature reviews by 
expert panels, showed that increased consumption of milk and calcium probably 
protects against colorectal cancer (World Cancer Research Fund 
International/American Institute for Cancer Research, 2011), but that the 
evidence for increased fish and fruit and vegetable intake was less consistent 
and limited.  However, it should be noted that the WCRF report was published 
in 2011, and the meta-analysis by Wu et al. (2012) was performed after this 
date, potentially strengthening the evidence base. 
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The strength of evidence for increased dietary folate and garlic is weak, with 
some studies showing an increased risk whilst others show a decreased risk 
(Meng et al., 2014; Zhu, Zou, Qi, Zhong & Miao, 2014; McCullough et al., 2012; 
Gibson et al., 2011).  Li et al. (2014) found the strongest statistically significant 
association between increased zinc intake and decreased risk of colorectal 
cancer, when compared to other luminal gastrointestinal cancers in a meta-
analysis of 19 studies, however no comment was made by the WCRF, 
suggesting that stronger evidence is still required (World Cancer Research 
Fund International/American Institute for Cancer Research, 2011).  The WCRF 
also stated that the evidence supporting the protective effects of vitamin D rich 
foods against colorectal cancer development was limited (World Cancer 
Research Fund International/American Institute for Cancer Research, 2011).  
 
Aspirin 
In a meta-analysis of 248 studies over a 61 year period, Algra and Rothwell 
(2012) also suggested that regular low dose aspirin may be protective in the 
prevention of many carcinomas, supporting the findings of previous studies 
which suggested protection against colorectal cancers arising via both sporadic 
and familial pathways (Burn et al., 2011; Rothwell et al., 2010).  The evidence 
provided by the systematic review by Algra and Rothwell (2012) appears to be 
strong, demonstrating a consistently associated reduction in risk within the 17 
studies related to colorectal cancer.   
 
 
The next section will consider the diagnosis and treatment of colorectal cancer 
by both symptomatic and asymptomatic pathways. 
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1.2.4 DIAGNOSIS AND TREATMENT 
 
Colorectal cancer may be diagnosed in one of two ways.  Some patients may 
have symptoms such as a change in bowel habit, rectal bleeding or iron 
deficiency anaemia.  Alternatively, some patients may be asymptomatic and 
diagnosed via the BCSP, which will be further explored in section 1.2.6.  
 
Diagnosis and treatment of symptomatic patients 
Symptomatic patients are diagnosed and treated according to National Institute 
for Clinical Excellence (NICE) clinical guidelines which are summarised in 
Figure 1.5. 
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Figure 1.5.  Diagnosis and treatment of colorectal cancer in symptomatic 
patients (Map of Medicine, 2013; Map of Medicine, 2012; National Institute 
for Clinical Excellence, 2011).  
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Diagnosis and treatment of asymptomatic patients 
 
Asymptomatic patients are diagnosed and treated according to English NHS 
BCSP clinical guidelines which are summarised in Figure 1.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6.  Diagnosis and treatment of colorectal cancer in asymptomatic 
patients via the NHS BCSP in England (Map of Medicine, 2012).  
 
 
The next section will examine the international and national strategies 
implemented to address colorectal cancer.  
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1.2.5 INTERNATIONAL COLORECTAL CANCER STRATEGY 
According to the WHO publication ‘Fight Against Cancer: Strategies that 
Prevent, Cure and Care’, “up to 40% of all cancer deaths can be avoided by 
reducing tobacco use, improving diets and physical activity, and lowering 
alcohol consumption” (World Health Organization, 2007, p.3).  These are known 
risk factors for the development of colorectal cancer and therefore international 
strategies for the prevention of colorectal cancer seek to address the above 
issues.   
 
International screening 
Dysplastic (adenomatous) polyps may be detected and removed before they 
become invasive adenocarcinoma.  As a result, many countries have begun 
national or regional screening of appropriate at-risk populations.  When these 
tests give positive results second-line colonoscopy, double barium enema or 
flexible sigmoidoscopy may be used for further investigation and/or removal of 
polyps (International Cancer Screening Network, 2013; von Karsa, n.d.).  Fully 
rolled-out schemes are summarised in Table 1.4.   
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Table 1.4.  International screening programmes for colorectal cancer (International Cancer Screening Network, 2013; 
Zavoral et al., 2009; von Karsa, n.d.). 
 
Country Start date National 
scheme 
 
Population Test(s) used Testing  
interval 
Austria - Yes >50 years Faecal occult blood test and colonoscopy 
Colonoscopy 
1-2 yearly 
10 yearly 
Australia 2006 Yes 55-65 years Faecal occult blood test and colonoscopy 2 yearlya 
Belgium 1994 No 50-74 years Faecal occult blood test and colonoscopy 5 yearly 
Bulgaria - Yes >31 years Faecal occult blood test and colonoscopy 1 yearly 
Canada - No Various Faecal occult blood test and colonoscopy, barium enema or flexible 
sigmoidoscopyb 
2 yearly 
Finland - No 60-69 years Faecal occult blood test and colonoscopy 2 yearly 
France 2008 Yes 50-74 years Faecal occult blood test and colonoscopy 2 yearlyc 
Germany 2002 Yes >55 years Faecal occult blood test and colonoscopy  
Colonoscopy 
1-2 yearly 
10 yearly 
Greece - Yes >50 years Faecal occult blood test and colonoscopy 
Colonoscopy 
5 yearly 
5 yearly 
Hungary 2008  Yes 50-70 years Faecal occult blood test and colonoscopy 2 yearly 
Israel - Yes 50-84 Faecal occult blood test and colonoscopy 1 yearly 
Italy 2007 Yes 50-69 Faecal occult blood test and flexible sigmoidoscopy 2 yearly 
Japan 1992 Yes >40years Faecal immunochemistry testingd 1 yearly 
Korea (republic) 2004 Yes >50 years Faecal occult blood test and colonoscopy 1 yearly 
Latvia - Yes >50 years Faecal occult blood test and colonoscopy 1 yearly 
Portugal 2008 No 50-70 years Faecal occult blood test and colonoscopy 2 yearly 
Slovak Republic - Yes >50 years Faecal occult blood test and colonoscopy - 
United Kingdom 2006 Yes 60-69 Faecal occult blood test and colonoscopy 2 yearly 
United States Various Yes >50 years Faecal occult blood test and colonoscopy 
Flexible sigmoidoscopy, double contrast barium enema, computed 
tomographic colonography 
Colonoscopy 
1 yearly 
5 yearly 
 
10 yearly 
Uruguay 2005 Yes 50-70 years Faecal occult blood test and colonoscopy 1 yearly 
aChoo & Norton (2010); bCanadian Cancer Society (2014); cLeuraud, Jezewski-Serra, Viguier & Salines (2013); dRoss (2010).
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1.2.6 NATIONAL COLORECTAL CANCER STRATEGY  
 
Lifestyle campaigns and policies 
Like many other countries, the English strategy for colorectal cancer is based 
on prevention via lifestyle campaigns and policies, plus a national screening 
programme.   
 
These campaigns include ‘Change 4 Life’ (Change 4 Life, 2013), ‘5 a day’ (NHS 
Choices, n.d.) and ‘Be clear on cancer’ (NHS, 2012).  The government also has 
published policies on alcohol and smoking (Great Britain. Department of Health, 
2011b; Great Britain. Department of Health, 2013b; Great Britain. Department of 
Health, 2013d). Some of the campaigns and policies which relate to colorectal 
cancer in England, either directly or indirectly are summarised in Figure 1.7. 
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Figure 1.7.  Advertising from UK government lifestyle and cancer 
campaigns (Change 4 Life, 2013; NHS Cancer Screening Programmes, 
2013a; NHS Cancer Screening Programmes, 2013b; NHS, 2012; NHS 
Smokefree, n.d.; William Joseph, n.d.). 
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National screening programme 
In addition to preventative lifestyle schemes a national screening programme for 
colorectal cancer has been in place in England since 2006 (NHS Cancer 
Screening Programmes, 2014a) following a successful pilot study in Coventry 
and North Warwickshire (The Institute of Cancer Research, 2006).  The 
pathway for colorectal cancer screening is described in Figure 1.6.  The BCSP 
offers biennial Faecal Occult Blood Test (FOBt) screening as a first line test to 
all men and women aged 60-69 in England (NHS Cancer Screening 
Programmes, 2014a).  Similar programmes began in Scotland in 2007, Wales in 
2008 and Northern Ireland in 2010 (Cancer Research UK, 2009a).  In Scotland 
the screening age range is 50-74 years, and it is gradually being extended to 
those aged 70-74 in England and Wales (Cancer Research UK, 2009a).  In 
England people over 70 can choose to opt-in to the programme by requesting a 
FOBt kit via a national helpline (NHS Cancer Screening Programmes, 2014a), 
however as of December 2013, 98 percent of BCSP centres had already 
extended the age range to 75 years (Great Britain. Department of Health, 
2013e).  According to Cancer Research UK (2009a) approximately two percent 
of FOBt are positive, with second-line colonoscopy offered.   
 
By November 2013 over 17,500 cases of colorectal cancer had been detected 
since the programme began in England in 2006 (Great Britain. Department of 
Health, 2013e).  In the three year period between 2009-2010 and 2011-2012, 
the national average for uptake of colorectal cancer screening was 57.4 percent 
(Cancer Research UK, n.d.).  Locally, 53.8 percent of people aged 60-69 in 
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NHS Southampton CCG took part in screening during the same period (Cancer 
Research UK, n.d.).  
 
Further screening developments  
There are a number of further screening programmes in development, which 
are discussed in the following section. 
 
Bowel scope screening 
Since 2013 a pilot for bowel scope screening has been running in six bowel 
screening centres in England (NHS Cancer Screening Programmes, 2014b).  
This pilot is investigating the use of once-only flexible sigmoidoscopy for people 
between 55 and 60 years and has been developed further to a randomised 
controlled trial which suggested that incidence and mortality could be reduced 
by 33 percent and 43 percent respectively in those attending screening (Atkin et 
al., 2010).  It is expected that national coverage will be achieved by 2016 (Great 
Britain. Department of Health, 2013e). 
 
Faecal Immunochemical Testing 
A further pilot has been running in England to assess the feasibility, practicality 
and cost-effectiveness of faecal immunochemical testing (FIT).  Also called 
immunochemical FOBt (iFOBt) it is similar to, but more sensitive than, FOBt 
(Colon Cancer Alliance, 2014).  If successful, the use of iFOBt is hoped to 
increase uptake and provide more accurate results (Great Britain. Department 
of Health, 2013e).  Although advantageous in terms of sensitivity, it is more 
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expensive and it has been suggested that it be used as a second-line test in 
patients who have a positive FOBt (Fraser et al., 2007). 
 
National clinical trials 
As of 20th February 2014 there were 200 active UK clinical trials in relation to 
colorectal cancer (UK Clinical Research Network, n.d. a).  Specifically, 160 
were related to the colon and 136 were related to the rectum (with some trials 
relating to both).  Four trials related to the anus and appendix (UK Clinical 
Research Network, n.d. b).  
 
As of 17 April 2014, there were 118 active UK trials listed on the Cancer 
Research UK website, in relation to colorectal cancer.  This included: 
 37 out of 118 recruiting 
 46 out of 118 closed 
 35 out of 118 closed with results 
(Cancer Research UK, 2014r) 
 
As of 17 April 2014, local patients were being accepted into six active trials 
specifically relating to colorectal cancer.  These trials are summarised in Table 
1.5 (Cancer Research UK, 2014s). 
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Table 1.5.  Local involvement in UK colorectal cancer clinical trials. 
 
Trial name Study type Description Trial intervention Standard Recruitment 
period 
 
Phase 
Copernicusa Interventional For patients with rectal cancera Neoadjuvant chemotherapy and 
radiotherapy plus adjuvant 
chemotherapya 
Adjuvant 
chemotherapya 
15/05/12-
31/05/14a 
2a 
FOXFIREb Interventional 5-Fluorouracil, OXaliplatin and 
Folinic acid +/- Interventional 
Radio-Embolisation for patients 
with colorectal liver metastasesc 
Radioembolisation / selective internal 
radiation therapy (SIRT) combined with 
adjuvant chemotherapyb 
Adjuvant 
chemotherapyb 
15/02/10-
30/06/14b 
3b 
FOxTROTd  Interventional Fluoropyrimidine, Oxaliplatin and 
Targeted-Receptor pre-Operative 
Therapy for patients with high-
risk, operable colon cancere 
Neoadjuvant chemotherapy 
 
 
Monoclonal antibody (Panitumumab) 
therapy plus adjuvant chemotherapyd 
Adjuvant 
chemotherapy 
 
Adjuvant 
chemotherapyd 
01/04/08-
31/10/14d 
3d 
Exercisef Interventional For patients with locally advanced 
rectal cancer who have received 
neoadjuvant chemoradiotherapyf 
9 week exercise programme after 
neoadjuvant chemoradiotherapyf 
Neoadjuvant 
chemotherapyf 
01/10/13-
31/12/14f 
2f 
NSCCGg Observational National Study of Colorectal 
Cancer Genetics for patients with 
a first degree relative with 
colorectal cancerg,h 
Family history questionnaire  
 
Molecular assessment of blood and 
tissue samplesg   
- 01/08/13-
30/09/15g 
- 
MARVELi Observational Molecular pAthologic and MRI 
investigation of the prognostic and 
predictive importance of 
extramural VEnous invasion 
(EMVI) in rectaL cancerj 
Compare the profile of EMVI negative 
and positive tumours before and after 
neoadjuvant chemoradiotherapy, and 
relate this to survival outcomesj 
- 01/06/13-
30/06/18i 
2i 
aCancer Research UK (2014t); bCancer Research UK (2014u); cUK Clinical Research Network (n.d. c); dCancer Research UK (2013c);  
eUniversity of Birmingham (2014); fCancer Research UK (2013d); gCancer Research UK (2014v); hThe Institute of Cancer Research (2014); 
iCancer Research UK (2013e); jUK Clinical Research Network (n.d. d). 
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The next section will review the diagnostic process, including the patient 
pathway and the role of the histopathology service in the diagnosis and 
management of colorectal cancer. 
 
1.3 HISTOPATHOLOGY 
 
1.3.1 THE ROLE OF THE HISTOPATHOLOGY DEPARTMENT 
Oxford Dictionaries (2014a) define histopathology as “the study of changes in 
tissues caused by disease.” The role of histopathology in the management of 
patients with suspected or confirmed colorectal carcinoma is described in 
Figure 1.8. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8.  The role of histopathology in the management of a patient with 
suspected or known colorectal carcinoma. 
 
 
 
To provide an initial 
histological diagnosis on 
biopsies or polyps 
To type, grade and stage 
the surgically resected 
tumour  
To request external 
specialist molecular testing 
 
To communicate the 
findings to the 
multidisciplinary team 
To provide further 
histological diagnosis 
when recurrence 
suspected 
To perform 
immunohistochemical 
testing 
To assess any 
other background 
pathology in the 
resection specimen  
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Initial histological diagnosis of colorectal cancer 
Initial histological diagnosis is made by a histopathologist on biopsy or polyp 
material removed during endoscopic examination.  The histological tissue will 
have been gained via colonoscopic examination, either from a patient with 
suspicious symptoms such as a change in bowel habit or rectal bleeding, or 
from an asymptomatic patient with a positive FOBt.  Figure 1.9 demonstrates 
the difference between the types of colorectal specimens removed at 
colonoscopy for histopathological examination. The relationship of 
histopathology to the symptomatic and asymptomatic patient pathways can be 
seen in section 1.2.4 (Figures 1.5 and 1.6). 
 
 
 
 
Figure 1.9.  Examples of mucosal biopsies (a); polyp biopsy (b) and 
polypectomy specimens (c).  
 
The resulting tissue samples are ‘processed’ by healthcare scientists or support 
staff, by placement in a small cassette, followed by dehydration and 
impregnation with alcohols and paraffin wax.  A one cell layer thick section is 
cut from the resulting block of tissue and is bonded to a glass slide.  This is 
stained with haematoxylin and eosin to demonstrate nuclear and cytological 
morphology and facilitate microscopic diagnosis.  Patients with suspected 
malignancy or high grade dysplasia are discussed at the lower gastrointestinal 
multidisciplinary team (MDT) meeting.  These patients will already be known to 
the clinical team.  Patients with unsuspected malignancy are flagged to the 
a b c 
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clinical team and are also discussed at the meeting, in line with good practice 
guidelines from the Royal College of Pathologists (RCPath) (The Royal College 
of Pathologists, 2013a).  
 
Macroscopic assessment of colorectal cancer resection specimens 
The handling and assessment of resection specimens within histopathology is 
summarised in Figure 1.10.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10.  Handling of colorectal cancer resection specimens within 
histopathology. 
 
Specimens are prepared for fixation (a); representative blocks are selected (b); 
lymph nodes are harvested (c); all lymph nodes are sampled (d).   
 
a b 
c d 
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Microscopic assessment of colorectal cancer specimens  
Microscopic assessment of colorectal cancer specimens involves typing, 
grading and staging of the tumour. 
 
Typing 
Over 95 percent of malignant colorectal tumours are adenocarcinoma (Cancer 
Research UK, 2013f), however a small percentage are of a different type, e.g. 
neuroendocrine tumour, squamous carcinoma or lymphoma.  Within the 
adenocarcinoma group there are also subtypes which are directly associated 
with the various known molecular pathways to colorectal malignancy (Bettington 
et al., 2013), e.g. mucinous adenocarcinoma and serrated adenocarcinoma.   
 
Grading 
Adenocarcinomas may be graded as either well, moderate or poor (The Royal 
College of Pathologists, 2014).  Well to moderately graded tumours retain 
glandular differentiation, whilst poorly graded tumours lack glandular 
differentiation and form sheets of tumour, sometimes with single cell infiltration.  
The presence of ‘signet ring’ cells where the cytoplasm acquires mucus and 
pushes the nucleus to the edge of the cell, denotes poor differentiation 
(Fleming, Ravula, Tatishchev & Wang, 2012).  The RCPath use a two-tiered 
grading system in order to reduce interobserver variation and improve 
prognostic significance (Fleming et al., 2012), whereby well and moderately 
differentiated tumours are combined in the colorectal cancer minimum dataset 
(The Royal College of Pathologists, 2014).  
 
35 
 
Staging 
Colorectal adenocarcinomas are staged according to the RCPath minimum 
dataset for colorectal cancer, which uses the Union for International Cancer 
Control (UICC) Tumour Nodes Metastases (TNM) version 5 staging system 
(The Royal College of Pathologists, 2014; Wittekind, Greene, Hutter, 
Klimpfinger & Sobin, 2005).  Many  countries use TNM version 7, however due 
to perceived inadequacies in the assessment of discontinuous tumour foci due 
to significant inter-observer variability, the UK continues to use the TNM5 
system (Doyle & Bateman, 2012; Nitsche et al., 2011).  Table 1.6 demonstrates 
the required minimum data that is included when reporting colorectal carcinoma 
resection specimens. 
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Table 1.6.  Required minimum data when reporting colorectal carcinoma 
resection specimens (The Royal College of Pathologists, 2014). 
 
Dataset item 
 
Response 
Type of tumour Adenocarcinoma 
Other 
Grade of tumour Well- moderate 
Poor 
Depth of invasiona pT1   - Submucosa  
pT2   - Into muscularis propria 
pT3   - Beyond muscularis propria  
pT4a - Adjacent organs  
pT4b - Serosa 
Involvement of circumferential resection 
margin (rectal tumours) 
Not involved (R0) 
Involved (R1) 
Completeness of excision Excised (R0) 
Not excised (R1) 
Lymphovascular invasion Yes 
No 
Number of lymph nodes retrieved Number 
Number of metastatic lymph nodesa pN0 – 0 metastatic lymph nodes 
pN1 – 1-3 metastatic lymph nodes 
pN2 – 4 or more metastatic lymph nodes  
Confirmation of distant histologically 
confirmed metastases 
pMx – Cannot assess 
pM0 – No 
pM1 – Yes 
Pathological TNM stagingb pT1 
pT2 
pT3 
pT4a 
pT4b 
pN0 
pN1 
pN2 
pMx 
pM0 
pM1 
Dukes staging A   - Into muscularis propria 
B   - Beyond muscularis propria 
C1 - Node positive, not involving high tie (apical) 
node 
C2 - Node positive, involving high tie (apical) node 
aTNM5; bPatients who have received long course neoadjuvant chemoradiotherapy are 
designated with a ‘y’ prefix, e.g. ypT3 ypN0 ypMx. 
 
Additional testing 
Immunohistochemical testing for the protein products of DNA mismatch repair 
genes seen in patients with microsatellite instable tumours may be performed 
within histopathology.  DNA mismatch repair genes are usually lost in pairs - 
mutL homolog 1 (MLH1) with mutS homolog 2 (MSH2), and mutS homolog 6 
(MSH6) with postmeiotic segregation increased 2 (S. cerevisiae) (PMS2) 
(Boland & Goel, 2010).  Features suspicious for defective DNA mismatch repair 
genes are right sided tumours, mucinous morphology, poor differentiation and 
37 
 
increased numbers of tumour-infiltrating lymphocytes (Boland & Goel, 2010).  
DNA mismatch repair gene status is important because there is evidence that 
patients with deficient mismatch repair genes have improved survival and do 
not benefit from receiving 5-fluorouracil adjuvant chemotherapy (Sargent et al., 
2010).  Molecular testing for Kirsten rat sarcoma viral oncogene homolog 
(KRAS) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) gene 
mutations in patients with metastatic colorectal carcinoma may be performed 
because status is known to affect the response to commonly used 
chemotherapeutic agents (De Roock et al., 2010).  Cetuximab combined with 
oxaliplatin-containing chemotherapy is contraindicated in patients with 
metastatic colorectal carcinoma with KRAS or NRAS mutations at exons 2, 3 
and 4, and in patients with unknown RAS status, because this group has been 
shown to have inferior overall survival and progression-free survival (Medicines 
and Healthcare Regulatory Agency, 2014).  In contrast, patients who express 
epidermal growth factor receptor (EGFR) and have wild-type (normal) RAS 
status should be treated with a combination of Cetuximab combined with 
Oxaliplatin as studies have shown that they respond better to this 
chemotherapeutic combination (Medicines and Healthcare Regulatory Agency, 
2014).  
 
The staffing of Histopathology 
Traditionally in the UK the technical preparation of colorectal cancer specimens 
is performed by healthcare scientists and support staff, whilst the clinical 
diagnostic work is performed by medically trained histopathologists.  However, 
since the development of a specimen dissection qualification by a Joint 
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RCPath/IBMS Working Group (2004) some clinical roles may now be performed 
routinely by expertly trained (advanced practitioner) healthcare scientists.  A 
comparison of the roles performed by different staff groups within 
histopathology traditionally and locally is described in Figure 1.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11.  A comparison of traditional and local roles for 
histopathology staff in the handling of colorectal cancer specimens. 
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The next section will examine the development of extended and expert roles for 
healthcare scientists within histopathology departments, and how this fits the 
need for service delivery redesign within the modern NHS. 
 
1.3.2 EVOLVING ROLES FOR HEALTHCARE SCIENTISTS 
Healthcare scientist is an umbrella term for the various scientists that work 
within the NHS.  This includes clinical scientists and biomedical scientists.  
Cellular Pathology, comprising histopathology, cytopathology and the mortuary, 
remains the only pathology department without clinical scientist involvement.  
This is for historic reasons, because diagnostic work has always been 
performed by the medically trained pathologist workforce.  In contrast, non-
diagnostic technical support roles have historically been performed by 
scientifically trained staff.  Originally known as medical laboratory technicians 
(MLTs), this group of staff were skilled and knowledgeable but not educated to 
degree level.  Staff are now known as Biomedical Scientists and require a high 
level of scientific qualification and registration with the Health and Care 
Professions Council (HCPC) in order to practice within the UK (Health and Care 
Professions Council, 2014).  The professional body of Biomedical Scientists is 
the Institute of Biomedical Science (IBMS) and with over 20,000 members 
(Institute of Biomedical Science, 2014a) many of the 21,929 HCPC registered 
biomedical scientists are also members of the institute (Health and Care 
Professions Council, 2014).  As the level of education has changed, so have the 
aspirations of the workforce (NHS Careers, n.d.).  Unfortunately to this day in 
many histopathology departments within the UK the job role remains technically 
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driven, with a general lack of development into clinical roles (Institute of 
Biomedical Science, 2014b).   
 
Changing needs of the NHS 
Although modern requirements of the NHS are different to those when it was 
first established in 1948 by Aneurin Bevan (NHS Choices, 2013c), the core 
principles on which it was based remain.  In 2011 the Department of Health 
published the NHS Constitution, setting out modern guiding principles (NHS 
Choices, 2013c).  This was updated for England in 2013 (Great Britain. 
Department of Health, 2013f).  A comparison of the original 1948 principles with 
those set out in the NHS Constitution for England in 2013 is given in Table 1.7. 
 
Table 1.7.  A comparison of the guiding principles of the NHS in 1948 and 
2013 (Great Britain. Department of Health, 2013f; NHS Choices, 2013c). 
 
 1948 principles 
 
2013 principles 
Principle 1 Meets the needs of 
everyone 
Provides a comprehensive service available to 
all 
Principle 2 Free at the point of delivery 
 
Based on clinical need, not the ability to pay 
Principle 3 Based on clinical need, not 
the ability to pay 
Aspires to the highest standards of excellence 
and professionalism 
Principle 4 - 
 
Aspires to put patients at the heart of everything 
it does 
Principle 5 - Works across organisational boundaries and in 
partnership with other organisations in the 
interest of patients, local communities and the 
wider population 
Principle 6 - Committed to providing best value for taxpayers’ 
money and the most effective, fair and 
sustainable use of finite resources 
Principle 7 - 
 
Accountable to the public, communities and 
patients that it serves 
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Table 1.7 shows that the original guiding principles set out in 1948 remain to the 
current day.  The additional principles set out in the NHS Constitution refer to 
professionalism, accountability and financial management, and describe the 
rights to which patients and staff are entitled, the pledges which the NHS is 
committed to achieve and the responsibilities that patients and staff owe to one 
another in order to ensure a fair and effective service (Great Britain. Department 
of Health, 2013f).  All providers of NHS services, whether NHS or private, are 
legally required to justify their decisions and actions using the NHS Constitution 
(Great Britain. Department of Health, 2013f).   
 
The difference between the original principles and the new constitution is that 
there is now also an emphasis on shared responsibility by both the NHS and 
the patient.  Although the NHS provides treatment and prevention in terms of 
screening, advice and policies, it realises that resources are finite and therefore 
also expects the patient to employ preventative measures such as participation 
in public health programmes.  The constitution clearly states “Please recognise 
that you can make a significant contribution to your own, and your family’s, 
good health and wellbeing, and take personal responsibility for it.” (Great 
Britain. Department of Health, 2013f, p.11).  The government hope that this 
shared responsibility will reduce the cost to the NHS of preventable disease 
caused by social factors, e.g. obesity, smoking and alcohol.  As well as causing 
acute disease which costs the NHS billions per year, these factors also 
contribute to the development of heart disease, diabetes and cancer, which 
together place a large cost burden onto the NHS.  For example, in 2013/2014 
NHS England had an overall budget of £95.6 billion (NHS England, 2013).  The 
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cost of obesity to the NHS rose from £479.3 million in 1998 (National Audit 
Office, 2001) to £4.2 billion in 2007 (Butland et al., 2007) and is projected to 
reach £27 billion by 2015 (Butland et al., 2007).  Smoking was estimated to cost 
the NHS £5.2 billion in 2005/2006 (Health and Social Care Information Centre, 
2013a), whilst alcohol misuse is estimated to cost the NHS £3.5 billion every 
year (Health and Social Care Information Centre, 2013b). 
 
Although improving the overall health of the nation together with improved 
treatment modalities appears to be of obvious benefit to all, it may actually 
place further burden on the NHS because people are living longer with complex 
health problems.  In 1948 the average life expectancy was 66 years for men 
and 71 years for women (McSmith, 2008, para. 19) compared to 78.7 years for 
men and 82.6 years for women in 2010-2012 (Office for National Statistics, 
2012).  The models against which the NHS was established were based on a 
shorter lifespan with less long-term morbidities.  According to the Office for 
National Statistics (2011) the number of people over the age of 85 rose from 
416,000 in 1971 to over 1.1 million in 2009, with the number projected to reach 
over 2.6 million by 2032.  Around 70 percent of the total health and care 
expenditure in England is attributed to people with long-term conditions (Great 
Britain. Department of Health, 2012).  The elderly and those with long-term 
conditions place the greatest burden on the NHS and if both of these groups 
continue to increase, so will the pressure on the health service. 
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Costs for diagnostics and treatments were also simpler and cheaper in 1948.  
For example, in 1948 X-ray was the only available radiology test (The British 
Institute of Radiology, 2013).  Computerised tomography (CT) and magnetic 
resonance imaging (MRI) scanning were not established until the 1970s (The 
British Institute of Radiology, 2013), whilst positron emission tomography CT 
(PET-CT) scanning was first used in the 1990s (Townsend, 2008).  The 
development of complex, expensive tests such as those used in radiology also 
partly explains the increasing cost pressures on the modern NHS.  The model 
on which the NHS was based is no longer applicable and therefore although the 
principles may remain the same, the model of service delivery must be 
reformed or there is risk of collapse.  A 2012 report by The King’s Fund 
describes the requirement to make £20 billion of efficiency savings by 2015 as 
the main pressure on the NHS, with a further £20-30 billion of savings to be 
found by 2019-2020 (Appleby, 2012).  Without additional funding to develop 
new services, the NHS must redevelop its available resources to meet current 
and future workload demands (The Kings Fund, 2012).  The organisation of 
many departments, including pathology, is based on historic and outdated 
working practices that provide poor productivity and a lack of value for money 
(The Kings Fund, 2012). 
 
In response to the pressures outlined above, the many guidelines and policies 
published by the Department of Health are increasingly related to addressing 
the need to get the best value for money from finite resources (Great Britain. 
Department of Health, 2008a; Great Britain. Department of Health, 2008b; 
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Department of Health, 2006; Great Britain. Department of Health, 2004; Great 
Britain. Department of Health, 2000). 
 
In order to achieve a competent, efficient and cost-effective modern health 
service, opportunities for extended and more appropriate job roles for highly 
educated and skilled non-medically qualified staff are being developed (Great 
Britain. Department of Health, 2010; Great Britain. Department of Health, 
2008a; Great Britain. Department of Health, 2008b; Great Britain. Department of 
Health, 2006).  These changes are beginning to occur within pathology 
departments with a number of publications promoting these extended roles.  
They are described in more depth in the next section and are summarised 
below in Figure 1.12 with an accompanying timeline for each publication. 
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Figure 1.12.  Publications promoting the implementation of extended roles 
for Healthcare Scientists within histopathology departments in the UK 
(Great Britain. Department of Health, 2010; Great Britain. Department of 
Health, 2008a; Great Britain. Department of Health, 2008b; The Royal 
College of Pathologists, 2007; Great Britain. Department of Health, 2006; 
Great Britain. Department of Health, 2004; Joint RCPath/IBMS Working 
Group, 2004; Great Britain. Department of Health, 2000; van Schalkwyk, 
n.d.). 
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Pre-Carter report (2000 – 2005) 
In 2000 the Department of Health published ‘The NHS Plan’, setting out a plan 
for investment and reform via modernisation of services (Great Britain. 
Department of Health, 2000).  This included the recommendation to break down 
old-fashioned demarcations between staff and barriers between services and 
extended roles for nurses and other staff (Great Britain. Department of Health, 
2000).  In 2004 the Modernising Pathology Services publication built on this and 
recommended further re-profiling of the pathology workforce (Great Britain. 
Department of Health, 2004).  Although specimen dissection is traditionally 
performed by medically qualified histopathologists, for years it has been routine 
practice in many UK histopathology departments for biomedical scientists to 
perform dissections, usually those of lower complexity, but to an equivalent or 
greater standard than medically trained counterparts (Ashworth, 1994; Biggart & 
Allen, 1994).  Although routine practice, it was also ad hoc because not all 
histopathologists were in favour of this change, seeing it as a threat to the 
boundaries of their professional role.  This was clearly demonstrated by the 
protectionist responses to the 1994 article by Ashworth entitled ‘The future for 
histopathology: protectionism or prudence?’ (Ball, 1994).  Between 2002 and 
2003 a pilot study was undertaken involving 12 sites to assess the feasibility of 
implementation of formally extending the role of biomedical scientists in 
specimen description, dissection and sampling (Joint RCPath/IBMS Working 
Group, 2004).  The final report, published in 2004, presented an overwhelming 
positive response with no evidence of a negative effect on the quality of the 
service (Joint RCPath/IBMS Working Group, 2004).  Ten years on, this role is 
seen as the norm in more proactive departments, and is driven and supported 
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by modern, younger consultant histopathologists.  For example, twenty-nine 
candidates have successfully passed the histological dissection exam, 
qualifying as advanced practitioners, since 2010 (C. Ward, personal 
communication, October 23, 2014). 
 
2006 – Report of the Review of NHS Pathology Services in England (The 
Carter Report) 
In 2006 the Report of the Review of NHS Pathology Services in England (The 
Carter Report) was published (Great Britain. Department of Health, 2006) and 
made a number of key comments and recommendations, including the 
following: 
 
 
 
 
 
 
 
 
 
 
 
 
(Great Britain. Department of Health, 2006)  
 
 Comment: 
With greater involvement of medically qualified pathologists in 
multidisciplinary teams, the roles of clinical and biomedical scientists 
are also being transformed. 
 
 Recommendation 1: 
There is a need to review the roles and structures of the workforce to 
ensure that it is equipped to deliver modernised, affordable high 
quality pathology services for the future. 
 
 Recommendation 2: 
Pathology needs to achieve productivity gains and improve efficiency 
and effectiveness.  This would require an integrated pathology service 
model with inputs matched to skill and knowledge requirements with 
development of a workforce profile to optimise the desired service 
outputs (different from the workforce that has evolved to date). 
 
 Recommendation 3: 
There are clear opportunities for the extension of roles beyond 
traditional delivery boundaries. 
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The document identified a number of workforce themes for development 
including professional demarcations, workforce planning, recruitment and 
retention, career pathways, skill mix, training and the professions.  These are 
summarised in Appendix A. 
 
 
Although formal extended practice roles were becoming more commonplace in 
nursing and radiography (Royal College of Nursing, 2012; Kelly, Piper & 
Nightingale, 2008; Woodford, 2006; Furlong & Smith, 2005) the only advanced 
practitioner roles in pathology at the time of the Carter report with reporting 
responsibilities were within gynaecological cytology as part of the NHS Cervical 
Screening Programme (NHSCSP) (Smith & Hewer, 2003).  The Carter report 
(Great Britain. Department of Health, 2006) helped drive the formal 
development of further advanced practitioner roles within cellular pathology.  
These included advanced practitioner reporting roles for diagnostic 
cytopathology (Institute of Biomedical Science, 2014c; The Royal College of 
Pathologists, 2007), ophthalmic histopathology (Institute of Biomedical Science, 
2014d; Meeney & Mudhar, 2013) and most recently gastrointestinal and 
gynaecological histopathology (The Royal College of Pathologists, 2013b; van 
Schalkwyk, n.d.). 
 
Post-Carter report (2007 – 2014) 
The 2007 proposal for a formal extended role for scientists allowing reporting of 
diagnostic cytopathology specimens sought to address the severe shortage of 
consultant histopathologists and cytopathologists (The Royal College of 
Pathologists, 2007).  It sought to enhance career incentives for scientists and to 
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reduce the workload for consultant histopathologists (Institute of Biomedical 
Science, 2014c).  The report ‘Pathology: towards a competence based 
workforce’ suggested that the skills of expertly qualified and experienced 
scientists could be used more appropriately (Great Britain. Department of 
Health, 2008a).  The most recent development of an extended reporting role 
within histopathology is a three year workplace training scheme for reporting 
gastrointestinal and gynaecological specimens (The Royal College of 
Pathologists, 2013b; van Schalkwyk, n.d.).  These are known high volume 
workloads where a clear role for reporting consultant level healthcare scientists 
has been identified. Working at consultant level is linked to attainment of a 
professional doctorate qualification in accordance with the Modernising 
Scientific Careers (MSC) career and training pathway (Great Britain. 
Department of Health, 2010, p.32).  As of November 2014, there are 47 trainees 
within this programme in the UK - with 38 in the first year, four in the second 
year and five in the third and final year of training (E. Taylor, personal 
communication, October 23, 2014; E. Taylor, personal communication, 
November 25, 2014). 
 
Increasing the evidence base 
After the success of the 2004 biomedical scientist specimen dissection pilot, 
further evidence of good practice began to emerge.  In one article, the quality of 
dissection by scientists was assessed which showed a saving of 16 hours of 
consultant time each month with no reduction in dissection quality (Duthie, 
Nairn, Milne, McTaggart & Topping, 2004).   
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An audit of lymph node harvesting in colorectal cancer by Shaw et al. (2008) 
showed that biomedical scientist lymph node harvesting was more efficient than 
that of consultant histopathologist colleagues, stating that lymph nodes should 
be harvested by a biomedical scientist “for the best chance of accurate staging 
and consequent correct planning of adjuvant treatment and prognosis” (Shaw et 
al., 2008, p.298). 
 
An audit of colorectal lymph node harvesting by Horne, Carr & Walker (2011) 
demonstrated a higher median lymph node harvest by the advanced 
practitioner, with less need to return to specimens for resampling when 
compared to medically-trained colleagues, which in turn minimised any 
reporting delays caused by inadequate primary nodal harvesting.      
 
An audit of the quality of biomedical scientist dissection of colorectal cancer 
specimens by Sanders et al. (2012) showed that performance targets were 
exceeded by the biomedical scientist and compared favourably with the 
performance of histopathologists, with no detrimental effect on quality or safety, 
and therefore patient management.  In keeping with the findings of Duthie et al. 
(2004), consultant cut-up and reporting time savings were identified.  Further 
conclusions from this study were professional advancement for biomedical 
scientists, efficient use of consultant time and the development of a team 
approach to cancer reporting (Sanders et al., 2012).  A letter describing similar 
responses was published in response to this article, in order to further 
strengthen the evidence base (Horne & Green, 2012). 
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An audit by Haynes & Lindley (2012), assessing the quality of the reporting 
duodenal biopsies by a biomedical scientist cut-up practitioner, demonstrated a 
high level of competency comparable to that of a medically qualified 
histopathology trainee with two-three years of experience.   
 
An audit by Horne & Green (2013), assessing the quality of the reporting of 
colorectal carcinoma resection specimens by an advanced practitioner 
healthcare scientist, demonstrated a high level of concordance with the final 
pathologists’ report, but also indicated areas for future education.  Conclusions 
from the audit were that with appropriate training and education non-medical 
trainees should be considered equal to medical trainees and are an important 
addition to the clinical histopathology team.  With further appropriate training 
and assessment they could also provide a reporting service by developing a 
level of competence and confidence enabling independent practice (Horne & 
Green, 2013). 
 
Medical dominance 
Despite national recommendations and guidance (Institute of Biomedical 
Science, 2014c; Institute of Biomedical Science, 2014d; Great Britain. 
Department of Health, 2008a; Great Britain. Department of Health, 2008b; The 
Royal College of Pathologists, 2007; Great Britain. Department of Health, 2006; 
Great Britain. Department of Health, 2004; Joint RCPath/IBMS Working Group, 
2004; Great Britain. Department of Health, 2000; van Schalkwyk, n.d.) and an 
increasing evidence base (Horne & Green, 2013; Haynes & Lindley, 2012; 
Sanders et al., 2012; Horne et al., 2011; Duthie et al., 2004) the driving force 
52 
 
within histopathology continues to be the medical workforce, who have 
professional power, dominating clinical roles, education, publication and 
dissemination.  There remains a clear hierarchical structure, with major 
decisions made by consultant staff, often in an autocratic manner.  Willis (1989, 
p. 202) argues that gender and class relations of wider society are reproduced 
within the social organisation of health care and represented by domination and 
subordination leading to a clear hierarchy.  Directly associated with this is the 
distinction between the technical division of labour, denoting occupational 
position, and the amount of medical knowledge held (Willis, 1989, p. 202).  
Willis describes how hierarchal health care structures developed prior to the 
development of scientific medicine, which itself only strengthened and extended 
the hierarchy further as historically, medical staff have had control over scientific 
knowledge (Willis, 1989, p. 202).  To control their dominance, medical doctors 
have depended upon statutory registration legislation of their own profession, 
with statutory control over the occupational territories of other health 
occupations (Willis, 1989, p. 202).  Willis (1989, p. 202) argues that as a result 
“competitors have been subordinated, limited or excluded so as to maintain the 
dominant structural position of medicine through the patronage of the state, 
mainly in the form of licensing regulation which reproduce medical dominance”.   
 
This medical dominance explains the historical hierarchy within histopathology, 
with a clear division between medical staff (histopathologists) and technical staff 
(medical laboratory technicians).  The development of scientists, with an 
associated level of education, knowledge and aspirations has occurred within 
other pathology disciplines via the development of clinical scientists and 
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associated RCPath consultant level qualifications (The Royal College of 
Pathologists, n.d.); however this has failed to happen in histopathology.  
Instead, there has been a splintering of staff into ‘medical’ and 
‘scientific/technical’ groups with resulting inability to challenge medical 
dominance.  In reality there are now three groups within histopathology – 
‘medical’, ‘scientific’ and ‘technical/support’.  The education, knowledge and 
skills of these groups are becoming increasingly clearly defined; however the 
hierarchical structure of two groups remains, with dominance of medical staff 
and persisting subordination of scientific and technical/support staff.    
 
The establishment of extended roles for non-medically trained professionals in 
histopathology is less developed than for other professional groups, most 
notably nurses.  There are a number of case studies within other fields which 
have demonstrated how “the creation of new roles commonly threatens the 
power and status of elite professionals through the substitution of their labour” 
(Currie, Lockett, Finn, Martin & Waring, 2012).  A 2012 article by Currie et al. 
which reviewed 11 NHS case studies where new nursing or medical roles were 
introduced threatening the power and status of consultants, showed that they 
firstly tried to undermine the threat by delegating routine tasks in order to 
maintain existing resources and control service delivery to maintain their 
position, and secondly co-opted other elite powerful professionals from outside 
their group to engage in the work in order to maintain existing arrangements 
(Currie et al., 2012).  Willis (1989, p. 203) argues how occupations competing 
for medicine’s core activities of diagnosis and prescription are likely to 
experience the most opposition.  This may explain the divisions within 
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histopathology where the work is clearly defined into two groups - preparative 
and diagnostic.  The reasons for a lack of challenge to medical dominance 
within this field are because the core work of medical staff is to diagnose the 
pathology of samples prepared for them by scientific or technical/support staff.   
 
1.3.3 SUMMARY 
In summary, colorectal cancer is a burden, with 1.36 million new cases 
diagnosed worldwide in 2012 (World Cancer Research Fund International, 
2013), and the figure expected to reach 2.4 million by 2035 (World Cancer 
Research Fund International, 2013).  In the UK 30.2 cases per 100,000 people 
were diagnosed in 2012 (International Agency for Research on Cancer, 2014b), 
and it is the third most common cancer in the UK, after breast and lung in both 
men and women separately (Cancer Research UK, 2014o).  Colorectal cancer 
has known molecular pathways but is also known to be related to diet, obesity, 
lack of physical activity and smoking (World Health Organization, 2007).  In 
2003 18.6 people per 100,000 died from colorectal cancer in the UK, but since 
then mortality rates have been in decline (Cancer Research UK, 2014p).  This 
may be due to a combination of improved diagnostics and treatments (De 
Roock et al., 2010), government preventative lifestyle campaigns and policies 
(Change 4 Life, 2013; Great Britain. Department of Health, 2013b; Great Britain. 
Department of Health, 2013d; NHS, 2012; Great Britain. Department of Health, 
2011b; NHS Choices, n.d.) and the introduction of bowel screening in 2006 
which offers biennial FOBt screening to people aged 60-69 in England (NHS 
Cancer Screening Programmes, 2014a).  In the approximate two percent of 
people who have a positive FOBt, second-line colonoscopy is offered.  Earlier 
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detection of these lesions is leading to the removal of a greater number of pre-
invasive dysplastic polyps and early cancers (Great Britain. Department of 
Health, 2013e; Logan et al., 2012).   
 
The social causes of colorectal cancer place a large cost burden onto the NHS 
and therefore the government has sought to improve the overall health of the 
nation, in order to reduce acute and chronic costs to the health service.  
Although this appears to be beneficial, it actually places a greater burden as 
people are surviving longer, but with complex morbidities (Great Britain. 
Department of Health, 2012; Office for National Statistics, 2011).  The model of 
service delivery must therefore be reformed, and as there is no additional 
funding to develop new services (Appleby, 2012) the NHS must redevelop its 
available resources to meet current and future workload demands (The Kings 
Fund, 2012).  As a result of this, opportunities for extended and more 
appropriate job roles for highly educated and skilled, non-medically qualified 
staff are being developed (Great Britain. Department of Health, 2010; Great 
Britain. Department of Health, 2008a; Great Britain. Department of Health, 
2008b; Great Britain. Department of Health, 2006), including within pathology 
with extended dissection and reporting roles for biomedical scientist advanced 
practitioners (The Royal College of Pathologists, 2013b; Joint RCPath/IBMS 
Working Group, 2004; van Schalkwyk, n.d.).  Introduction of these roles has 
been shown to compare favourably with existing working practices, with no 
detrimental effect on quality or safety, and demonstration of improved practice 
in some areas (Horne & Green, 2013; Haynes & Lindley, 2012; Sanders et al., 
2012). 
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The following chapter will identify the research problem which has led to 
development of this thesis.  The current evidence will be assessed, with the gap 
in the literature identified.  The proposed aims and outcomes of the research 
will then be defined.  
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2. LITERATURE REVIEW 
This chapter contains an introduction to the research problem and existing 
methods in place to try and address it.  This is followed by a review of the 
literature published in English regarding the use of manual dissection, further 
fixation and glacial acetic acid, ethanol, water and formalin (GEWF).  The 
review will begin by outlining the search strategy, before critically appraising the 
literature.  The chapter will end with key conclusions, identification of the gap in 
the literature which this thesis will seek to fill and proposed aims and outcomes.      
 
2.1 THE PROBLEM 
 
2.1.1 LYMPH NODE RETRIEVAL 
 
Required numbers of lymph nodes 
The RCPath recommend that all lymph nodes should be identified in colorectal 
cancer “as the number of lymph nodes identified in resection specimens from 
patients with stage II and stage III colon cancer has been positively correlated 
with survival” (The Royal College of Pathologists, 2014, p.11). This is based 
upon the internationally agreed standard of retrieving at least 12 lymph nodes 
for adequate staging (The Royal College of Pathologists, 2014; Washington, 
2008). 
 
Just one nodal tumour deposit upstages the malignancy from pN0 to pN1 (The 
Royal College of Pathologists, 2014).  This is important as node-positive 
patients (pN1) are considered for adjuvant chemotherapy whereas node 
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negative patients (pN0) usually are not, unless they have other high risk 
features (Sommariva et al., 2010).  The requirement for at least 12 lymph nodes 
is based on evidence demonstrating the prognostic significance of lymph node 
retrieval (Tsai et al., 2007; Wong et al., 2007; Chen & Bilchik, 2006) as the 
presence of nodal metastases is the most important prognostic factor overall 
when determining long-term survival (Chen & Bilchik, 2006).  Some literature 
suggests that more lymph nodes should be retrieved for adequate staging (Tsai 
et al., 2007), but 12 is the current consensus (The Royal College of 
Pathologists, 2014).  The problem occurs when inadequate numbers of lymph 
nodes are retrieved, which may occur for a number of reasons (Jakub, Russell, 
Tillman & Lariscy, 2009).   
 
Factors known to affect lymph node retrieval 
The following factors are thought to affect lymph node retrieval: fixation; 
neoadjuvant therapy; anatomy; time; diligence; technique and experience. 
 
Fixation 
Studies have shown that extended fixation of adipose tissue allows retrieval of 
further and smaller lymph nodes which may harbour micrometastases (Lindboe, 
2011; Van Steenbergen, van Lijnschoten, Rutten, Lemmens & Coebergh, 
2009). 
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Neoadjuvant therapy and anatomy 
There is a known paucity of lymph nodes in specimens where patients have 
received neoadjuvant chemoradiotherapy prior to surgery (Marks et al., 2010; 
Morcos, Baker, Al Masri, Haddad & Hashem, 2010).  Neoadjuvant 
chemoradiotherapy is given to patients with rectal cancer as either a long or 
short course in an attempt to either shrink the tumour or prevent local 
recurrence respectively (The Association of Coloproctology of Great Britain and 
Ireland, 2007).  In a 2010 study, Morcos et al. suggest that it is the radiotherapy 
component of the treatment which has the greatest effect on lymph node size, 
exerting its effects to reduce the yield within a few weeks of therapy.  There is 
also a known paucity of lymph nodes within the mesorectum, in comparison to 
more proximal anatomical areas of the colon, e.g. the caecum (Bernhoff et al.,  
2012; McDonald, Renehan, O’Dwyer & Haboubi, 2012; El-Gazzaz, Hull, 
Hammel & Geisler, 2010; Lemmens et al., 2006; Baxter et al., 2005).  For these 
reasons it is more common to see inadequate lymph node retrieval in these 
specimens, with some authors suggesting that the target of 12 lymph nodes 
may be unrealistic (Miller, Robb, Cummings & Johnstone, 2012; Marks et al., 
2010).  
 
Time, diligence, technique and experience 
It has also been shown that the degree of diligence and technique used by the 
histopathologist can influence lymph node assessment (Scabini & Ferrando, 
2012; Lemmens et al., 2006), whilst an inexperienced dissector is more likely to 
miss smaller lymph nodes (Sanders et al., 2012; Horne et al., 2011). 
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2.1.2 INADEQUATE LYMPH NODE RETRIEVAL 
Inadequate lymph node retrieval may occur due to any of the above reasons.  
The Royal College of Pathologists (2014) comment that the numbers of lymph 
nodes retrieved from a resection specimen may be related to factors such as 
the extent of resection or neoadjuvant therapy - however pathological 
examination of the specimen is likely to be the most important factor.  There is a 
risk of understaging (as pN0/stage I-II) if lymph node harvesting is sub-optimal 
and not enough nodes are identified (Choi, Law & Poon, 2010).  Understanding 
the importance of pathological examination, the RCPath therefore recommend 
that “resections should be allowed to fix for a minimum of 24-48 hours before 
further dissection and block taking; this facilitates subsequent thin transverse 
slicing through the tumour and the identification of lymph nodes” (The Royal 
College of Pathologists, 2014, p.10).  
 
2.1.3 TECHNIQUES FOR SECONDARY LYMPH NODE RETRIEVAL  
Locally the 2014 guidelines set out by the RCPath are adhered to (The Royal 
College of Pathologists, 2014); although there are occasions where inadequate 
numbers of lymph nodes are retrieved.  This is usually due to poor technique, 
inexperience, inadequate fixation or the use of neoadjuvant therapy (Horne et 
al., 2011).  A number of adjunct preparatory techniques have been described in 
the literature in order to facilitate improved lymph node retrieval.  These involve 
the use of lymph node revealing solutions or dyes and sentinel lymph node 
mapping, which are summarised with examples in Table 2.1. 
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Table 2.1.  Adjunct preparatory techniques used to facilitate improved 
lymph node retrieval. 
 
Lymph node revealing solutions 
 
Dyes and sentinel lymph node mapping 
Acetone (Vogel, Kirtil, Oellig & Stolte, 2008) Methylene blue (Märkl et al., 2008) 
Acetone/isopropyl alcohol & 
wintergreen/cedarwood oil (Hyder, Tablott & 
Maycroft, 1990) 
Near-infrared fluorescence imaging 
(Schaafsma et al., 2013) 
Acetone and xylene (Schmitz-Moorman, 
Thomas, Pohl & Söhl, 1982) 
 
Acetone, alcohol and xylene (Hida et al., 
1994) 
 
Alcohol (Wang, Safar, Wexner, Denoya & 
Berho, 2009) 
 
Alcohol and xylene (Jass, Miller & Northover, 
1986) 
 
GEWF (Gregurek & Wu, 2009)   
Xylene (Cohen, Wexner, Schmitt, Nogueras & 
Lucas, 1994) 
 
 
Standard local practice is to return to the residual specimen, which is stored in 
formalin (where it will continue to fix) and perform a repeat, or secondary lymph 
node harvest.  If the specimen has been initially handled by an inexperienced 
dissector then somebody with more experience may perform the secondary 
dissection, e.g. consultant histopathologist or advanced practitioner healthcare 
scientist.  This may be done either in isolation, or preferably with the less 
experienced person present in order to provide further training and advice for 
improving practice. 
 
Occasionally, when the target of 12 lymph nodes still fails to be met after 
secondary lymph node harvest, the total number and size of lymph nodes 
retrieved is given in the final histopathology report, with comment made on 
possible reasons for the inadequate harvest. 
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In addition to national guidelines (The Royal College of Pathologists, 2014), 
there is a growing body of evidence suggesting that the use of adjunct 
preparatory techniques may facilitate adequate lymph node retrieval in 
colorectal cancer specimens, especially in cases where there is a paucity of 
lymph nodes (see Table 2.1).  Locally, there has been some previous 
experience with the ad hoc use of lymph node retrieval solutions in difficult 
cases.  The ex-vivo use of dyes and sentinel lymph node mapping has not been 
considered as part of this thesis because it appears to be a more complicated 
and time-costly technique (Schaafsma et al., 2013). 
 
The following section comprises a literature review, assessing the current 
evidence relating to the use of lymph node retrieval solutions.   
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2.2 REVIEW OF CURRENT EVIDENCE 
 
2.2.1 DATA COLLECTION 
Searches of medical and scientific databases were performed to identify all of 
the literature published in English on the use of further fixation and GEWF on 
colorectal cancer specimens, in relation to lymph node harvest. 
 
Inclusion criteria were: 
 
 
 
 
 
 
Initial exclusion criteria were: 
 
 
 
 
Table 2.2 shows the databases searched, the search terms and strategies 
used, with both initial and relevant results generated. 
 
 
 
 
 Studies not related to colorectal cancer – as this thesis will focus on 
this specific field only. 
 
 Studies related to other adjunct techniques – as this thesis will focus 
on GEWF only. 
 Studies written in the English language. 
 
 Studies related to further fixation and colorectal cancer – to assess 
the literature related to the control group in this thesis. 
 
 Studies related to the use of GEWF or acetic acid and colorectal 
cancer – to assess the literature related to the intervention group in 
this thesis. 
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Table 2.2. Search strategy and results. 
 
Database 
 
Search terms Boolean 
operator 
No. of 
results 
No. of 
relevant 
results 
 
Medline® 
 
“colon cancer” OR “colorectal cancer” OR “rectal 
cancer” 
“fixation” OR “further fixation” 
 
“colon cancer” OR “colorectal cancer” OR “rectal 
cancer” 
GEWF 
 
AND 
 
 
 
AND 
 
 
364 
 
 
 
4 
 
 
5 
 
 
 
4 
 Related citations – new articles   4 
Medline® 
MeSH 
 
“colon neoplasms” OR “colorectal neoplasms” 
OR “sigmoid neoplasms” OR “rectal neoplasms” 
“tissue fixation” 
 
“colon neoplasms” OR “colorectal neoplasms” 
OR “sigmoid neoplasms” OR “rectal neoplasms” 
“acetic acid” 
 
AND 
 
 
 
AND 
 
 
 
90 
 
 
 
58 
 
 
5 
 
 
 
5 
CINAHL 
PlusMeSH 
 
“colonic neoplasms” OR “colorectal neoplasms” 
OR “rectal neoplasms” 
“tissue fixation” OR “GEWF” 
 
“tissue fixation” 
 
“GEWF” 
 
AND 
 
 
 
 
 
0 
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1 
 
 
0 
 
1 
 
1 
Google 
Scholar 
 
“colon cancer” OR “colorectal cancer” OR “rectal 
cancer” 
“further fixation” 
 
“colon cancer” OR “colorectal cancer” OR “rectal 
cancer” 
“GEWF” 
 
“colon cancer” OR “colorectal cancer” OR “rectal 
cancer” 
“lymph node retrieval solution” OR “lymph node 
revealing solution” 
 
AND 
 
 
 
AND 
 
 
 
AND 
 
 
57 
 
 
 
59 
 
 
 
116 
 
 
0 
 
 
 
8 
 
 
 
0 
 
Google 
 
 
“colon cancer” OR “colorectal cancer” OR “rectal 
cancer” 
“further fixation” 
 
“colon cancer” OR “colorectal cancer” OR “rectal 
cancer” 
“GEWF” 
 
“colon cancer” OR “colorectal cancer” OR “rectal 
cancer” 
“lymph node retrieval solution” OR “lymph node 
revealing solution” 
 
AND 
 
 
 
AND 
 
 
 
AND 
 
 
800 
 
 
 
2420 
 
 
 
183 
 
 
0 
 
 
 
0 
 
 
 
1 
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Table 2 demonstrates how the basic Medline® search using terms for colorectal 
cancer and further fixation found 364 articles.  Of these, only five met the 
inclusion criteria (Lindboe, 2011; Gregurek & Wu, 2009; Kelder et al., 2008; 
Švec, Horák, Novotný & Lysy, 2006; Newell, Sawka, Rudrick & Driman, 2001).  
Four articles meeting the inclusion criteria were identified relating to colorectal 
cancer and GEWF (Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; 
Newell et al., 2001).   
 
The Medline® MeSH search using the headings colorectal, colonic, sigmoid or 
rectal neoplasms and tissue fixation found 90 articles.  Of these, five met the 
inclusion criteria (Lindboe, 2011; Gregurek & Wu, 2009; Kelder et al., 2008; 
Švec et al., 2006; Newell et al., 2001).  There was no heading for GEWF, and 
so a key constituent of it, acetic acid, was searched instead.  This found 58 
articles, of which five met the inclusion criteria (Lindboe, 2011; Gregurek & Wu, 
2009; Švec et al., 2006; Newell et al., 2001; Koren et al., 1997).  
 
The CINAHL PlusMeSH search using the headings “colorectal neoplasms” 
“colonic neoplasms” or “rectal neoplasms” with “tissue fixation” or “GEWF” 
found no articles which met the inclusion criteria.  Searching for “tissue fixation” 
as a lone term found 61 articles, of which only one met the inclusion criteria 
(Gregurek & Wu, 2009).  A lone term search for “GEWF” also only identified the 
article by Gregurek & Wu (2009). 
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Google Scholar identified 43 articles in relation to further fixation of colorectal 
specimens, but none of these met the inclusion criteria.  31 articles were 
identified in relation to GEWF, with eight meeting the inclusion criteria (Tasi, 
Chen, Liu & Wu, 2012; Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; 
Iversen, Laurberg, Hagemann-Madsen & Dybdahl, 2008; Kelder et al., 2008; 
Švec et al., 2006; Newell et al., 2001). 
 
A search of Google and related citations within Medline® for each article 
identified two further articles which met the inclusion criteria (Saleki & Haeri, 
2002; Ustün, Őnal, Tuğyan & Rezanko, 1999). 
 
Each of the selected articles was either downloaded as a Portable Document 
Format (PDF) and printed, or photocopied within the local Medical School 
library.  Each article was read in full to ensure relevance.  
 
Although it initially met the inclusion criteria, the case control study by Ustün et 
al. (1999) was excluded from the literature review due to design bias which 
made the results impossible to interpret.  In this study the effects of GEWF were 
studied on colon, breast and bladder resections.  No specific results were 
presented for the colonic specimens, and those results which were presented 
were combined for all specimen types which made the results unclear.  This 
also introduced selection bias because these specimens were too variable to be 
compared, i.e. they failed to consider whether the numbers of retrievable 
perivesical lymph nodes available would be similar to those in the mesocolon or 
mesorectum.  For results to be valid each specimen type should have been 
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evaluated separately or they should have used stratified study groups.  For 
these reasons the article was excluded.    
Final exclusion criteria were: 
 
 
 
 
 
 
Table 2.3 summarises the studies included within this literature review. 
 
 Studies not related to colorectal cancer – as this thesis will focus on 
this specific field only 
 
 Studies related to other adjunct techniques – as this thesis will focus 
on GEWF only 
 
 Studies related to cancers from numerous specimen types, including 
the colorectum – as this thesis will focus on colorectal cancer 
specimens only 
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Table 2.3.  Summary of studies. 
 
Author, year 
 
Country of origin Adjunct 
technique 
Study design Sample size Time in adjunct 
solution (hrs) 
Number of 
cases manually 
dissected 
Number of 
cases in 
intervention 
 
Koren et al., 1997 Israel GEWF Diagnostic test study 30a and then b 6 30 30 
Newell et al., 2001 Canada GEWF Case control study 32a + 35b 12-18 32 35 
Saleki and Haeri, 2002 Iran GEWF Diagnostic test study 35a and then b 6 35 35 
Švec et al., 2006 Czech Republic GEWF Case control study 34a + 59b 24 34 59 
Iversen et al., 2008 Denmark GEWF Randomised controlled trial 59a + 61b 16-48 59 61 
Kelder et al., 2008 The Netherlands GEWF Case control study 117a + 125b - 117 125 
Gregurek & Wu, 2009 United States GEWF Case control study 40a + 45b 24 40 45 
Lindboe, 2011 Norway Formalin/GEWF 
GEWF 
Diagnostic test study 
Diagnostic test study 
c8a and then b 
d423b 
24 
48 
8 
- 
8 
423 
Storli et al., 2011 Norway GEWF Case control study 204a + 217b 48 76 62 
Tasi et al., 2012 Taiwan GEWF Diagnostic test study 8a and then b 18 8 8 
amanual dissection; bGEWF; cpilot study 2007; dmain study 2008-2010. 
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2.2.2 DATA ANALYSIS 
Articles were appraised using the appropriate Critical Appraisal Skills 
Programme (CASP) checklist for diagnostic test studies, case control studies or 
randomised controlled trials, as defined in Table 2.3. (Critical Appraisal Skills 
Programme, 2010a; Critical Appraisal Skills Programme, 2010b; Critical 
Appraisal Skills Programme, 2010c).  No studies were excluded during the 
screening or full evaluation process.  A list of 16 questions was also prepared 
(see Table 2.4) and results of these were collated for each article and used to 
generate more detailed summary of studies tables (Tables 2.8, 2.10 and 2.11).  
 
Table 2.4.  Questions asked to generate data for summary of studies 
tables. 
 
Number 
 
Question 
1 Time taken to perform lymph node retrieval after intervention? 
2 Number of cases manually dissected? 
3 Mean number of lymph nodes identified by manual dissection? 
4 Number of cases in GEWF? 
5 Mean number of additional lymph nodes after intervention? 
6 Statistically significant difference in lymph node numbers after intervention? 
7 Metastatic incidence after manual dissection? 
8 Metastatic incidence after intervention? 
9 Lymph node size after manual dissection? 
10 Lymph node size after intervention? 
11 Statistically significant difference in lymph node size after intervention? 
12 Upstaging after intervention? 
13 Statistically significant upstaging after intervention? 
14 Number of metastatic lymph nodes after manual dissection? 
15 Number of metastatic lymph nodes after intervention? 
16 Statistically significant difference in number of metastatic lymph nodes after 
intervention? 
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2.3 RESULTS 
Only one study discussing the use of further fixation to improve the lymph node 
harvest in colorectal cancer was identified within the literature (Lindboe, 2011).  
Ten studies discussing the use of GEWF in colorectal cancer to improve the 
lymph node harvest were identified within the literature (Tasi et al., 2012; 
Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; Iversen et al., 2008; 
Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001; 
Koren et al., 1997).  These have been published in the last 15 years, with Koren 
et al. (1997) the first to describe its use (see Table 2.3).  
 
 
2.3.1 NUMBER OF LYMPH NODES HARVESTED 
Table 2.5 summarises the number of lymph nodes harvested within each study, 
with any associated statistical significance.  Consideration of the quality of 
underlying manual dissection practice in terms of achieving targets is also 
summarised. 
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Table 2.5.  Number of lymph nodes harvested. 
 
Author, year 
 
Mean number 
of nodes after 
manual 
dissection 
Mean 
number of 
nodes after 
intervention 
Statistically 
significant 
difference in 
number of nodes                               
(p value) 
 
Achieving 
national 
targets with 
manual 
dissection 
Koren et al., 1997 2.94 8.6a - No 
Newell et al., 2001 6.8 10.2 Yes (0.002)b No 
Saleki and Haeri, 2002 6.26 13.0a - No 
Švec et al., 2006 5.9 14.7 Yes (0.05)b No 
Iversen et al., 2008 9.5 16.5 Yes (<0.001)b No 
Kelder et al., 2008 5.0 13.0 Yes (<0.001)b No 
Gregurek and Wu, 2009 18.3 19.96 No (0.53)b Yes 
Lindboe, 2011c 
Lindboe, 2011d 
Lindboe, 2011e 
11.4 
11.4 
- 
5.9a 
6.0f 
16.8 
- 
- 
- 
No 
Storli et al., 2011 10.98g 15.61g Yes (<0.01) No 
Tasi et al., 2012 7.6 4.7a Yes (<0.05) No 
aadditional lymph nodes; bsignificance = p ≤0.005; cpilot study - further fixation; dpilot study – 
GEWF; emain study – GEWF; fthird dissection; gthree sites with differing interventions 
 
 
All but one of the studies found an increase in the number of lymph nodes 
harvested after the use of GEWF in comparison to manual dissection after 
standard fixation (Tasi et al., 2012; Lindboe, 2011; Gregurek & Wu, 2009; 
Iversen et al., 2008; Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; 
Newell et al., 2001; Koren et al., 1997).  Five studies attributed statistical 
significance to these findings (Tasi et al., 2012; Iversen et al., 2008; Kelder et 
al., 2008; Švec et al., 2006; Newell et al., 2001), whilst one stated that there 
was no statistical significance (p=0.53) (Gregurek & Wu, 2009).   In four studies 
this was not assessed as no statistical analysis was performed.  Storli et al. 
(2011) did describe a statistically significant increase in mean lymph nodes 
(10.98 to 15.61; p<0.01); however their results were not solely related to the 
use of further fixation or GEWF and were based on the comparison of two 
cohorts of specimens at different hospitals, investigated seven years apart from 
each other.  
 
72 
 
They compared the use of GEWF, but also the endeavour to improve lymph 
node sampling by pathologists.  As there are no specific results relating solely 
to GEWF, its potential statistical significance is not considered here.   
 
None of the studies found a decrease in the average number of lymph nodes 
harvested after GEWF was used (Tasi et al., 2012; Lindboe, 2011; Storli et al., 
2011; Gregurek & Wu, 2009; Iversen et al., 2008 Kelder et al., 2008; Švec et al., 
2006; Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 1997). 
 
All authors except for Koren et al. (1997) stated a recommended minimum 
lymph node harvest target as 12.  This was based on guidelines from the 
Committee of the College of American Pathologists (Tasi et al., 2012; Saleki & 
Haeri, 2002; Newell et al., 2001), the UICC TNM classification of malignant 
tumours (Kelder et al., 2008; Švec et al., 2006) and the United States National 
Cancer Institute (Lindboe, 2011, Storli et al., 2011; Gregurek & Wu, 2009).  
Iversen stated 12 as their target, but failed to identify a reference.  Only 
Gregurek & Wu (2009) achieved this target at manual dissection, finding a 
mean of 18.3 lymph nodes per case.  This suggests that there was an 
underlying problem with primary manual dissection, which would have 
introduced immediate bias into the results of many of the studies.  This theory is 
supported by Denham, Kerstetter & Hermann (2012, p. 349) who stated that 
“only 36-41% of hospitals are routinely attaining the minimum 12 lymph node 
recommendations”.  Although these findings are of concern, it is important to 
note that they are only based on data from a number of US and Canadian 
institutions, and European or worldwide variation is not considered. 
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2.3.2 LYMPH NODE SIZE 
Table 2.6 summarises the size of lymph nodes measured after manual 
dissection and intervention, with any associated statistical significance. 
 
Table 2.6.  Lymph node size. 
 
Author, year 
 
Node size after 
manual 
dissection (mm) 
 
Node size after 
intervention 
(mm) 
Statistically significant 
difference in node size  
(p value) 
Koren et al., 1997 - 0.5-7.0 - 
Newell et al., 2001 7.0a 5.0a Yes (0.046)b 
Saleki and Haeri, 2002 0.429 
0.568a 
0.268 
0.35a 
Yes (<0.0000001)b 
Yes (0.00572)a,b 
Švec et al., 2006 - - - 
Iversen et al., 2008 - - - 
Kelder et al., 2008 6.0c 
9.0a 
4.0c 
6.0a 
Yes (<0.001)b 
Yes (<0.001)b 
Gregurek and Wu, 2009 - - - 
Lindboe, 2011d 
Lindboe, 2011e 
Lindboe, 2011f 
4.3 
4.3 
- 
3.8 
2.5 
- 
- 
- 
- 
Storli et al., 2011 - - - 
Tasi et al., 2012 2.6 2.1 No (>0.11) 
ametastatic lymph node; bsignificance = p ≤0.005; cadditional lymph nodes;  
dpilot study - further fixation; epilot study – GEWF; fmain study – GEWF.    
   
 
Five studies found the average size of lymph nodes to be smaller after the use 
of GEWF (Tasi et al., 2012; Lindboe, 2011; Kelder et al., 2008; Saleki & Haeri, 
2002; Newell et al., 2001).  Only Tasi et al. (2012) failed to attribute statistical 
significance to this finding (p>0.11).  Newell et al. (2001) and Kelder et al. 
(2008) only assessed the mean size of metastatic lymph nodes, finding them to 
be significantly smaller after the use of GEWF.  Newell et al. (2001), Saleki and 
Haeri (2002) and Kelder et al. (2008) found the average size of lymph nodes to 
be smaller, both generally and also in metastatic lymph nodes.  Lindboe (2011) 
found the average size of lymph nodes harvested to be smaller after further 
fixation, and then to be even smaller after treatment with GEWF.  The 
importance of adequate fixation of colorectal cancer specimens to facilitate 
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adequate lymph node harvesting has been stressed (van Steenbergen et al., 
2009; Burroughs & Williams, 2000: Poller, 2000), however the effect on lymph 
node size was not discussed.  It is likely that smaller lymph nodes will be 
harvested after further fixation and a subsequent secondary dissection for two 
reasons.  Firstly, disruption of the fat by initial dissection will facilitate improved 
penetration of the tissues by the fixative; secondly, the larger lymph nodes will 
have already been identified in the initial primary dissection, only leaving any 
smaller lymph nodes to be found at secondary dissection. 
 
Gregurek and Wu (2009), Kelder et al. (2008) and Newell et al. (2001) attributed 
the ability to identify smaller nodes with GEWF to the tan/white colour of the 
lymph node within the yellow fat which facilitated detection.  For example, 
Kelder et al. (2008) found five micrometastases (5.9%) with manual dissection, 
but after GEWF there were 18 micrometastases (14.2%) and two isolated 
tumour cells (1.6%).  
 
2.3.3 METASTATIC INCIDENCE  
Metastatic incidence is the number of metastatic lymph nodes divided by the 
total number of dissected lymph nodes (Saleki & Haeri, 2002).   
 
The majority of studies either did not calculate metastatic incidence or had 
findings that were unclear (Tasi et al., 2012; Lindboe, 2011; Storli et al., 2011; 
Gregurek & Wu, 2009; Iversen et al., 2008; Kelder et al., 2008; Švec et al., 
2006; Newell et al., 2001; Koren et al., 1997).   
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Only one study identified a statistically significant decrease in metastatic 
incidence after GEWF (p=0.023) (Saleki & Haeri, 2002), explaining that it was 
due to the larger number of lymph nodes dissected after the use of GEWF.   
 
Gregurek and Wu (2009), Kelder et al. (2008) and Koren et al. (1997) described 
an increase in the number of metastatic lymph nodes after treatment with 
GEWF, but did not calculate the metastatic incidence.  Gregurek and Wu (2009) 
claimed that their findings were not statistically significant (p = 0.19).  Newell et 
al. (2001) described an increased number of metastatic lymph nodes in the 
group treated with GEWF, but did not calculate the metastatic incidence either. 
 
Iversen et al. (2008) described a small decrease in the number of metastatic 
lymph nodes in the groups treated with GEWF.  They did not calculate the 
metastatic incidence but did comment that their study was underpowered to test 
this specific outcome (Iversen et al., 2008).  Lindboe (2011) noted that a slightly 
lower proportion of cases contained metastases in 2008-2010 in comparison to 
1995-2006 (39.0% vs 42.6%) but explained that this was most likely due to 
earlier diagnosis today due to “attention to clinical symptoms of the disease and 
the liberal use of colonoscopy.” (Lindboe, 2011, pp.352-353).   
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2.3.4 PROGNOSTIC FACTORS 
 
Upstaging 
Table 2.7 summarises upstaging with associated statistical significance. 
 
Table 2.7.  Upstaging. 
 
Author, year Upstaging after intervention  
 
Statistically significant 
upstaging (p value) 
 
Koren et al., 1997 Yes (8/30) - 
Newell et al., 2001 - - 
Saleki and Haeri, 2002 Yes (3/35) - 
Švec et al., 2006 - - 
Iversen et al., 2008 - - 
Kelder et al., 2008 - - 
Gregurek and Wu, 2009 - - 
Lindboe, 2011a 
Lindboe, 2011b 
Lindboe, 2011c 
No 
No 
- 
- 
- 
- 
Storli et al., 2011 - - 
Tasi et al., 2012 - - 
apilot study - further fixation; bpilot study – GEWF; cmain study – GEWF. 
 
Koren et al. (1997) and Saleki and Haeri (2002) reported upstaging after the 
application of GEWF.  In both cases, adjuvant therapy was prompted.  Koren et 
al. (1997) found upstaging in eight cases whilst Saleki and Haeri (2002) found 
upstaging in three cases.  A number of authors did not comment on upstaging, 
but this was mainly because the control and intervention groups were different 
and so it was not appropriate to do so (Tasi et al., 2012; Lindboe, 2011; Storli et 
al., 2011; Gregurek & Wu, 2009; Kelder et al., 2008; Iversen et al., 2008; Newell 
et al., 2001). 
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2.4 DISCUSSION 
This section seeks to critically appraise the literature and identify a gap in 
evidence which this thesis will fill. 
 
2.4.1 PROCESS VARIATION 
There is a gap in the literature with regard to the use of GEWF for a number of 
reasons.  Firstly, relatively few studies exist; secondly, there are no UK studies; 
and thirdly, the existing studies all have design flaws with confounding factors, 
leading to the introduction of bias and potential invalidation of any conclusions 
(Tasi et al., 2012; Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; 
Iversen et al., 2008; Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; 
Newell et al., 2001; Koren et al., 1997).  Hartman, Forsen, Wallace and Neely 
(2002) described the main types of scientific bias as publication bias 
(researching the topic), selection bias (susceptibility bias), exposure bias 
(performance bias), detection bias (measurement bias), analysis bias (transfer 
bias) and interpretation bias.  Examples of these types of bias can be found in 
Appendix B.  
 
Selection bias 
Table 2.8 summarises how the studies were exposed to selection bias.  The 
different types of selection bias are then discussed in further depth. 
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Table 2.8.  Summary of studies - exposure of the studies to selection bias.  
 
Author, year 
 
Selection bias 
 
 
Inclusion 
criteria 
clear? 
Exclusion 
criteria 
clear? 
Power 
calculation? 
Randomisation 
used? 
Balanced 
study 
groups? 
Comparable 
study 
groups? 
Comparable 
study 
period? 
All 
confounders 
considered? 
 
Koren et al., 1997 Yes Yes No No - - - No 
Newell et al., 2001 Yes No No No Yes Yes Yes No 
Saleki and Haeri, 2002 Yes Yes No No - - - No 
Švec et al., 2006 Yes No No No No Yes No Yes 
Iversen et al., 2008 Yes No Yes Yes Yes Yes Yes No 
Kelder et al., 2008 Yes Yes No No Yes Yes - No 
Gregurek and Wu, 2009 Yes No No No Yes Yes Yes No 
Lindboe, 2011a 
Lindboe, 2011b 
Yes 
Yes 
No 
No 
No 
No 
No 
No 
- 
- 
- 
- 
- 
- 
No 
No 
Storli et al., 2011 Yes Yes No No Yes Yes No No 
Tasi et al., 2012 Yes Yes No No - - - No 
apilot study; bmain study. 
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Inclusion and exclusion criteria 
All authors provided clear inclusion criteria (Tasi et al., 2012; Lindboe, 2011; 
Storli et al., 2011; Gregurek & Wu, 2009; Iversen et al., 2008; Kelder et al., 
2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 
1997).  Importantly, a number of authors also gave clear exclusion criteria such 
as excluding patients who were found to have three or more metastatic lymph 
nodes at manual dissection (Saleki & Haeri, 2002; Koren et al., 1997) or known 
distant metastatic disease (Kelder et al., 2008).  Inclusion and exclusion criteria 
are summarised below in Table 2.9. 
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Table 2.9.  Inclusion and exclusion criteria in existing studies. 
 
Author, year Inclusion Exclusion 
 
Koren et al., 1997 Colonic resections for 
adenocarcinoma 
<10 lymph nodes harvested at 
manual dissection 
<3 metastatic lymph nodes 
≥10 lymph nodes harvested at 
manual dissection  
≥3 metastatic lymph nodes 
harvested at manual dissection 
Newell et al., 2001 Colorectal resections for 
adenocarcinoma 
- 
Saleki and Haeri, 2002 Colorectal resections for 
colorectal cancer 
<12 lymph nodes harvested at 
manual dissection 
Clinical M0 status 
≥12 lymph nodes harvested at 
manual dissection 
≥4 metastatic lymph nodes 
harvested at manual dissection 
Non-adenocarcinoma 
Švec et al., 2006 AR or AP resection with total 
mesorectal excision for 
colorectal cancer 
Higher colonic tumours 
Iversen et al., 2008 Colorectal resections for 
colorectal cancer 
- 
Kelder et al., 2008 Colonic resections for colorectal 
cancer 
Distant metastatic disease 
Adenomas or polyps 
Rectal cancer 
Previous colorectal surgery 
Gregurek and Wu, 2009 Colorectal resections for 
colorectal cancer 
- 
Lindboe, 2011 Colonic resections for colorectal 
cancera 
Colorectal resections for 
colorectal cancerb 
Rectal specimensa 
-b 
Storli et al., 2011 Colonic resections for stage II 
or III colorectal cancerc 
Stage I or IV tumoursc 
Double resection 
Subtotal colectomy 
Rectal specimens 
Tasi et al., 2012 Colorectal resections for 
colorectal cancer 
≤12 lymph nodes harvested at 
manual dissection 
Neoadjuvant therapy 
 
apilot study; bmain study; cUnited States ‘stage grouping’ system for colorectal cancer (see 
Appendix C) (American Cancer Society, 2014). 
 
Newell et al. (2001) and Gregurek and Wu (2009) made no exclusions, which 
opened their studies to bias.  For example, by including rectal tumours in their 
studies they failed to account for the known paucity of lymph nodes in this 
region of the colorectum (Baxter et al., 2005; Topor, Acland, Kolodko & 
Galandiuk, 2003), or for the effects of neoadjuvant therapy on this region (Miller 
et al., 2012; Latkauskas et al., 2010).  Iversen et al. (2008) also made no 
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exclusions, but their study was appropriately powered and randomised to 
account for any confounding factors. 
 
Tasi et al. (2012), Lindboe (2011), Storli et al. (2011), Kelder et al. (2008) and 
Koren et al. (1997) excluded rectal specimens from their study.  Kelder et al. 
(2008) and Tasi et al. (2012) excluded rectal specimens due to the known 
effects of neoadjuvant therapy on lymph node harvesting, rather than for purely 
anatomical reasons.  The studies by Storli et al. (2012) and Koren et al. (1997) 
only referred to colonic specimens, making no comment on specific exclusion of 
rectal specimens.  The exclusion of rectal specimens from the 2007 pilot study 
by Lindboe (2011) may have simply been due to chance as only eight 
specimens were entered into it.   
 
Švec et al. (2006) excluded higher colonic specimens from their studies, 
comparing neo-adjuvant and non neoadjuvant cases only.  By excluding higher 
colonic specimens, which may contain more harvestable lymph nodes, Švec et 
al. (2006) sought to ensure that the control and intervention groups in their 
study were matched and that any effects might be due to the use of GEWF 
rather than to natural anatomical variation or the use of neoadjuvant therapy.   
 
Power 
A major design flaw in all but one of these studies was the failure to use a 
power calculation to provide an appropriate sample size (Tasi et al., 2012; 
Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; Kelder et al., 2008; 
Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 1997).  
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Eng (2003, p. 310) defined the importance of a power calculation as follows: “in 
a study comparing two groups of individuals, the power (sensitivity) of a 
statistical test must be sufficient to enable detection of a statistically significant 
difference between the two groups if a difference is truly present”.  It may be 
that these studies are of an appropriate size, however in the absence of an 
appropriate power calculation it remains unclear.  The conclusions from these 
studies may not be reliable as there may not be sufficient power in the results 
for them to be meaningful (Lau & Kuk, 2011).  Only Iversen et al. (2008) used a 
sample size calculation to power their study and account for the bias and 
confounding factors within it.   
 
Randomisation and blinding 
Iversen et al. (2008) also used a randomisation scheme to try and minimise bias 
even further.  Like all other studies they were unable to use blinding (Tasi et al., 
2012; Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; Iversen et al., 
2008; Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 
2001; Koren et al., 1997).  This is because of the distinctive smell and texture of 
GEWF which would make it instantly recognisable (Iversen et al., 2008; Newell 
et al., 2001).  
 
Comparability 
Most of the studies which compared two groups were balanced and matched 
which was a design strength (Storli et al., 2011; Gregurek & Wu, 2009; Kelder 
et al., 2009; Iversen et al., 2008; Newell et al., 2001).  Švec et al. (2006) had 
unbalanced study groups, with 59 and 34 cases in the control and intervention 
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groups respectively.  A higher percentage of cases received neoadjuvant 
therapy in the control group than in the intervention group (66.1% vs 58.8%) 
(Švec et al., 2006).  Both of these factors would immediately introduce bias and 
eliminate any confidence in the results, especially considering the lack of power 
that the study was already subject to.  Both Švec et al. (2006) and Storli et al. 
(2011) were subject to a further design flaw, in that comparison of their groups 
was during a different time period where it would be difficult to prove whether 
personnel, practices and the levels of experience were the same.   Švec et al. 
(2006) examined the control cohort between 2000 and 2002, whilst the study 
cohort was examined between 2003 and 2005.  Storli et al. (2011) left an even 
greater gap, comparing cases from 2000 with those from 2007.  It would be 
difficult to exclude the possibility that any differences identified might be at least 
partly due to different personnel, practices or experience levels. 
 
Exposure bias 
Table 2.10 summarises how the studies were exposed to publication, exposure, 
detection, analysis and interpretation bias.  Each type of bias is then discussed 
in further depth. 
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Table 2.10.  Summary of studies - exposure of the studies to other types of bias.  
 
Author, year 
 
Publication 
bias 
Exposure bias Detection 
bias 
Analysis bias Interpretation bias Could the 
research 
findings be 
trustworthy? 
 
 
 
 
 
 
Clear 
fixation 
time? 
Clear 
intervention 
time?  
 
Blinding? Statistics 
used? 
Statistics 
described? 
Research 
hypothesis 
proven according 
to the author? 
 
 
Koren et al., 1997 - Yes Yes No No No Yes No 
Newell et al., 2001 - Yes Yes No Yes Yes Yes No 
Saleki and Haeri, 2002 - Yes Yes No Yes No Yes No 
Švec et al., 2006 - No Yes No Yes Yes Yes No 
Iversen et al., 2008 - Yes Yes No Yes Yes Yes Possibly 
Kelder et al., 2008 - Yes No No Yes Yes - No 
Gregurek and Wu, 2009 - No Yes No Yes Yes Yes No 
Lindboe, 2011a 
Lindboe, 2011b 
- 
- 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
No 
No 
No 
Yes 
- 
No 
No 
Storli et al., 2011 - Yes Yes No Yes Yes No No 
Tasi et al., 2012 - No Yes No Yes Yes Yes No 
apilot study; bmain study. 
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An example of exposure bias was by Gregurek and Wu (2009), who allowed 
pathologists to choose which technique they wished to use according to their 
own preference.  This was inappropriate as it could have introduced selection 
bias, giving the opportunity for pathologists to select cases that they thought 
would harvest more or less lymph nodes, depending on what they wanted the 
results to show.   
 
Detection bias 
Research involving the use of GEWF will always have an immediate detection 
bias.  Studies can be well powered and use randomisation but detection bias 
will be introduced by the inability to use blinding as “GEWF has its own 
characteristic macroscopic appearance, which is impossible to hide.” (Iversen et 
al., 2008, p. 1207).  Either consciously or unconsciously, dissectors would then 
have the ability to alter their practice which could skew the results.  Newell et al. 
(2001, p. 644) admit to this limitation, commenting that “those pathologists using 
the standard technique would likely examine pericolic fat more thoroughly.”  It is 
surprising that whilst being aware of this limitation, Newell et al. (2001) failed to 
minimise its effects via study design, by means of powering their study with an 
appropriate sample size.  As well as powering and randomising their study, 
Iversen et al. (2008) also asked the pathologist involved in dissecting the 
majority of specimens in their study whether they had been biased towards one 
method or the other.  The reply was ‘no’ but this response could also be open to 
a biased answer, e.g. for fear of appearing to favour one or other technique to 
influence results, or for fear of being part of poor research.  
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Analysis bias 
Lindboe (2011) introduced analysis bias into his studies by failing to statistically 
analyse the results (Lindboe, 2011).  The pilot study in 2007, consisting of eight 
consecutive cases, had too small a sample size for any results to be valid and 
trustworthy, yet Lindboe (2011, p. 352) claimed that “an extra over-night fixation 
in formalin leads to detection of many more lymph nodes (mean 5.9).” and that 
“the optimal method for detecting a maximal number of nodes is probably the 
use of various fat clearance techniques.”.  This information was then used to 
change working practices within their department, increasing both workload and 
costs - perhaps unnecessarily.  The main study performed by Lindboe (2011) 
between 2008 and 2010 consisted of 423 cases, yet no statistical analysis was 
carried out on this large cohort either, so the authors cannot claim any statistical 
significance to their conclusions.  Saleki and Haeri (2002) claimed statistically 
significant differences in nodal size and number of metastatic lymph nodes after 
GEWF, yet they failed to describe which statistical analyses were used to reach 
these conclusions, undermining any potential validity. 
 
Interpretation bias 
Many of the studies were open to interpretation bias because the authors based 
their conclusions on flawed data due to poor study design (Tasi et al., 2012; 
Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; Kelder et al., 2008; 
Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 1997).  
Tasi et al. (2012), Kelder et al. (2008), Švec et al. (2006) and Newell et al. 
(2001) claimed that there was a statistically significant difference in the number 
of lymph nodes harvested when GEWF was used.  These may have been 
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appropriate conclusions, even though their studies were not powered and were 
open to bias and confounding factors.  Gregurek and Wu (2009) reported no 
statistically significant difference in the number of lymph nodes harvested when 
GEWF was used.  This conclusion was inappropriate because their study was 
also not powered and was open to bias and confounding factors.  If these 
factors had been controlled then they may have reached a different conclusion.  
Gregurek and Wu (2009, p. 83) also concluded that “GEWF did not increased 
the yield of LNs from colorectal cancer specimens”.  It was inappropriate to 
reach this conclusion because their study may have been underpowered and 
open to bias, with the findings potentially due to chance (Gregurek & Wu, 2009).  
Švec et al. (2006) commented on length of specimen, size of lymph nodes and 
time spent harvesting lymph nodes in only 18 out of the 59 cases in their study 
cohort.  They did not explain why this data had not been collected on the other 
41 cases, but this limited data had little meaning.  Authors should not have 
proposed the routine use of GEWF (Tasi et al., 2012; Lindboe, 2011; Saleki & 
Haeri, 2002; Koren et al., 1997) - instead they should have admitted the 
limitations of their study design and recommended that further well-powered, 
randomised studies were performed in order to increase the evidence base. 
 
Confounding factors 
Table 2.11 summarises the confounding factors which could introduce bias into 
the studies.  Each factor is then discussed in further depth. 
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Table 2.11. Summary of studies - confounding factors which could introduce bias. 
 
 Confounding factor 
 
Author, year Unaccounted 
effects of 
anatomical 
variation? 
Unaccounted 
effects of 
staging 
variation? 
Unaccounted 
effects of 
neoadjuvant 
therapy? 
Unaccounted 
effects of surgical 
practice 
variation? 
Unaccounted quality 
of manual dissection 
practice? 
Unaccounted 
variation in time 
spent harvesting 
lymph nodes? 
 
Koren et al., 1997 Yes Yes - Yes Yes Yes 
Newell et al., 2001 Yes Yes Yes Yes Yes Yes 
Saleki and Haeri, 2002 Yes Yes Yes Yes Yes Yes 
Švec et al., 2006 No No Yes No Yes Yes 
Iversen et al., 2008 No No No No Yes Yes 
Kelder et al., 2008 No Yes No No Yes Yes 
Gregurek and Wu, 2009 No Yes Yes Yes No Yes 
Lindboe, 2011a 
Lindboe, 2011b  
No 
Yes 
Yes 
Yes 
- 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
Storli et al., 2011 No No - Yes Yes Yes 
Tasi et al., 2012 No Yes No Yes No Yes 
apilot study; bmain study. 
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Anatomical and molecular variation 
Evidence has shown that there is variability in the number of lymph nodes 
harvested from the mesentery depending on the anatomical site (Shen et al., 
2009; Baxter et al., 2005; Prandi et al., 2002) and molecular behaviour of the 
tumour (Denham et al., 2012). According to Denham et al. (2012) tumours with 
microsatellite instability are associated with an increased lymph node yield, 
although they do concede that no research has been performed to explain the 
association, suggesting that it may be secondary to cytokine release (Denham 
et al., 2012).  Shen et al. (2009), Baxter et al. (2005) and Prandi et al. (2002) 
found that more lymph nodes are retrieved in hemicolectomy specimens from 
the right side when compared to those from the left side.  It has been shown 
that fewer lymph nodes are retrieved from anterior resection (AR) or 
abdominoperineal (AP) resections due to their smaller size (Baxter et al., 2005; 
Topor et al., 2003).  Refer to Table 2.12 for the anatomical sites of tumours in 
existing studies.   
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Table 2.12.  Anatomical sites of tumours. 
 
Author, year Colonic Colonic - 
right sided 
 
Colonic - 
left sided 
Rectal Colorectal 
Koren et al., 1997 - - - - 30 
Newell et al., 2001 - 35 27 5 - 
Saleki and Haeri, 2002 35 - - - - 
Švec et al., 2006 - - - - 93 
Iversen et al., 2008a  17 39 59 - 
Kelder et al., 2008 - 131 111 0 - 
Gregurek and Wu, 2009b - 50 33 1 - 
Lindboe, 2011c 
Lindboe, 2011d 
- 
- 
3 
189 
5 
129 
- 
105 
- 
- 
Storli et al., 2011 138 - - - - 
Tasi et al., 2012 - - 6 2 - 
aNo anatomical site specified in five cases  
bNo anatomical site specified in one case 
cPilot study 
dMain study 
 
In one study, Topor et al. (2003) found that more than 80 percent of rectal 
lymph nodes were smaller than 3mm in diameter.  It is therefore surprising that 
some authors (Lindboe, 2011; Saleki & Haeri, 2002; Newell et al., 2001; Koren 
et al., 1997) did not consider anatomical variation when comparing lymph nodes 
retrieved from different sites within the colorectum. 
 
Staging variation 
Storli et al. (2011) and Švec et al. (2006) accounted for the TNM staging when 
designing their study, including only stage II and III tumours.  This was to 
identify whether “an increase in the number of harvested lymph nodes will also 
increase the share of stage III (lymph node positive) patients” (Storli et al., 
2011, p. 2797).  This is known as the so-called ‘Will Rogers phenomenon’ of 
stage migration (Sormani, 2009; Dhar et al., 2005) and has also been identified 
in other studies (Compton, 2007; Wright et al., 2003).   
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Švec et al. (2006, p. 428) included only pT2 and pT3 tumours (into or through 
muscularis propria) because they said “the number of recovered LNs depends 
on pT, concomitant pathologic conditions, and carcinoma site location”.  These 
effects have been previously demonstrated by other authors, who have shown 
that more lymph nodes are found with a greater depth of tumour invasion (Leibl, 
Tsybrovskyy & Denk, 2003) in patients with a background of concomitant 
conditions such as diverticular disease (Leibl et al., 2003) and in the right side 
of the colon when compared to the left side (Shen et al., 2009; Baxter et al., 
2005; Prandi et al., 2002).   It has been suggested that fewer lymph nodes are 
harvested from early colorectal cancers (Saklani, Udy, Chandrasekaran, Davies 
& Beynon, 2012; Chou et al., 2010) so by failing to either stratify cases 
according to stage (Tasi et al., 2012; Gregurek & Wu, 2009; Kelder et al., 2008; 
Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 1997) or design an 
adequately powered study to account for this confounding factor (Tasi et al., 
2012; Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; Kelder et al., 
2008; Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 1997), the majority 
of studies would open themselves to further potential bias.  Kelder et al. (2008, 
p. 527) commented on the variation, stating that “in patients with a T1 tumor 
less nodes were removed compared to the other T-stages” however they 
included T1 tumours in their results, claiming that “the T-stage influenced the 
number of retrieved nodes significantly” (Kelder et al., 2008, p. 525).  Only 17 
out of the 242 patients in their study had early tumours (Kelder et al., 2008).  
Although there is evidence to suggest that fewer lymph nodes are harvested 
from early colorectal cancers (Saklani et al., 2012; Chou et al., 2010), Kelder et 
al. (2008) did not power their study and therefore should not have assigned 
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significance as the results may still have been due to chance.  Storli et al. 
(2011, p. 2800) commented that although “stage 1 [tumours] may perhaps have 
fewer detectable lymph nodes TNM stages were not a significant variable for 
the overall lymph node count in our study”.  Without appropriate power to 
account for the bias within their study this conclusion cannot be relied upon. 
 
Age variation 
None of the authors considered the effects of patient age on the lymph node 
harvest (Tasi et al., 2012; Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 
2009; Kelder et al., 2009; Iversen et al., 2008; Švec et al., 2006; Saleki & Haeri, 
2002; Newell et al., 2001; Koren et al., 1997) even though it has been 
suggested that mean lymph node numbers decrease with increasing age 
(McDonald et al., 2012; Chou et al., 2010; Shen et al., 2009).  In one study, 
Shen et al. (2009) commented that the average number of lymph nodes was up 
to 18.2 for patients less than 50 years old.  In contrast, it was as little as 14.4 for 
patients between 61 and 70 years old - however this does meet the current 
standard for harvesting a minimum of 12 lymph nodes for adequate staging 
(The Royal College of Pathologists, 2014).  It should be noted that although 
Shen et al. (2009) did not power their study, it was large, consisting of 434 
consecutive cases of colorectal cancer.  Although Iversen et al. (2008) did not 
comment on any effect of age on lymph node harvest, they may well have 
accounted for this confounding factor by appropriately powering their study. 
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Neoadjuvant therapy 
The effects of neoadjuvant therapy on rectal cancer specimens are well 
documented.  There is a paucity of lymph nodes within the rectum (Baxter et al., 
2005; Topor et al., 2003) and neoadjuvant therapy is known to make them 
smaller and more difficult to harvest (Miller et al., 2012; Latkauskas et al., 
2010).  It is therefore surprising that many studies did not take this into account 
during their design (Lindboe, 2011; Gregurek & Wu, 2009; Švec et al., 2006; 
Saleki & Haeri, 2002; Newell et al., 2001).  Lindboe (2011, p. 353) included 
neoadjuvant therapy treated cases within his main study and commented that 
although other studies had shown neoadjuvant therapy to reduce the number 
and size of harvested lymph nodes “this study could not confirm this finding” - 
yet the authors actually made no attempt to confirm the findings statistically 
because their study was open to bias and no statistical analysis was performed.  
Tasi et al. (2012) and Kelder et al. (2008) excluded neoadjuvant therapy cases 
whilst Storli et al. (2011) and Koren et al. (1997) only studied colonic resections, 
and did not discuss any specific exclusion of rectal specimens or those patients 
who had received neoadjuvant therapy.   
 
Surgical practice variation 
It is possible that surgical practices may have had an effect on lymph node 
paucity in studies with a low mean number of lymph nodes, because the extent 
of the mesocolic or mesorectal excision is directly correlated with harvestable 
lymph nodes (Morris, Maughan, Forman & Quirke, 2007).  It is possible that 
some of the studies with a poor lymph node retrieval rate were associated with 
suboptimal surgical excisions.  This confounding factor was commented on by a 
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number of authors (Storli et al., 2011; Iversen et al., 2008; Kelder et al., 2008; 
Švec et al., 2006). Švec et al. (2006) considered the influence of surgical 
technique, and by ensuring patients were operated on by only two surgeons 
sought to reduce some exposure bias.  The study by Kelder et al. (2008), 
involving eight surgeons, commented that the operating surgeon may have had 
an effect on the number of lymph nodes harvested before and after GEWF, but 
used multivariate analysis to demonstrate that this was not a significant factor.  
Lindboe (2011, p. 353) admitted that during their lengthy study period there had 
been “a continuous change in the staff of surgeons, but whether or not this has 
affected their average dedication and skill is uncertain.”  This statement further 
opens the study by Lindboe (2011) to bias.  Storli et al. (2011) considered the 
effects of surgical practice in a separate cohort of their 2011 study, concluding 
that more radical surgery significantly increased lymph node yield.  This would 
have been an expected outcome because more radical surgery involves the 
removal of a greater amount of mesentery.  It should also be noted that their 
study was open to bias and numerous confounding factors and was not 
powered or randomised and therefore their conclusions may not be reliable.  
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Primary manual dissection practice variation 
Table 2.13 demonstrates the large variation in primary manual dissection 
practice, noting the small proportion of studies which met national targets for 
primary manual dissection. 
 
Table 2.13.  Variation in manual dissection practice. 
 
Author, year Mean number of nodes 
after primary manual 
dissection 
 
Achieving national targets with 
primary manual dissection 
Koren et al., 1997 2.94 No 
Newell et al., 2001 6.8 No 
Saleki and Haeri, 2002 6.26 No 
Švec et al., 2006 5.9 No 
Iversen et al., 2008 9.5 No 
Kelder et al., 2008 5.0 No 
Gregurek and Wu, 2009 18.3 Yes 
Lindboe, 2011 11.4 No 
Storli et al., 2011 10.98 No 
Tasi et al., 2012 7.6 No 
 
Many of the studies did not achieve the recommended targets of a minimum of 
12 lymph nodes (The Royal College of Pathologists, 2014) during primary 
manual dissection (Tasi et al., 2012; Lindboe, 2011; Iversen et al., 2008; Kelder 
et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001), with 
the mean number of lymph nodes retrieved ranging from 2.9 (Koren et al., 
1997) to 18.3 (Gregurek & Wu, 2009).  Koren et al. (1997) included 30 
‘problematic’ cases in their study where less than ten lymph nodes were 
harvested at manual dissection, however they did not state that what their 
national harvesting target was.  Only Gregurek and Wu (2009) achieved the 
recommended target at manual dissection.  Storli et al. (2011) who had three 
different study groups with different interventions did not provide separate 
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results for those cases treated with GEWF, making it impossible to assess its 
value. 
 
Kelder et al. (2008) only found a mean of five lymph nodes by manual 
dissection in 117 colonic specimens.  The highest number of lymph nodes 
found in any specimen in this study was only 17, even after secondary 
dissection (Kelder et al., 2008).  This was lower than the average number found 
by manual dissection by Gregurek and Wu (2009). In studies where manual 
dissection was associated with a poor lymph node retrieval rate, the quality of 
underlying dissection practice should have been questioned.  This issue has 
been supported by a number of authors who note the importance of enthusiasm 
and skill of both pathologist and surgeon (Švec et al., 2006; Ustün et al., 1999; 
Sanchez, Luna-Perez, Alvarado, Labastida & Herrera, 1996).  Gregurek and 
Wu (2009) commented on the amount of time and skill required to manually 
harvest lymph nodes.  In their study they found that educating pathologists in 
appropriate manual dissection practice gave more powerful results than the use 
of lymph node retrieval solutions (Gregurek & Wu, 2009).  However there was 
potential bias in their study which may have led to these findings (Gregurek & 
Wu, 2009).  Dissectors were allowed to choose which method to use (detection 
bias) and the intervention results were inappropriately compared to those of the 
previous year when different staff may have been involved.  Iversen et al. 
(2008) failed to clarify how many pathologists and/or surgeons were involved in 
their studies and what their level of experience was. This could also introduce 
detection bias – for example, via the involvement of an inexperienced dissector 
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who might miss smaller lymph nodes in comparison to a dissector highly 
experienced in manual dissection. 
 
Time spent harvesting lymph nodes 
Many authors failed to comment on the potential introduction of detection bias in 
terms of the time spent by the dissector harvesting lymph nodes from 
specimens treated with GEWF (Tasi et al., 2012; Lindboe, 2011; Storli et al., 
2011; Kelder et al., 2008; Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 
1997).  The potential for bias will always exist because of the inability to blind 
the dissector due to the characteristic appearance of the solution.  Švec et al. 
(2006) did measure the time spent performing the lymph node harvest after 
GEWF – but only in eight out of the 59 cases within their study cohort.  This was 
confusing and gave their result (mean of 32.4 minutes per specimen) little 
useful meaning (Švec et al., 2006).   The pathologist who dissected 76.7% of 
specimens in the study by Iversen et al. (2008 p. 1207) said that “time spent 
was unaffected by the preparation method”.  Iversen et al. (2008) should have 
assessed all pathologists, although conclusions may still have been affected by 
detection bias; whereby dissectors may have adjusted time spent depending on 
technique used.   
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2.4.2 NUMBER OF LYMPH NODES HARVESTED AFTER GEWF 
Table 2.14 demonstrates the change in the number of lymph nodes after 
intervention with GEWF, noting any statistical significance claimed by the 
authors.   
 
Table 2.14.  Number of lymph nodes harvested after the use of GEWF. 
 
Author, year 
 
Mean number of 
nodes after 
manual dissection 
Mean number of 
nodes after 
intervention 
Statistically 
significant difference 
in number of nodes 
(p value)   
                         
Koren et al., 1997 2.94 8.6a - 
Newell et al., 2001 6.8 10.2 Yes (0.002)b 
Saleki and Haeri, 2002 6.26 13.0a - 
Švec et al., 2006 5.9 14.7 Yes (0.05)b 
Iversen et al., 2008 9.5 16.5 Yes (<0.001)b 
Kelder et al., 2008 5.0 13.0 Yes (<0.001)b 
Gregurek and Wu, 2009 18.3 19.96 No (0.53)b 
Lindboe, 2011c 
Lindboe, 2011d 
Lindboe, 2011e 
11.4 
11.4 
- 
5.9a 
6.0f 
16.8 
- 
- 
- 
Storli et al., 2011 10.98g 15.61g Yes (<0.01) 
Tasi et al., 2012 7.6 4.7a Yes (<0.05) 
aadditional lymph nodes; bsignificance = p ≤0.005; cpilot study - further fixation; dpilot study – 
GEWF; emain study – GEWF; fthird dissection; gthree sites with differing intervention. 
 
All of the authors found an increase in the number of lymph nodes harvested 
after the use of GEWF in comparison to manual dissection (Tasi et al., 2012; 
Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; Iversen et al., 2008; 
Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001; 
Koren et al., 1997).  The biggest difference in compared study and intervention 
groups was by Kelder et al. (2008), who harvested 160% more lymph nodes in 
the GEWF group.  It should be noted that this difference was from a mean of 5 
to a mean of 13 (Kelder et al., 2008), and as the number achieved with GEWF 
is only marginally above what was expected from manual dissection, the validity 
of the results are in question due to poor underlying dissection practice because 
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it is being presumed that the effect was due to the use of GEWF when it may 
have been due to further fixation or a more experienced or careful dissector 
carrying out the secondary lymph node harvest.  The biggest difference in 
studies where additional lymph nodes were harvested within the same 
specimen group was by Koren et al. (1997) who harvested 292% more lymph 
nodes after GEWF (mean 2.94 vs mean 11.54 after).  Again, poor underlying 
manual dissection practice puts the reliability of these findings into question. 
 
Although Gregurek and Wu (2009) found a slight increase in the average 
number of lymph nodes harvested with GEWF there was no statistical 
significance and they concluded that GEWF did not increase the yield of lymph 
nodes from colorectal cancer specimens.  They could not prove this because 
their study was open to substantial bias and confounding factors and therefore 
this conclusion is unreliable and misleading. 
 
2.4.3 LYMPH NODE SIZE 
Some authors considered the importance of lymph node size because of the 
debate regarding the clinical significance of colorectal cancer metastases in 
small lymph nodes (Märkl et al., 2012; Dhar et al., 2005).  Dhar et al. (2005, p. 
20) concluded that metastatic lymph node size was a “strong prognostic 
variable in colorectal carcinoma” whilst more recently Märkl et al. (2012, p. 
1413) said that “minute lymph nodes [<1mm] have virtually no role in correct 
histopathological lymph node staging”.  They did however note that “the 
detection of relatively small lymph nodes (1-5mm) is important for an exact 
lymph node staging.  Moreover, our data suggest that the lymph node size is of 
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prognostic relevance.” (Märkl et al., 2012, p. 1420).  Linear regression analysis 
was used and it demonstrated a strong dependency between total lymph node 
numbers and lymph node diameter (Märkl et al., 2012).  Märkl et al. (2012) 
focused on eliminating many of the confounding factors which had affected 
other similar studies, e.g. exclusion of rectal cancers and using a single centre 
to perform the study.  They also supported the association between a high 
number of harvested lymph nodes and a favourable outcome in colon cancer.  
Märkl et al. (2012) appear to have sound results; however it should be noted 
that no sample size calculation was described and it therefore is unclear 
whether the study is sufficiently powered to justify the conclusions reached.   
 
The relevance of the marked increase in micrometastases and isolated tumour 
cells, as noted in the study by Kelder et al. (2008) is unknown as there 
continues to be debate in the existing literature, with further research required in 
this area (Märkl et al., 2012).   
 
2.4.4 METASTATIC INCIDENCE 
Many authors discussed metastatic incidence, but failed to specifically calculate 
it.  Only Saleki and Haeri (2002) calculated metastatic incidence, and they 
attributed statistical significance to their findings.  Unfortunately they failed to 
explain which statistical methods were used to reach this conclusion.  Their 
study was also widely open to bias and confounding factors and was not 
appropriately powered - therefore their conclusions cannot be relied upon.   
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2.4.5 PROGNOSTIC FACTORS 
 
Upstaging 
Only three studies considered the effects of GEWF and secondary dissection 
on upstaging, but without statistical significance to support their claims 
(Lindboe, 2011; Saleki & Haeri, 2002; Koren et al., 1997).  Saleki and Haeri 
(2002) and Koren et al. (1997) both reported upstaging after the use of GEWF, 
ranging from 8.6% (Saleki & Haeri, 2002) to 60% (Koren et al., 1997).  They 
found that eight out of 30 (Koren et al., 1997) and three out of 35 (Saleki & 
Haeri, 2002) cases were upstaged from Dukes B to Dukes C which prompted 
adjuvant therapy (Saleki & Haeri, 2002; Koren et al., 1997).  Both of these 
studies had poor underlying manual dissection practice with an average of 6.26 
and 2.9 lymph nodes harvested respectively (Saleki & Haeri, 2002; Koren et al., 
1997).  It is possible that upstaging would have been lessened or not identified 
at all if initial manual dissection had been adequately performed.   It should be 
noted that the metastatic lymph nodes identified with GEWF had a mean 
measurement of 0.35mm (compared to 0.568mm at manual dissection) (Saleki 
& Haeri, 2002) which may have been difficult to identify at manual dissection.  
Saleki and Haeri (2002), who upstaged three out of 35 cases from Dukes B to 
Dukes C, concluded that GEWF was especially useful in Dukes B cancers, but 
they should not have reached this conclusion for a number of reasons: they 
assigned no statistical significance to this finding; their study was poorly 
designed; their study was open to bias and numerous confounding factors. 
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2.5 CONCLUSIONS 
A number of studies have shown GEWF to be a safe and efficient lymph node 
retrieval solution (Tasi et al., 2012; Lindboe, 2011; Storli et al., 2011; Iversen et 
al., 2008; Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et 
al., 2001; Koren et al., 1997).  Kelder et al. (2008) and Koren et al. (1997) also 
reported GEWF to be quick, cheap, and easy to prepare and handle.  A 
common shortcoming of almost all of the studies in this literature review was 
absence of the following: a power calculation to define an appropriate sample 
size; randomisation; attempts to minimise bias; attempts to minimise 
confounding factors.   
 
Eng (2003, p. 310) states that “the power (sensitivity) of a statistical test must 
be sufficient to enable detection of a statistically significant difference between 
the two groups if a difference is truly present.”  If power is insufficient then the 
results of the statistical test are erroneous and there might actually be an 
underlying difference, giving a false negative result (Eng, 2003).  All but one of 
the studies in this literature review failed to perform a power calculation and 
were therefore at risk of false negative results (Tasi et al., 2012; Lindboe, 2011; 
Storli et al., 2011; Gregurek & Wu, 2009; Kelder et al., 2008; Švec et al., 2006; 
Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 1997).  Iversen et al. 
(2008) was the only study to use a power calculation and randomisation to 
minimise bias and provide trustworthy and statistically significant results.  
Comment was made by Iversen et al. (2008) on the inability to perform blind 
studies due to the characteristic macroscopic appearance of GEWF and the 
measurement bias this would lead to (Newell et al., 2001), but this would be 
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unavoidable in any research studying the effects of GEWF, due to its 
characteristic appearance.  The use of GEWF may have led to upstaging, 
prompting adjuvant therapy, but this was not statistically or reliably proven by 
either Saleki and Haeri (2002) or Koren et al. (1997), who made this claim.  The 
greatest confounding factor in the majority of the studies was the poor 
underlying manual dissection practice.  Only one out of the ten reviewed studies 
was able to meet the expected target of a minimum of 12 lymph nodes at 
manual dissection (Gregurek & Wu, 2009).  This suggests that there may have 
been pre-existing expertise or training issues which should have been 
addressed before any research in this field was commenced.  This literature 
review confirms that it is essential that lymph node harvesting be done in a 
correct and timely manner, whether manually or with the use of GEWF, as 
correct staging and subsequent treatment have important prognostic relevance. 
 
2.6 AIMS AND OBJECTIVES 
 
2.6.1 THE LITERATURE GAP 
The studies which have been published in relation to the use of GEWF, suggest 
that its use will identify an increased number of lymph nodes, and that this may 
lead to stage migration (upstaging) from node negative to node positive, 
resulting in the triggering of adjuvant chemotherapy.  However, these studies 
suffer from poor study design and the findings should be questioned. GEWF 
has been shown to facilitate identification of smaller lymph nodes, which may be 
especially useful for cases where neoadjuvant therapy has been given, as there 
is often a paucity of lymph nodes which are also smaller in size.  Ad hoc 
experience using this chemical solution supports these findings however they 
104 
 
need to be confirmed via an appropriately designed study with statistically 
significant results.    
 
A gap in the literature remains due to the limited amount of available literature 
and poor design of, and bias in the majority of existing studies.  In fact there is 
only one well designed study within the literature (Iversen et al., 2008).   
 
2.6.2 AIMS OF THE RESEARCH 
 
This thesis seeks to fill the evidence gap which has clearly been demonstrated 
by this literature review.  This study will be appropriately designed, with a power 
calculation to ensure appropriate sample size to provide statistically significant 
results which can be trusted.  This will be the first study of its kind to be carried 
out within the UK.  Bias will be considered and it will be minimised wherever 
possible, with stratification into groups where there are known to be clear 
differences in lymph node harvest, i.e. where neoadjuvant therapy has been 
used.  Iversen et al. (2008) stratified cases into groups of colon vs rectum 
specimens, accounting for paucity of lymph nodes in the rectum rather than the 
effects of neoadjuvant therapy.  As a result of this there is no reliable evidence 
within the literature regarding the value of using GEWF on rectal specimens of 
patients who have received neoadjuvant therapy.  This thesis will be the first to 
address this issue.  The other confounding factors will be accounted for via the 
use of an appropriate sample size.   
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2.6.3 OBJECTIVES OF THIS RESEARCH 
The primary objective of this research is to compare the effects of further 
fixation in formalin and GEWF on the lymph node harvest of patients with 
colorectal cancer, with or without neoadjuvant therapy via a controlled trial. 
 
The proposed outcomes of the primary objective can be summarised as the 
following three research questions: 
  
 
 
 
 
 
 
 
Secondary objectives will involve development of a new departmental protocol 
for the macroscopic handling of colorectal cancer specimens based upon the 
findings of the research study.  This will involve either no change, treatment with 
GEWF either before or after primary dissection, or further fixation of specimens 
before secondary dissection. 
 
The findings of this research study will also be disseminated via publication in 
appropriate journals, with key conclusions presented locally, nationally and 
internationally. 
 Question 1:  
Does the use of GEWF result in a statistically significant greater lymph 
node harvest in comparison to further fixation in formalin? 
 
 Question 2:  
Does the use of GEWF identify statistically significant smaller lymph 
nodes at secondary dissection in comparison to further fixation in 
formalin? 
 
 Question 3: 
Does the use of GEWF result in statistically significant upstaging, 
leading to the requirement for adjuvant chemotherapy? 
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The following chapter will outline the materials and methods used in the design 
of this research study. 
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3. METHODOLOGY AND METHOD 
This chapter outlines the methodology used in answering the research question.  
It will cover study design; outcomes; bias; population; recruitment and 
exclusions; data collection, methods of data analysis and good clinical practice. 
 
3.1 RESEARCH METHODOLOGY 
Oxford Dictionaries define research as “the systematic investigation into and 
study of materials and sources in order to establish facts and reach new 
conclusions” (Oxford Dictionaries, 2014b).  According to Kothari (2004) one of 
the major ways in which research can be categorised is descriptive versus 
analytical.  Descriptive research is usually qualitative whilst analytical research 
is quantitative. 
 
The decision regarding which method to use in one’s research is commonly 
based upon the initial question of quantitative versus qualitative.  Shields and 
Twycross (2003, p. 24) explain that “quantitative research methods are used 
when something needs to be measured, while qualitative methods are used 
when a question needs to be described and investigated in some depth”.  
Quantitative research uses measurement and statistics to reach its conclusions 
and is more commonly seen in traditional science and medicine.  Qualitative 
research is more common within the field of social science, and explores 
meaning, attitudes and opinions using words, descriptions and quotes, with the 
use of non-numerical data (Kothari, 2004; Muijs, 2004; Shields & Twycross, 
2003).  These two epistemologies appear to have different underlying 
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philosophies; quantitative research is seen as positivist, whilst qualitative 
research is considered subjective (Muijs, 2004).   
 
The apparent dichotomy between the two methodologies and their associated 
philosophies are not always so unambiguous as they may be combined, where 
they become referred to as ‘mixed methods’.  Medicine itself can also be 
ambiguous.  An example of this is histopathology, which is both realistic and 
subjective and where diagnostic error and poor interobserver agreement 
between histopathologists is a well-known phenomenon (Parkash, Bifulco, 
Feinn, Concato & Jain, 2010; Treanor, Lim, Magee, Bulpitt & Quirke, 2009; 
Downs-Kelly et al., 2008).   
 
According to Muijs (2004) quantitative and qualitative research methods are 
most suited to answering the following types of research question, as listed in 
Table 3.1. 
 
Table 3.1.  The appropriate use of quantitative vs qualitative research 
methods (Muijs, 2004).   
 
Question to be answered 
 
Methodology 
A quantitative or numerical answer is required Quantitative 
A numerical change needs to be measured Quantitative 
Phenomena need to be explained using statistical methods Quantitative 
A hypothesis needs to be tested Quantitative 
A problem needs to be explored in depth Qualitative 
A hypothesis or theory needs to be developed Qualitative 
The issues to be studied are particularly complex Qualitative 
The meaning of particular events or circumstances need to be 
understood 
Qualitative 
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The Centre for Evidence Based Medicine (2013) uses further subdivisions, 
more specifically defining the various types of research study designs into a 
‘design tree’.  Within this design tree analytical studies are divided into 
experimental and observational.  Experimental studies test hypotheses and 
discover new relationships (Kothari, 2004) whilst observational studies directly 
observe, rather than manipulate, individuals or groups in their natural settings 
(Carlson & Morrison, 2009).  This is shown in Figure 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.  The design tree (Centre for Evidence Based Medicine, 2013). 
 
 
Case-control 
study 
Cross 
sectional 
(Analytic) 
(Randomised) 
Crossover 
Cohort study (Randomised) 
Parallel group 
Observational 
Analytic 
 
Experimental Qualitative Survey  
(Cross sectional) 
Analytic Descriptive 
All studies 
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All of the 10 studies evaluated within the literature review posed hypotheses 
and sought to answer them using experimental or observational analytic 
methods.  Nine were case-control studies (Tasi et al., 2012; Lindboe, 2011; 
Storli et al., 2011; Gregurek & Wu, 2009; Kelder et al., 2008; Švec et al., 2006; 
Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 1997) and one was a 
randomised controlled trial (Iversen et al., 2008).  Gregurek and Wu (2009) also 
included a qualitative survey to the dissectors involved in the study, seeking 
their feedback on the differences between the two experimental procedures 
used, therefore employing a mixed methodology.       
 
3.2 STUDY DESIGN 
The Centre for Evidence Based Medicine (2013) design tree, as demonstrated 
in Figure 3.1, and the study design flowchart shown in Figure 3.2 were used to 
help choose the appropriate design for this study. 
 
 
 
 
 
 
 
 
 
Figure 3.2.  Choosing the appropriate study design (S. Kilburn, personal 
communication, 2009). 
 
 
Yes 
Can the independent variable be manipulated?                 
Can the research design decide who gets the 
intervention or risk factor? 
No 
OBSERVATIONAL ANALYTIC 
e.g. case-control study            
e.g. cohort study 
 
Looking at associations or causal links? 
Does a hypothesis need to be tested? 
 
No 
OBSERVATIONAL DESCRIPTIVE 
 e.g. cross-sectional study              
Yes 
EXPERIMENTAL                                
 e.g. randomised controlled trial 
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The study required an experimental design, i.e. a controlled trial because: 
 A hypothesis was to be tested 
 The independent variable could be manipulated (adjunct preparatory 
technique) 
 
3.3 OUTCOMES 
The outcomes can be defined as follows: 
 
 
 
 
 
 
 
 
3.4 BIAS 
 
3.4.1 RANDOMISATION 
A known problem with colorectal resection specimens was that each case could 
not be separated into two halves, i.e. with one half receiving the intervention 
whilst the other received the standard technique.  This was due to the need to 
adequately stage cancers by selecting appropriate blocks of tumour before 
lymph node retrieval was commenced.  This could only be done with the entire 
specimen intact so that anatomical and pathological aspects could be 
correlated.  It would have been unethical to separate specimens as it may have 
 Outcome 1:  
Increased lymph node retrieval using GEWF (intervention 1) as 
opposed to further fixation (intervention 2). 
 
 Outcome 2:  
Small lymph node retrieval using GEWF (intervention 1) as opposed 
to further fixation (intervention 2). 
 
 Outcome 3: 
Evidence of upstaging within the stratified groups which was 
statistically significantly related to the intervention used. 
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been detrimental to diagnosis.  This limitation could have introduced selection 
bias as intervention and standard could not be directly compared within the 
same specimen.  It was impossible to minimise bias without risking adversely 
affecting staging.   
 
To overcome this limitation, random allocation of samples to either adjunct 
preparatory technique was used in order to reduce bias.  Other studies involving 
resection specimens had a similar study design to the proposed design 
(Gregurek & Wu, 2009; van Steenbergen et al., 2009; Iversen et al., 2008; 
Kelder et al., 2008; Märkl et al., 2008; Newell et al., 2001). 
 
The allocation was concealed from the chief investigator, as knowledge of 
allocation could have been a source of sample bias (Higgins et al., 2011).  
Blinding was not possible as the chief investigator was able to recognise the 
preparation technique at secondary dissection via the smell and appearance of 
the specimen.  A power calculation, performed by the University of Portsmouth 
statistician, recommended that a large sample size be used to adjust for any 
potential bias that this may have caused. Refer to section 3.5.1 for a description 
of the sample size calculation, which was also performed by the statistician. 
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3.4.2 ANONYMISATION 
Once specimens were entered into the study they were assigned a study 
number and anonymised.  Specimens were anonymised from the chief 
investigator, but a link was maintained to the patient, held in a password 
protected spreadsheet and accessible to the specialist gastrointestinal 
consultant histopathologists and cut up staff.  This information was not shared 
with the chief investigator.    
 
Anonymisation of specimens formed a large part of the study design and was a 
requirement of ethical approval, in line with the Human Tissue Act, 2004, code 
of practice 1 (Human Tissue Authority, 2004).  This is discussed in more detail 
in section 3.9.1.  There are two main methods of obtaining samples for 
histopathological research since the introduction of the Human Tissue Act in 
2004; obtaining specific patient consent for the study or anonymisation or 
pseudo-anonymisation (where a coding system is used).  None of the studies 
investigating the use of GEWF and included within the literature review 
considered the use of anonymisation (Tasi et al., 2012; Lindboe, 2011; Storli et 
al., 2011; Gregurek & Wu, 2009; Iversen et al., 2008; Kelder et al., 2008; Švec 
et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 1997).  Only 
two studies commented on the need for ethical approval (Storli et al., 2011; 
Iversen et al., 2008), but no comment was made regarding any anonymisation 
requirements in the one Norwegian study granted ethical approval (Storli et al., 
2011).  The ethical requirements within Norway are different to those within the 
UK and the need for anonymisation or pseudonymisation where general 
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consent has been given is unclear.  Healthcare research in Norway is governed 
by the Health Research Act, 2009 which states that: 
 
 
 
 
 
 
 
 
(Norway. Regionale Komiteer for Medisinsk og Helsefaglig Forskningsetikk, 
2009)  
 
Histopathological research studies are often performed retrospectively, using 
information retrieved from laboratory information management systems (LIMS) 
or by performing further work on material from tissue blocks.  These are often 
classified as audit and therefore do not require ethical approval to proceed.  The 
literature gives no examples of histopathological research describing 
anonymisation of specimens in accordance with ethical guidelines but this may 
simply be because articles are required to be succinct, without detailed 
methodological explanation, in order to achieve publication (N.J. Carr, personal 
communication, January 6, 2014).  Figure 3.3 demonstrates how anonymisation 
was incorporated into the design of the study: 
 
 
 
 
 
“§ 14. Broad consent  
Pursuant to Section 13, research participants may consent to human 
biological material and personal health data being used for specific, broadly 
defined research purposes.  
 
The regional committee for medical and health research ethics may specify 
conditions for use of broad consent and may order the project manager to 
obtain new consent if the committee deems it necessary.  
 
Participants who have given broad consent are entitled to receive 
information about the project at regular intervals.”  
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Figure 3.3.  Anonymisation of specimens during the study. 
 
Groups 1A and 1B 
Specimen pot filled 
with formalin and 
specimen left at room 
temperature for 24 
hours 
Secondary lymph node retrieval 
performed 
Specimens allocated randomly into either study group  
1 or 2 
Groups 2A and 2B 
Specimen pot filled 
with GEWF and 
specimen left at room 
temperature for 24 
hours 
Tissue block selection and primary lymph 
node retrieval performed 
Primary 
dissection 
Secondary 
dissection 
First copy of research 
label number placed onto 
original specimen pot 
alongside patient 
identification label 
Second copy of research 
label number placed onto 
a clean pot and specimen 
transferred into it 
Original pot with patient 
identifiable label and first 
copy of research label 
stored in a separate area 
(not accessed by chief 
investigator) 
Research number and 
patient identifier added to 
spreadsheet by laboratory 
staff (withheld from chief 
investigator) 
Specimen pot filed by 
laboratory staff 
Research number 
removed and original 
patient identification label 
replaced by laboratory 
staff 
Anonymised slides from secondary dissection sent to 
chief investigator for review and secondary dissection 
data collection 
Slides passed to relevant consultant histopathologist for 
addition of secondary data to patient report 
Slides returned to laboratory for relabeling with specimen 
number and refiling 
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3.4.3 STRATIFICATION 
In order to ensure that potentially confounding factors (baseline variables) were 
evenly distributed (Kendall, 2003), samples were stratified into one of two 
groups, according to whether the patient received neoadjuvant therapy or not.  
This was because the use of neoadjuvant therapy is known to be related to 
retrieval of fewer, smaller lymph nodes (Kelder et al., 2008).    Evidence has 
shown that lymph node retrieval in specimens receiving long course 
neoadjuvant therapy is markedly affected (Marks et al., 2010).  Neoadjuvant 
therapy is usually only given to patients with rectal cancer because there is a 
known greater risk of local recurrence in these specimens (Lim et al., 2010; 
Chau et al., 2006; Chari et al., 1995) although there are exceptions, e.g. 
patients in clinical trials.  In this thesis, neoadjuvant therapy is only classed as 
such when it is ‘long course’, i.e. lasting for five weeks (Sajid, Siddiqui, Kianifard 
& Baig, 2010).   
 
Stratification into these groups ensured that there was appropriate allocation of 
these specimens into all groups.  Within each stratified group, samples were 
then allocated into one of two intervention groups according to the 
randomisation strategy (see Figure 3.4).  
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Figure 3.4.  Randomisation strategy. 
 
The randomisation strategy was carried out using an automated randomisation 
programme by the University of Portsmouth statistician. Specimens were 
enrolled consecutively into the study by laboratory staff after primary dissection.  
This was always done in the absence of the chief investigator, who was either 
absent from or in another area of the laboratory, in order to prevent the 
introduction of bias; if the chief investigator was present then they may have 
become aware of the specimen number and linked research number.  
  
Many prospective studies consider ‘sample attrition’, where participants drop 
out of the study for any number of reasons (Kendall, 2003).  In terms of 
recruitment, this was not an issue because participants were only recruited 
once their resections had been performed, and if they met the appropriate 
inclusion criteria.  At this stage the only loss of participants was where consent 
for use of their specimen for research and audit purposes was withheld or 
where the specimen was inappropriate, e.g. not a curative resection of 
adenocarcinoma - but these specimens would not be entered into the study.   
Group 1 
24 hours further fixation 
Group 2 
24 hours GEWF 
Group 1A 
Further fixation 
Non-neoadjuvant 
cases 
Group 1B 
Further fixation 
Neoadjuvant 
cases 
Group 2A 
GEWF 
Non-neoadjuvant 
cases 
Group 2B 
GEWF 
Neoadjuvant 
cases 
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Within the study sample attrition did occur later at the data analysis stage, 
where slides were not always available for assessment.  The reasons for this 
will be discussed in more detail in section 3.7.3. 
 
3.5 POPULATION 
An audit of the local LIMS showed that between 2009 and 2011 approximately 
200 colorectal cancer specimens were received into the department per year 
(Clinisys, 2010; CliniSys, 2014).  Of these, approximately 16% and 15% of 
patients received either short or long course neoadjuvant therapy respectively 
prior to surgery (CliniSys, 2010; CliniSys, 2014).  These figures are 
demonstrated in Table 3.2.   
 
Table 3.2.  Number of cases of colorectal cancer received locally between 
2009 and 2011 (CliniSys, 2010; CliniSys, 2014).   
 
Region of the 
colorectum 
No. of  
non-neoadjuvant cases  
(percentage) 
 
No. of 
long-course neoadjuvant cases 
(percentage) 
 2009 
(n=206) 
2010 
(n=186) 
2011 
(n=198) 
2009 
(n=206) 
2010 
(n=186) 
2011 
(n=198) 
 
Caecum 34/206 
(16.5%) 
32/185 
(17.3%) 
27/198 
(13.6%) 
0/206  
(0%) 
0/185 
(0%) 
0/198  
(0%) 
Ascending colon 14/206  
(6.8%) 
30/185 
(16.2%) 
23/198 
(11.6%) 
0/206 
(0%) 
0/185 
(0%) 
0/198 
(0%) 
Hepatic flexure 10/206  
(4.9%) 
9/185 
(4.9%) 
9/198 
(4.5%) 
0/206 
(0%) 
0/185 
(0%) 
0/198 
(0%) 
Transverse colon 12/206 
(5.8%) 
12/185 
(6.5%) 
14/198 
(7.1%) 
0/206 
(0%) 
0/185 
(0%) 
0/198 
(0%) 
Splenic flexure 4/206 
(1.9%) 
2/185 
(1.1%) 
8/198 
(4.0%) 
0/206 
(0%) 
0/185 
(0%) 
0/198 
(0%) 
Descending colon 3/206  
(1.5%) 
8/185 
(4.3%) 
5/198 
(2.5%) 
0/206 
(0%) 
0/185 
(0%) 
0/198 
(0%) 
Sigmoid colon 48/206 
(23.3%) 
46/185 
(24.9%) 
52/198 
(26.3%) 
0/206 
(0%) 
0/185 
(0%) 
0/198 
(0%) 
Rectum 61/206 
(29.6%) 
29/185 
(15.7%) 
42/198 
(21.2%) 
20/206 
(9.7%) 
17/185 
(9.2%) 
18/198 
(9.1%) 
Totals 186/206 
(90.3%) 
168/185 
(90.8%) 
180/198 
(90.9%) 
20/206 
(9.7%) 
17/185 
(9.2%) 
18/198 
(9.1%) 
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3.5.1 SAMPLE SIZE 
The required sample size was estimated in order to cost the study and evaluate 
the length of time it would take (Chan, 2003).  With both groups an increased 
number of lymph nodes was expected (from chief investigator experience and 
review of the literature). 
 
Group 1 - secondary dissection following further formalin fixation  
There was little reliable evidence within the literature regarding the numbers of 
additional lymph nodes retrieved after further fixation (Lindboe, 2011; van 
Steenbergen et al., 2009; Poller, 2000). Therefore the local LIMS was audited 
for evidence of resampling where less than 12 lymph nodes were harvested at 
primary dissection.  In a two year audit of local colorectal cancer lymph node 
harvest, secondary dissection was only performed in cases where less than 12 
lymph nodes were identified originally (CliniSys, 2010).  Sixty-three out of 413 
(15%) of cases were resampled with a mean of x 1.5 additional lymph nodes 
found.   
 
Therefore, from this limited data, one would expect to find 1.5 times as many 
lymph nodes after resampling (in cases where lymph nodes are already difficult 
to find). 
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Group 2 - secondary dissection following treatment with GEWF  
A greater increase in the number of lymph nodes found in this group was 
expected (Gregurek & Wu, 2009; Iversen et al., 2008; Kelder et al., 2008; Švec 
et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001; Ustün et al., 1999; Koren 
et al., 1997) and are reported in Table 3.3. 
 
Table 3.3.  What the literature says regarding the use of GEWF. 
 
Author, year Mean lymph nodes 
retrieved with 
primary dissection 
Mean additional lymph nodes 
retrieved with secondary 
dissection after GEWF 
 
Percentage 
increase 
Švec, 2006 6 9 (sum 15) x 2.5 
Newell, 2001 7 3 (sum 10) x 1.4 
Gregurek, 2009 18 2 (sum 20) x 1.1 
Iversen, 2008 9 7 (sum 16) x 1.8 
Iversen, 2008 10 7 (sum 17) x 1.7 
Kelder, 2008 5 8 (sum 13) x 2.6 
Saleki, 2002 6 7 (sum 13) x 2.2  
Koren, 1997 3 6 (sum 9) x 3 
Ustün, 1999 5 2 (sum 7) x 1.4 
Ustün, 1999 6 1 (sum 7) x 1.2 
 
The literature stated that between x 1.1 and x 3 additional lymph nodes were 
retrieved when using GEWF (Gregurek & Wu (2009) and Koren et al. (2008) 
respectively), which gave a mean increase of 2.0 lymph nodes and a median 
increase of 1.8 lymph nodes.  Therefore, on average one would expect to find 
twice as many lymph nodes using GEWF when compared to primary dissection 
alone. 
 
The difference between the two groups: 
 
 
 
Group 1: secondary dissection after further fixation x 1.5 
 
Group 2: secondary dissection after GEWF  x 2 
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In conclusion, the expected difference between Group 1 (further fixation) and 
Group 2 (GEWF) was 33%.  The mean number of lymph nodes expected from 
the two groups and the standard deviation of the lymph nodes retrieved was: 
  
Group 1 - secondary dissection after further fixation: 
According to departmental audit data (CliniSys, 2010), mean primary lymph 
node retrieval for all dissectors combined was 16.  At secondary manual 
dissection x 1.5 lymph nodes would be expected to be retrieved, giving a mean 
of 24 lymph nodes with a standard deviation of 12.3. 
  
Group 2 - secondary dissection after GEWF: 
According to the literature, mean primary lymph node retrieval was 16 
(Gregurek & Wu, 2009; Iversen et al., 2008; Kelder et al., 2008; Švec et al., 
2006; Saleki & Haeri, 2002; Newell et al., 2001; Ustün et al., 1999; Koren et al., 
1997) and after GEWF this would be expected to be x 2, giving a mean of 32 
lymph nodes with a standard deviation of 2.7. 
 
From previous studies (Gregurek & Wu, 2009; Iversen et al., 2008; Kelder et al., 
2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001; Ustün et al., 
1999; Koren et al., 1997) and departmental audit data (CliniSys, 2010), the 
average number of total lymph nodes after secondary dissection was expected 
to be 24. A total of 180 patients were required to detect a 25% increase in the 
total number of lymph nodes after GEWF with a power of 90% at a two-sided 
5% level of significance, with an assumed standard deviation of 12.3 lymph 
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nodes in each group (R. Ogollah, personal communication, October 26, 2011).  
The sample size and power calculation is shown in Table 3.4.   
 
Table 3.4.  Sample size and power calculation for the study. 
 
Mean no. of 
lymph nodes in 
group 1 
 
Mean no. of lymph 
nodes expected in 
group 2 
 
Percentage 
increase 
Power 
(%) 
Number in 
each group 
Total 
sample 
size 
24 36 50.0 90 24 48 
24 32 33.3 90 51 102 
24 30 25.0 90 90 180 
24 29 20.8 90 129 258 
24 36 50.0 90 18 36 
24 32 33.0 90 39 78 
24 30 25.0 90 67 134 
24 29 21.0 90 96 192 
 
(R. Ogollah, personal communication, October 26, 2011) 
 
An additional 10% was then added to this figure of 180, which gave a sample 
size of 198.  Many researchers add between 10% and 30% to the sample size 
to compensate for any problems with non-responders or missing values (Naing, 
Winn & Rusli, 2006; Israel, 1992).  In this thesis, the figure of 198 was rounded 
up to 200, to make the final agreed sample size. 
 
3.6 RECRUITMENT AND EXCLUSIONS 
Colorectal cancer specimens were received as part of routine practice into the 
department conducting the study.  Colorectal cancer specimens were defined 
as adenocarcinomas of any part of the colon or rectum.   
 
Specimens were received into the laboratory with a consent form which stated 
that tissues could be used for ‘audit, teaching and research’ with a tick box 
option.  See Appendix D for an example of a local consent form.  Consent was 
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recorded onto the local LIMS and also noted on the request form.  If consent 
was not given then the specimen was excluded from the study.   
 
Exclusion criteria are listed in Table 3.5 below, with the rationale for exclusion 
from the study. 
 
Table 3.5.  Exclusion criteria. 
 
Criteria Rationale for exclusion 
 
No informed patient consent Not ethical to use in study 
Primary resection of non-adenocarcinoma Tumour behaviour, e.g. metastatic potential 
may differ 
Primary resection of dysplastic disease 
with unexpected tumour found 
Inadequate mesenteric resection 
Primary resection of benign disease with 
unexpected tumour found 
Inadequate mesenteric resection 
Resection of recurrent adenocarcinoma Previous mesenteric resection 
Specimen received and prepared on a day 
before the chief investigator was absent 
from the department and unable to perform 
a timely secondary dissection 
Inappropriate time in intervention chemical 
 
According to departmental protocol, based upon national guidelines, colorectal 
cancer specimens should be dissected after a minimum 24-48 hours fixation 
(The Royal College of Pathologists, 2014).  Appropriate fixation has been 
shown to increase lymph node yield (Burroughs & Williams, 2000).  The length 
of fixation before primary dissection varied depending on the day of arrival into 
the department and is shown in Table 3.6.  These factors were out of control of 
the laboratory but were recorded as part of data collection.   
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Table 3.6.  Fixation and dissection of colorectal cancer specimens. 
 
Day specimen 
resected 
 
Day of receipt to 
laboratory 
 
Day of dissection Minimum 
number of 
hours fixation 
 
Initial 
inclusion in 
study 
Monday Tuesday Wednesday 48 Yesa 
Tuesday Wednesday Thursday 48 Yesa 
Wednesday Thursday Friday 48 No 
Thursday Friday Monday 96 Yesa 
Friday Monday Tuesday 96 Yesa 
Saturday Monday Tuesday 72 Yesa 
Sunday Monday Tuesday 48 Yesa 
aunless chief investigator absent from the department on the day of required secondary 
dissection. 
 
 
3.6.1 PROBLEMS WITH RECRUITMENT AND EXCLUSIONS 
Initially secondary dissection was performed on routine working days, i.e. 
Monday to Friday.  This meant that any specimens received into the laboratory 
on a Thursday, and dissected on a Friday were excluded as this would require 
the chief investigator to attend the department on a non-working day.  This also 
meant that 14.3% (1 in 7) of specimens were automatically excluded from the 
study (see Table 3.6).  On review, 12 months into the data collection period, it 
was clear that data collection was slower than had been initially predicted.  By 
12 months, 101 specimens had been entered into the study, with 11 exclusions.  
At this point the decision was made to improve numbers further by including 
specimens dissected on a Friday, with the chief investigator attending work on 
Saturdays to perform specimen dissection if required.  Where possible, the chief 
investigator also attended to perform secondary dissections whilst on annual 
leave.  This organisation relied upon good communication between the chief 
investigator and staff working within the cut up laboratory.  
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3.7 DATA COLLECTION 
It was important to identify which data should be collected from the outset in 
order to avoid the acquisition of incomplete data.  The main outcomes were 
improved retrieval of lymph nodes and upstaging.  Improved retrieval of lymph 
nodes would be an important finding but if these lymph nodes did not contain 
tumour then there would be less benefit to the patient as treatment would 
remain the same.  There would be a benefit to the surgeons however, because 
the greater the number of lymph nodes retrieved, the more reliable the staging 
would be considered to be.  This is important because the presence of 
metastatic lymph nodes is one of the major factors determining whether or not 
adjuvant chemotherapy is given after surgery (Resch & Langner, 2013).  If 
lymph nodes found at secondary dissection were shown to contain tumour then 
this might benefit the patient if they had been previously staged as pN0 (node 
negative).  This might have been especially beneficial in patients with rectal 
cancers who had received neoadjuvant therapy as this has been shown to be 
detrimental to nodal harvesting (Miller et al., 2012; Marks et al., 2010, Morcos et 
al., 2010). 
 
A number of other associated variables were also measured - all of which were 
simple to measure and record, either at the dissection or reporting stage.  It was 
important to carefully consider all collectable data when designing the study 
because although the research hypothesis may not be proven, other findings 
may still be significant.  The measurable variables listed in Table 3.7 were 
developed into four data collection sheets; cut up data collection sheets A and B 
and microscopy data collection sheets C and D (see Appendices E-H).  
126 
 
Table 3.7.  Measurable variables to consider. 
 
Variable 
 
When will it be measured? How will it be measured? 
Site of tumour Primary dissection Cut up data collection sheet A 
Neoadjuvant therapy Primary dissection Cut up data collection sheet A 
Course of neoadjuvant therapy Primary dissection Cut up data collection sheet A 
Date of receipt Primary dissection Cut up data collection sheet A 
Length of fixation before primary dissection (days) Primary dissection Cut up data collection sheet A 
Date of primary dissection Primary dissection Cut up data collection sheet A 
Primary dissector Primary dissection Cut up data collection sheet A 
Size of mesentery Primary dissection Cut up data collection sheet A 
Time taken to perform dissection Primary dissection Cut up data collection sheet A 
Date specimen in solution Secondary dissection Cut up data collection sheet B 
Time specimen in solution Secondary dissection Cut up data collection sheet B 
Date of secondary dissection Secondary dissection Cut up data collection sheet B 
Time of secondary dissection Secondary dissection Cut up data collection sheet B 
Time taken to perform secondary dissection Secondary dissection Cut up data collection sheet B 
Number of lymph nodes harvested at primary dissection Reporting Microscopy data collection sheet C 
Range in size of lymph nodes negative for tumour at primary dissection Reporting Microscopy data collection sheet C 
Range in size of lymph nodes positive for tumour at primary dissection Reporting Microscopy data collection sheet C 
TNM5 staging – before secondary dissection Reporting Microscopy data collection sheet C 
Final TNM5 staging Reporting Microscopy data collection sheet C 
TNN7 staging – before secondary dissection Reporting Microscopy data collection sheet C 
Final TNM7 staging Reporting Microscopy data collection sheet C 
Intervention used Post-secondary dissection Randomisation 
Number of lymph nodes harvested at secondary dissection Post-secondary dissection Microscopy data collection sheet D 
Number of lymph nodes negative for tumour at secondary dissection Post-secondary dissection Microscopy data collection sheet D 
Number of lymph nodes positive for tumour at secondary dissection Post-secondary dissection Microscopy data collection sheet D 
Range in size of lymph nodes negative for tumour at secondary dissection Post-secondary dissection Microscopy data collection sheet D 
Range in size of lymph nodes positive for tumour at secondary dissection Post-secondary dissection Microscopy data collection sheet D 
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Receipt from theatre via main specimen reception 
Bowel contents washed out 
Bowel lumen wicked with formalin soaked paper towels and specimen left 
to fix in fresh formalin for a further 24 hours 
Specimen cut open to reveal the mucosal surface, 
with tumour/mesorectum left intact if possible 
Receipt from theatre via main specimen reception 
Specimen cut open to reveal the mucosal surface, 
with tumour/mesorectum left intact if possible 
Bowel contents washed out 
Bowel lumen wicked with formalin soaked paper towels and specimen 
left to fix in fresh formalin for a further 24 hours 
Before 
the 
study: 
During 
the 
study: 
Tissue block selection and lymph node retrieval performed 
Tissue block selection and lymph node retrieval performed 
Specimens allocated randomly into either study group A or B 
Groups 1A and 2A 
Specimen pot filled with GEWF and left at room temperature for 
24 hours  
Groups 1A and 2A 
Specimen pot filled with fresh formalin and left at room temperature for 24 hours 
Secondary dissection and further lymph node harvesting performed 
Primary 
dissection 
Secondary 
dissection 
Figure 3.5.  Routine practice for dealing with colorectal cancer specimens before and during the study. 
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3.7.1 DISSECTION 
Figure 3.5 demonstrates how specimen dissection continued to be performed 
as per protocol, based upon national guidelines (The Royal College of 
Pathologists, 2014).  Specimens were dissected by: 
 
 
 
 
The five consultant histopathologists specialise in gastrointestinal pathology and 
have many years of combined experience in specimen dissection and 
microscopic assessment of colorectal cancer specimens.  There are 
approximately 10 trainee histopathologists who have between 0 and 5 years of 
experience in specimen dissection and microscopic assessment of colorectal 
cancer specimens.  The advanced practitioner healthcare scientist (chief 
investigator) has 10 and 5 years of experience (in 2014) in specimen dissection 
and microscopic assessment of colorectal cancer specimens respectively.  The 
numbers of cases dissected by each group between 2009 and 2011 is 
summarised below, in Table 3.8. 
 
 
 
 
 
 
 
 Consultant gastrointestinal histopathologists. 
 
 Trainee histopathologists. 
 
 Advanced practitioner healthcare scientist. 
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Table 3.8.  Number of cases dissected by each group between 2009 and 
2011. 
 
 2009 
 
2010  2011  
 No. of 
dissectors 
within 
group 
No. of 
cases 
within 
group 
No. of 
dissectors 
within 
group 
No. of 
cases 
within 
group 
No. of 
dissectors 
within 
group 
No. of 
cases 
within 
group 
 
Consultant 5 75/206 
(36.4%) 
5 55/185 
(29.7%) 
5 49/198 
(24.7%) 
Advanced 
Practitioner 
1 43/206 
(20.9%) 
1 61/185 
(33.0%) 
1 89/198 
(44.9%) 
Trainee 15 88/206 
(42.7%) 
13 69/185 
(37.3%) 
15 60/198 
(30.3%) 
 
Table 3.8 also demonstrates the increasing experience and specialisation of the 
advanced practitioner within the field of gastrointestinal histopathology.  Having 
multiple dissectors with variable levels of experience and time to perform 
dissections could have created a potential confounding variable.  Sixty percent 
of existing studies included in the literature review did not clearly describe this 
(Tasi et al., 2012; Storli et al., 2011; Kelder et al., 2008; Saleki & Haeri, 2002; 
Newell et al., 2001; Koren et al., 1997).  Thirty percent of existing studies stated 
that only senior trainees or consultants were involved in the research, 
presumably to limit this potential confounding variable (Lindboe, 2011; Iversen 
et al., 2008; Švec et al., 2006).  The study by Gregurek and Wu (2009) did note 
a potential issue, admitting that the inclusion of two new first year trainees 
alongside those with more experience could introduce potential bias when 
comparing lymph node retrieval between groups. 
 
An audit of the local LIMS showed variation between the dissector groups in 
terms of the number of lymph nodes retrieved (CliniSys, 2010), although all 
groups achieved the recommended minimum number (The Royal College of 
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Pathologists, 2014).  This variability could only be removed if dissection was 
restricted to one group, but there would still be variability amongst individuals 
within each group.  The only group with a sole member was the advanced 
practitioner group which comprised the chief investigator.  It would have been 
unethical to limit resections to the chief investigator because of training and 
governance issues.  With the most recent audit suggesting approximately 200 
specimens received per annum (CliniSys, 2014; Clinisys, 2010) it would have 
taken much longer to reach the required sample size if only a percentage of 
specimens received had been entered into the study.  It would also have taken 
longer if only specimens dissected by the chief investigator had been included 
as only 89 colorectal cancer specimens (44.9%) were dissected and interpreted 
in 2011 by the advanced practitioner healthcare scientist (chief investigator) 
(CliniSys, 2014).   
 
Consideration was also given to whether there was an introduction of bias in 
cases entered into the study which had been dissected by the advanced 
practitioner (chief investigator) as part of routine practice.  It could be argued 
that there would be a bias as the chief investigator would recognise the 
specimen and therefore be biased in the treatment of it.  Ethically, this was not 
seen to be the case, and also enough cases were received for it to be difficult to 
attempt to track any individual case even if the chief investigator wished to.  In 
addition, a comparison between the practice of the scientifically trained 
advanced practitioner versus that of the medically trained histopathologists 
would be possible. 
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Another issue that was considered was how nodal dissection was performed.  
Two methods were routinely used: 
 
 
 
 
There are no guidelines as to what is the optimum method.  In the Dataset for 
Colorectal Cancer The Royal College of Pathologists (2014, p. 12) simply state 
that “care must be taken to ensure that all of the mesentery between the tumour 
and the highest lymph node is serially sliced if it has not already been included 
in the initial slicing”.  The method chosen locally depends on training and 
personal preference.  An audit of the local LIMS showed that both methods 
achieved similar lymph node retrieval rates (CliniSys, 2010).  Minor 
amendments were made to reporting proformas during the study to aid data 
collection and these are shown in Appendix I.  
 
3.7.2 INITIAL DATA COLLECTION 
Cases were routinely interpreted by the dissector.  This was done prospectively, 
with slides interpreted by the dissector, who then reviewed the case with the 
rostered consultant histopathologist.  This was in keeping with local routine 
practice.  There are no specific national guidelines regarding prospective versus 
retrospective reporting, however prospective reporting is considered best 
practice in order to fulfil the training needs of the trainee.  Prospective reporting 
enables trainees to experience a ‘real-time’ routine workload and to prepare 
them for independent practice (The Royal College of Pathologists, 2010; 
 Dissection of the mesentery/mesorectum from the bowel wall and 
palpation between forefingers and dissection board. 
 
 Incision of the mesentery/mesorectum whilst attached to the bowel 
wall and palpation between forefingers. 
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Tildsley & Dilly, 1991).  Details of measurements and relevant findings from 
every case included in the study were returned to the chief investigator and 
recorded in a database.  Table 3.7 shows at which point in the study this 
information was collected.  Any further lymph nodes identified at secondary 
dissection were interpreted by the chief investigator with additional review by 
one of the gastrointestinal specialty consultants.  This is a type of triangulation, 
known as observer triangulation.  Denzin (2009, p.303) advocates the value of 
observer triangulation, arguing that its use “removes the potential bias that 
comes from a single person, and ensures a greater reliability in observations”.  
In this study observer triangulation was used in order to improve the quality of 
the data.  Classification of lymph nodes and associated pN status was recorded 
using both TNM5 and TNM7 staging editions (Sobin, Gospodarowicz & 
Wittekind, 2009; Wittekind et al., 2005).  This is because lymph nodes are 
classified differently in the two editions: 
 
In TNM5 extramural tumour deposits without evidence of residual lymph nodes 
over 3 mm are counted as positive regional nodes (pN1 or pN2), whilst those 
which are smaller are classified as discontinuous extensions (pT3) (Sobin et al., 
2010). 
 
In TNM7 extramural tumour deposits are assessed according to contours 
(smooth versus irregular) rather than simply by size.  This encourages 
intraobserver variation because the pathologist is responsible for this 
interpretation (Sobin et al., 2010; Goldstein & Turner, 2000).   
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These additional findings were included within the final report before 
authorisation.  The department uses a reporting proforma and this was adapted 
to encompass the research findings as part of the final report.  Examples of 
microscopic reporting proformas used before and during the study are shown in 
Appendix 3.6. 
 
Laboratory protocols were written for each staff group involved in the research, 
i.e. consultant histopathologists, trainee histopathologists and the laboratory 
team (see Appendices J-L). 
 
The agreed pathway for data collection sheets A-D for the data collection period 
is shown in Figure 3.6. 
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Figure 3.6.  The agreed pathway for data collection sheets during the data 
collection period. 
 
*Data collection sheet C was not attached to the specimen request form when 
the advanced practitioner healthcare scientist (chief investigator) performed the 
primary dissection as part of routine practice, as this would break the 
anonymisation.  Instead, at review by the advanced practitioner a blank data 
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collection sheet C was provided to the consultant histopathologist.  The 
consultant would later retrieve the linked specimen number and research 
number from the database, complete data collection sheet C, and return 
anonymously to the chief investigator at a later date.   
 
3.7.3 PROBLEMS WITH DATA COLLECTION 
Despite careful organisation and communication there were problems with data 
collection and analysis where it involved the completion and returning of data 
sheets in the absence of the chief investigator.  Unfortunately due to the 
requirements for anonymisation much of the data had to be collected in this 
way.  The problems and associated solutions are summarised in Table 3.9: 
 
Table 3.9.  Problems with data collection and associated solutions. 
 
Data collection 
sheet 
 
Problem(s) Cause(s) Solution(s) 
 
A Sheet incomplete Staff too busy 
Forgetfulness 
Retrieval of data from LIMS 
Verbal questioning 
B n/a n/a n/a 
C Sheet not 
completed 
Sheet incomplete 
Sheet not returned 
Staff too busy 
Forgetfulness 
Remove reliance on 
authorisers to complete and 
return sheet 
D Sheet not returned 
 
Staff too busy 
Forgetfulness 
Remove reliance on 
authorisers to return sheet 
 
 
At 12 month review (study mid-point) it was clear that the greatest problem 
involved incomplete data sheets C and D by consultants.  Reasons for this were 
cited as ‘being too busy’ or ‘forgetting’ (B. Green, personal communication, 
December 6, 2013).  Although the information from sheet D had been 
completed by the chief investigator, who initially reviewed the slides from 
secondary dissection, this information remained incomplete as it required 
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validation by second review by the consultant.  Unfortunately this rarely 
occurred, and sheets C and D along with slides of nodes harvested from 
secondary dissection were not returned to the chief investigator.   
 
Figure 3.7 summarises the actual pathway for data collection sheets during the 
first half of the data collection period, with problems highlighted in yellow, vs the 
revised pathway for data collection sheets during the second half of the data 
collection period. 
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Figure 3.7. The actual pathway of data collection sheets during the first half of the data collection period vs the revised pathway 
during the second half of the data collection period. 
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3.7.4 SOLUTIONS TO DATA COLLECTION PROBLEMS 
 
Collection of data at cut up  
Data collection sheet A was usually well completed by cut up staff.  Any missing 
information could be recovered via verbal discussion, e.g. “how long did the 
dissection take?” or by a member of cut up staff looking up the information on 
the LIMS (to maintain anonymisation), e.g. “what was the tumour site?”. 
 
Collection of incomplete microscopic data from primary dissection 
Data collection sheet C was rarely returned by the authorising consultant.  It 
was always fully completed and returned by senior trainees with authorisation 
privileges.  Where it was returned by consultants it was usually incomplete, 
often with the size of lymph nodes at primary dissection unrecorded.  Some 
sheets were returned blank, with no information added. 
 
The majority of the information required was available within the LIMS, but due 
to anonymisation of the cases the chief investigator could not retrieve this 
independently.  The size of lymph nodes at primary dissection was not recorded 
within the final report and therefore could only be assessed by reviewing the 
slides. 
 
Therefore two strategies were put in place.  These are both shown in Figure 
3.8.  Firstly, a nominated person would sit with the chief investigator and 
provide the missing information from the LIMS, by cross-referencing the 
research number with the specimen number and identifying the missing data 
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from the final report.  The chief investigator then added this information into the 
results spreadsheet.  Secondly, the chief investigator identified which cases 
were missing data regarding lymph node size at primary dissection.  The 
research numbers of these cases and the missing data columns were copied 
into a new excel spreadsheet.  A dummy column of random dates was placed in 
a column to the left of the research number.  This file was saved and e-mailed 
to a nominated colleague who then added another column and cross-
referenced the specimen number into it before saving.  The corresponding 
column including the research number was then deleted and the spreadsheet 
was sorted according to the random date column.  This spreadsheet was then 
e-mailed back to the chief investigator who retrieved the slides from primary 
dissection from the filing system, counted and measured the negative and 
positive lymph nodes, and completed the new smaller spreadsheet.  Once 
completed this was returned to the colleague who again cross-referenced with 
the corresponding research number column before deleting the specimen 
number column.  The file was then re-emailed to the chief investigator who was 
able to input the anonymised data into the main results spreadsheet.  This 
process was repeated periodically, and although it took much longer than the 
original planned process, it avoided incomplete and non-returned data.   
 
 
 
 
 
 
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chief investigator gives 
research number to assistant 
Strategy 1 
Completion of missing data 
available on LIMS 
Assistant looks up cross-
referenced specimen number 
and histology report 
Missing data items given to 
chief investigator 
Missing data items entered into 
results spreadsheet by chief 
investigator 
Strategy 2 
Retrieval of slides to count and measure primary 
dissection lymph nodes 
Spreadsheet e-mailed to assistant 
Missing data entered onto spreadsheet 
Lymph nodes counted and measured 
Slides from primary dissection retrieved from 
archive 
Spreadsheet e-mailed to chief investigator 
Research number removed 
Specimen number cross-referenced and added 
Spreadsheet e-mailed to assistant 
Cases with missing data from results spreadsheet 
entered into new spreadsheet 
Cross-referenced research number re-added to 
spreadsheet 
Specimen number removed from spreadsheet 
Spreadsheet e-mailed to chief investigator 
Additional data added to original research 
spreadsheet 
Figure 3.8.  Dual strategy for collection of missing data items. 
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Validation of lymph nodes harvested secondary dissection 
A single gastrointestinal consultant agreed to review the slides with the chief 
investigator, in order to ensure validation of the results of the secondary lymph 
node harvests.  This was done as soon as possible after the chief investigator 
received the slides for review, in order to ensure timely intervention if a positive 
lymph node was identified.  Once the nodal harvest had been validated, the 
data was added to the results spreadsheet and the information was e-mailed to 
the relevant authorising consultant (see Appendix M).  If a positive lymph node 
was identified then this information was flagged urgently to the relevant 
authorising consultant via e-mail in order to facilitate any potential intervention, 
e.g. informing the MDT of upstaging (see Appendix N).   
 
3.8 DATA ANALYSIS 
 
3.8.1 STATISTICAL ANALYSIS 
This thesis seeks to answer three research questions: 
  
 
 
 
 
 
 
 
Question 1: 
Does the use of GEWF result in a statistically significant greater lymph node 
harvest in comparison to further fixation in formalin? 
Question 3: 
Does the use of GEWF result in statistically significant upstaging, leading to 
the requirement for adjuvant chemotherapy? 
Question 2: 
Does the use of GEWF identify statistically significant smaller lymph nodes 
at secondary dissection in comparison to further fixation in formalin? 
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Each research question requires statistical comparative analysis of two 
independent groups (further fixation in formalin vs GEWF) and therefore the 
independent samples t-test will be used to answer all research questions.   
 
The baseline from which the secondary dissection lymph node harvest is 
measured is not identical because of the difference in the experience and 
competence of the primary dissector groups.  Therefore for question 1 an 
analysis of variance (ANOVA) test will also be performed to account for this 
variable.  As there is only one variate (dissector group) then a one-way between 
subjects (univariate) ANOVA is most appropriate. 
 
The independent samples t-test and univariate ANOVA were performed using 
IBM SPSS Statistics, version 21 (IBM, 2012).   
 
3.9 GOOD CLINICAL PRACTICE 
 
3.9.1 ETHICS 
Colorectal cancer specimens were received as part of routine practice into the 
department where the study will take place.  Specimens were received into the 
laboratory with a consent form which stated that tissues may be used for ‘audit, 
teaching and research’ in the form of a tick box (see Appendix D).  Informed 
consent was recorded onto the LIMS and also noted on the request form.  If 
informed consent was not given then the specimen was excluded from the 
study.   
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Support was sought from the Pathology Governance Officer within the local 
Trust Research and Development department to ensure that the informed 
surgical consent provided for routine diagnostic histopathology was sufficient for 
this research.  According to the Human Tissue Authority (HTA) Code of Practice 
1 Consent – Consent requirements – Part 3: Tissue from living guidelines – 
paragraphs 117 to 119: 
 
 
    
 
 
 
 
 
 
 
 
 (Human Tissue Authority, 2004) 
 
Therefore, surgical informed consent was sufficient if the specimens were 
anonymised residual tissues, i.e. material left over from a diagnostic or 
therapeutic intervention (Human Tissue Authority, 2006, p.32).  The study was 
designed to ensure anonymisation of the specimens from the chief investigator, 
both to avoid bias, and also to comply with ethical requirements. 
 
“117.  Tissue from the living may be stored or used without consent, 
provided that: 
1.  the researcher is not in possession, and not likely to come into 
possession of information that identifies the person from whom it has come; 
and 
2.  the material is used for a specific research project with ethical approval 
 
118.  Data about the tissue does not have to be permanently or irrevocably 
unlinked and may be pseudonymised where, for example, a system of 
coding is used. 
 
119.  There may be occasions when a clinician involved in research may 
also have access to a secure database that would permit identification of a 
sample used in research and the identity of the patient whose material is 
being used.  Providing the research material is not identifiable to the 
researcher (e.g. coded by a laboratory accession number) and the 
researcher does not seek to link the sample to the patient, it will still be 
regarded as non-identifiable and the research will be permissible without 
consent if it is given ethical approval by a recognised research ethics 
committee.”   
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A favourable opinion was received from the North West Research Ethics 
Committee following online application via the Integrated Research Application 
System (IRAS) in December 2011 (see Appendix O).  Advice was sought from 
the local research governance lead for pathology throughout this process.  The 
local Trust provided sponsorship and gave site specific information (SSI) 
approval for the research (see Appendices P and Q).  Favourable ethical 
approval was also received from the University of Portsmouth Science Faculty 
Ethics Committee.  See Appendix Y for the research ethics review checklist 
(Form UPR16).  
 
3.9.2 CONFIDENTIALITY AND DATA STORAGE 
Specimens were handled according to Trust confidentiality and Caldicott 
guidelines, based on the Confidentiality NHS Code of Practice (Great Britain. 
Department of Health, 2003).  Anonymised data was held in a password 
protected excel spreadsheet, stored on the personal drive of the chief 
investigator’s NHS personal computer (PC).  This protected the document from 
loss in the event of failure of the hard drive, yet prevented access by others.  
The Trust Information Technology (IT) department would be able to access the 
document if requested.  The PC was situated within the chief investigator’s 
office.  Access to the department out of hours was by swipe card only.  During 
working hours the PC was locked when the chief investigator was absent.  This 
could only be unlocked when the password of the chief investigator was re-
entered.  The document containing the link between research number and 
specimen number was held on the network drive of departmental PCs in a 
password protected Excel spreadsheet.  The password was made available to 
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the gastrointestinal specialist consultant histopathologists and designated 
laboratory staff and was neither shared nor discussed with the chief 
investigator.  The Trust IT department would be able to access the document if 
required.  The PCs were held within the consultant offices and the cut up 
laboratory.  Access to the corridors containing these rooms was by swipe card 
and / or keypad code.  Department and university staff may have access to 
these corridors via swipe card or keypad code entry.  The consultant offices 
were locked out of hours and often when the consultants were out of the 
department.  A master key for these rooms was available, but was held behind 
doors requiring swipe card and key access.  The PCs in the cut up laboratory 
were behind doors where access at any time was only via swipe card access.  
Out of hours swipe card and keypad entry was required to access this 
equipment. 
 
Anonymised data was analysed by the chief investigator and supporting 
statistician - based at the local Trust and the University of Portsmouth.  The 
spreadsheet containing the linked study number and specimen number was not 
used to analyse data so there was no transfer of personal data.  Following 
completion, presentation, dissemination and defence of the study all data will be 
deleted from Trust PCs and data collection forms will be destroyed, in keeping 
with the instructions received as part of the ethical approval process. 
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3.9.3 HEALTH AND SAFETY 
Consideration was made of the health and safety implications of the use of 
GEWF.  None of the previous studies which used GEWF recorded any adverse 
effects during the making up or application of the chemicals (Gregurek & Wu, 
2009; Iversen et al., 2008; Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 
2002; Newell et al., 2001; Ustün et al., 1999; Koren et al., 1997).  Glacial acetic 
acid, ethanol, water and formalin are routinely used independently or within 
other compounds within the researcher’s laboratory.  Use of the chemicals 
within this study continued to adhere to standard departmental guidelines as 
follows: 
 
 
 
 
 
 
 
 
 
 
The use of each chemical was in accordance with Control of Substances 
Hazardous to Health (COSHH) standards.  COSHH sheets for glacial acetic 
acid, ethanol and formalin are shown in Appendix R.   
 
The following chapter will describe the results of the research study. 
 GEWF was made up within a fume cupboard (500ml acetic acid + 
500ml formalin + 1000ml distilled water + 3000ml absolute alcohol). 
 
 Persons making up or applying GEWF did so wearing appropriate 
personal protective equipment. 
 
 GEWF was stored in an appropriate container in an appropriate 
chemical cupboard until required for use. 
 
 GEWF was only used within the cut up room, and applied to 
specimens on downdraught benches which are purpose built to 
extract chemical fumes. 
 
 GEWF was disposed of down the sink with copious amounts of 
running tap water, as is standard practice for disposal of other 
chemicals such as formalin. 
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4. RESULTS 
This chapter contains the study demographics and results with statistical 
analysis.  The stratified populations within the study are discussed, with results 
presented for the entire sample and each of the stratified groups.  Results are 
shown for each of the adjunct techniques and they are compared to one 
another.  Finally statistical analysis is applied in order to answer the specific 
research questions. 
 
4.1. OBJECTIVES 
The objective of this research is to gain statistically significant results comparing 
the effects of further fixation and GEWF on the lymph node harvest of patients 
with colorectal cancer, with or without neoadjuvant therapy.  This objective will 
be met by answering the following three research questions: 
 
  
 
 
 
 
 
 
 
 
 
 
Question 1: 
Does the use of GEWF result in a statistically significant greater lymph node 
harvest in comparison to further fixation in formalin? 
Question 3: 
Does the use of GEWF result in statistically significant upstaging, leading to 
the requirement for adjuvant chemotherapy? 
Question 2: 
Does the use of GEWF identify statistically significant smaller lymph nodes at 
secondary dissection in comparison to further fixation in formalin? 
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4.2 INCLUSION CRITERIA 
Specimens were assessed as eligible for entry into the study by the chief 
investigator or in her absence, dissection laboratory staff.  The dissection 
laboratory lead and histopathologists were aware of inclusion criteria, as they 
had been given this information at the start of the study.  Other staff working in 
the dissection laboratory were rotational and did not assess cases for 
enrolment.  In cases where the primary dissector or assistant were unsure 
whether to enrol or not, checks were made with either the chief investigator or a 
gastrointestinal specialist consultant histopathologist.  Specimens were enrolled 
into the study if they met the following eligibility criteria defined below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3 EXCLUSIONS BEFORE ENROLMENT 
Specimens were excluded from the study before primary dissection if they did 
not meet the inclusion criteria or if other specifically defined features were 
present.  Exclusion criteria before enrolment are described in Table 4.1. 
 
 
 
Inclusion criteria: 
 
 Planned primary resection of adenocarcinoma with adequate 
mesenteric resection. 
 
 Previous biopsy diagnosis of adenocarcinoma. 
 
 Informed patient consent received. 
 
 Specimen received and prepared on a day before the chief 
investigator was present in the department and able to perform a 
timely secondary dissection. 
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Table 4.1.  Exclusion criteria before enrolment into the study. 
 
Criteria Rationale for exclusion 
 
No informed patient consent Not ethical to use in study 
Primary resection of non-adenocarcinoma Tumour behaviour, e.g. metastatic 
potential may differ 
Primary resection of dysplastic disease with 
unexpected tumour found 
Inadequate mesenteric resection 
Primary resection of benign disease with unexpected 
tumour found 
Inadequate mesenteric resection 
Resection of recurrent adenocarcinoma Previous mesenteric resection 
Specimen received and prepared on a day before the 
chief investigator was absent from the department 
and unable to perform a timely secondary dissection 
Inappropriate time in intervention 
chemical 
 
4.4 EXCLUSIONS AFTER ENROLMENT 
In total 225 specimens were entered into the study, 31 into the neoadjuvant arm 
and 194 into the non-neoadjuvant arm.  Twenty-five cases were excluded after 
enrolment and the reasons for this are summarised in Table 4.2. 
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Table 4.2.  Exclusions after enrolment in the study.  
 
Exclusion no Research 
number 
 
Stage of 
exclusion 
Reason for exclusion 
 
1 1150612 Pre-analysis In intervention chemical for 3 days 
2 3250612 Post analysis Primary data unavailable 
3 8210313 Pre-analysis Inadequate primary lymph node 
harvest 
4 9100513 Unclear Unclear 
5 43150612 Pre-analysis In intervention chemical for 3 days 
6 44150612 Pre-analysis In intervention chemical for 3 days 
7 48200612 Post-analysis Not carcinoma (lymphoma) 
8 52030712 Pre-analysis 1 day delay before putting specimen 
into intervention chemical 
9 58300712 Post-analysis Not carcinoma (adenoma) 
10 63070812 Pre-analysis 1 day delay before putting specimen 
into intervention chemical 
11 92051212 Post-analysis Primary data unavailable 
12 96110213 Post-analysis Primary data unavailable 
13 97120213 Pre-analysis Inadequate primary lymph node 
harvest 
14 121160513 Pre-analysis Specimen placed in wrong arm of the 
study 
15 137150713 Unclear Unclear 
16 138150713 Unclear Unclear 
17 139150713 Pre-analysis Inadequate primary lymph node 
harvest 
18 145 Unclear Unclear 
19 170051113 Unclear Unclear 
20 172081113 Pre-analysis Specimen placed in wrong arm of the 
study 
21 173111113 Post-analysis Data confusing 
22 200130214 Post-analysis Primary data unavailable 
23 201130214 Post-analysis Primary data unavailable 
24 210280314 Post-analysis Primary data unavailable 
25 223030614 Post-analysis Primary data unavailable 
 
Pre-analysis exclusions 
Pre-analysis exclusions were determined either during primary dissection or at 
secondary dissection and are listed in Figure 4.1.  At the start of the study five 
specimens were either not put into the intervention chemical soon enough 
[8,10], or were left in it for an extended period [1,5,6], due to a lack of 
understanding by staff within the dissection laboratory.  In two cases the 
specimen was entered into the wrong arm of the study [14,20], although in one 
of these it was only discovered to be incorrect at MDT meeting, when the 
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patient’s entry into the FoxTROT clinical trial was discussed.  Further checks 
revealed that the patient had received long-course neoadjuvant therapy as part 
of the trial.  In three cases an inadequate primary lymph node dissection was 
performed [3,13,17].  In one case it was reported to the chief investigator that 
the primary dissector trainee had stated that they did not need to do the harvest 
fully because it would have a secondary dissection on the following day 
anyway.  In the other cases the dissectors had not sampled all lymph nodes 
and it was not possible to distinguish between those nodes already sampled 
and new nodes.  
 
Post-analysis exclusions 
Seven cases were excluded post-analysis because the original slides from 
primary dissection were not returned to the department filing system 
[2,11,12,22,23,24,25].  In one of these cases the patient had been entered into 
the FoxTROT trial and the slides had been sent away as part of the study.  Two 
other cases were excluded because the final diagnosis was not 
adenocarcinoma [7,9].  These cases should not have been entered into the 
study because they were not biopsy proven adenocarcinomas, however this 
was not checked prior to entry.  In one case the final data was confusing as the 
specimen contained synchronous adenocarcinomas, but as they were within 
one region of the colon, only one lymph node dissection had been performed 
[21].  In five cases, the reason for exclusion was not recorded [4,15,16,18,19].  
The points at which post-analysis exclusions were made are demonstrated in 
Figure 4.2.   
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Receipt from theatre via main specimen reception 
Specimen cut open to reveal the mucosal surface, with tumour/mesorectum left intact if possible 
Bowel contents washed out 
Bowel lumen wicked with formalin soaked paper towels and fixed in fresh formalin for further 24 hours 
Secondary dissection and further lymph node harvesting performed 
Secondary 
dissection 
6 5 1 
Tissue block selection and lymph node retrieval performed 
Specimens allocated randomly into either study group 1 or 2 
Groups 1A and 1B 
Specimen pot filled with fresh formalin and  
left at room temperature for 24 hours 
  
Groups 2A and 2B 
Specimen pot filled with GEWF and  
left at room temperature for 24 hours 
Primary 
dissection 17 13 3 
20 14 
8 10 
Figure 4.1.  The points at which pre-analysis exclusions were made (yellow). 
Pre-analysis pathway 
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Additional data added to original research 
spreadsheet 
Post-analysis pathway 
Figure 4.2.  The points at which post-analysis exclusions were made 
(yellow). 
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154 
 
Completeness of data 
Cases were defined as incomplete if essential data was missing.  Essential and 
non-essential data items are defined in Table 4.3.   
 
Table 4.3.  Essential and non-essential data items.  
 
Essential data item 
 
Non-essential data item 
Sex Screening detected case 
Age at surgery Trial information 
Site of tumour Size of mesentery 
Neoadjuvant therapy information Time taken for primary dissection 
Date of surgery Predicted intervention chemical 
Date of receipt Time taken for secondary dissection 
Length of fixation before primary dissection Accuracy of lymph node detection at 
secondary dissection 
Date of primary dissection  
Dissector  
Consultant  
Date intervention chemical added  
Time intervention chemical added  
Arm of study  
Date of secondary dissection  
Time of secondary dissection  
Time in intervention chemical  
No. of lymph nodes retrieved at primary dissection  
No. of negative lymph nodes at primary dissection  
No. of positive lymph nodes at primary dissection  
Size of lymph nodes at primary dissection  
No. of lymph nodes retrieved at secondary 
dissection 
 
No. of negative lymph nodes at secondary 
dissection 
 
No. of positive lymph nodes at secondary dissection  
Size of lymph nodes at secondary dissection  
TNM staging before and after secondary dissection  
 
Exclusion of cases for essential incomplete data was always due to the inability 
to measure lymph node size at primary dissection, as this could only be 
measured from the original slides.  Once cases are reported the slides are 
returned to a designated filing area, however this is not done after each case 
and trays of slides often accumulate in consultant and trainee offices.  This is 
not deemed to be a problem, because the case has been reported, with the 
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result visible to the clinician and no delay for the patient.  It only becomes a 
problem when slides are required for meetings or for review, as was the case in 
this study.  Once slides are filed they are stored for a minimum of 10 years (The 
Royal College of Pathologists, 2009), in accordance with the Human Tissue Act 
(Human Tissue Authority, 2004).  The delay before filing is usually no longer 
than one month because there is a finite amount of space on desks for old 
cases to accumulate.  At the end of the study this one month return period was 
used to determine whether cases should be included in the study or not.  If 
slides were not returned within a one month period after reporting then the case 
was excluded from the study.   
 
Cases were included where non-essential data items were missing, which 
occurred in ten of the cases.  In three cases the mesentery was not measured, 
even though this information was included within the departmental protocol 
[49,82,143].  In two cases the time taken for primary dissection was not 
recorded by cut up staff [118,145].  In five cases the chief investigator forgot to 
record the predicated intervention chemical [34,35,61,64,69]. 
 
After all pre-analysis and post-analysis exclusions were made, 200 cases 
formed the completed study sample.  Although the initial sample size calculation 
only deemed a minimum 180 samples necessary, it was decided that the 
rounded up figure of 200 should be kept as the final sample size after 
exclusions were made.  The final sample comprised 173 non-neoadjuvant 
cases (86.5%) and 27 neoadjuvant cases (13.5%).  
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4.5 DETECTION OF THE ADJUNCT TECHNIQUE 
Although the chief investigator was not privy to the intervention chemical used, 
an attempt to detect the chemical was made at secondary dissection.  This was 
not difficult as specimens in GEWF had a very distinct sheen, vinegary smell 
and cold feel, in comparison to formalin which only had a distinct smell.  GEWF 
also degraded the gloves more quickly, with the chief investigator noticing the 
need to change gloves more often when using GEWF. 
 
4.6 POPULATION 
 
4.6.1 DEMOGRAPHIC DATA 
In this study, the following definitions are used: the ‘population’ are the patients 
with colorectal cancer, whose specimens were eligible for entry into the study.  
The ‘sample’ are the 200 patients entered into the study.  The ‘groups’ refer to 
the stratifications within the study, i.e. non-neoadjuvant vs neoadjuvant and 
further fixation in formalin vs GEWF.   
 
Table 4.4 demonstrates the general study data for the entire sample.  There 
were more men than women within the study (59.5% vs 40.5%).  The majority 
of patients were between the ages of 61-90 (81.0%).  Ten percent of the cases 
were screening detected - there is currently no data available to say whether 
this is in line with the national average. 
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Table 4.4.  General study data for the entire sample. 
 
Factor (n=200) 
 
Variable Number  
(percentage / range) 
 
Sex Male 119/200 (59.5%)  
 Female 81/200 (40.5%) 
Age 21-30 1/200 (0.5%) 
 31-40 4/200 (2.0%) 
 41-50 9/200 (4.5%) 
 51-60 20/200 (10.0%) 
 61-70 58/200 (29.0%) 
 71-80 67/200 (33.5%) 
 81-90 37/200 (18.5%) 
 91-100 4/200 (2.0%) 
Mean age  70.5 years (25-97)  
Screening detected Yes - screening detected 21/200 (10.5%)  
 No - symptomatic 179/200 (89.5%) 
Clinical trial Entered 1/200 (0.5%)  
 Not entered 199/200 (99.5%) 
Site of tumour Caecum 38/200 (19.0%) 
 Ascending colon 18/200 (9.0%)  
 Hepatic flexure 7/200 (3.5%)  
 Transverse colon 11/200 (5.5%) 
 Splenic flexure 4/200 (2.0%)  
 Descending colon 9/200 (4.5%) 
 Sigmoid colon 49/200 (24.5%) 
 Rectum 64/200 (32.0%) 
Neoadjuvant therapy None 166/200 (83.0%)  
 Long course  27/200 (13.5%) 
 Short coursea  7/200 (3.5%) 
aplaced within the non-neoadjuvant group. 
 
In this study 39% of cases were right sided whilst 61% of cases were left sided.  
This is similar to the anatomical distribution of colorectal cancers in the 2013 
Southampton population, as shown in Figure 4.3, where 37% of cases were 
right sided and 63% of cases were left sided. 
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      a. Anatomical distribution of colorectal cancers in Southampton            b. Anatomical distribution of colorectal cancers within the study sample 
 
Figure 4.3.  A comparison of the anatomical distribution of colorectal cancer patients in Southampton vs those within the 
study sample. 
 
Caecum 17.8% 
Sigmoid colon 
28.7% 
Descending 
colon 2.5% 
Splenic flexure 
4.4% 
Transverse 
colon 4% 
Hepatic flexure 
1.5% 
Ascending 
colon 8.9% 
Rectum 32.2% 
Caecum 19.0% 
Sigmoid colon 
24.5% 
Descending 
colon 4.5% 
Splenic flexure 
2.0% 
Transverse 
colon 5.5% 
Hepatic flexure 
3.5% 
Ascending 
colon 9.0% 
Rectum 32.0% 
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Thirteen and a half percent of the patients within this study received long-course 
neoadjuvant therapy.  This value is slightly higher than the expected figure of 
10%, however as the expected figure was based upon previous specimens 
received over a greater period of time, it is unsurprising that this figure differs 
slightly. 
 
Table 4.5 demonstrates the pathological data for the entire sample.  The mean 
time from surgery to primary dissection was 3 days.  This is probably due to the 
inclusion of weekends, where specimens sit fixing until the Monday because the 
department is not routinely open at weekends. 
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Table 4.5.  Pathological study data for the entire sample.  
 
Factor (n=200) Variable Number  
(percentage / 
range) 
 
Mean time from surgery and primary dissection  3 days (1-5) 
Dissector group Consultant (n=5) 66/200 (33.0%) 
 AP (n=1) 64/200 (32.0%) 
 Senior traineea (n=9) 48/200 (24.0%) 
 Junior traineeb (n=7) 22/200 (11.0%) 
Mean time for primary dissectionc (n=198) Overall 51 mins (14-150) 
 Consultant 32 mins(14-92) 
 AP 58 mins (25-105) 
 Senior traineea 52 mins (15-110) 
 Junior traineeb 84 mins (30-150) 
Predicted intervention chemicald Further fixation 98/195 (50.3%) 
 GEWF 97/195 (49.7%) 
Actual intervention chemical Further fixation 101/200 (50.5%) 
 GEWF 99/200 (49.5%) 
Mean time spent in intervention chemical Further fixation 25 hours (24-29) 
 GEWF 25 hours (24-32) 
Accuracy of predictiond Correct 193/195 (99.0%) 
 Incorrect 2/195 (1.0%) 
Mean time for secondary dissection  15.2 mins (1-45) 
TNM staging (y)pT0 8/200 (4.0%) 
 (y)pT1 15/200 (7.5%) 
 (y)pT2 39/200 (19.5%) 
 (y)pT3 93/200 (46.5%) 
 (y)pT4 45/200 (22.5%) 
 
ain second year or more of histopathology training; bin first year of histopathology training; cnot 
measured in 2/200 cases; dnot predicted in 5/200 cases. 
 
 
The advanced practitioner performed the primary dissection in 64 of the 200 
cases within the study (32.0%).  The consultants dissected slightly more 
(33.0%) but there were five dissectors within this group and therefore the single 
advanced practitioner dissected the most cases.   
 
The junior trainees, in their first year of histopathology training, dissected the 
least cases but this is because they have a lower workload than that of their 
more experienced colleagues.  The consultants spent less time performing 
primary dissection than the advanced practitioner or senior trainees.  This was 
probably due to their extensive experience, but possibly also because of other 
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factors competing for their time.  The level of experience of the advanced 
practitioner and senior trainees is equivalent, so the similar figures are 
expected.  The time taken by junior trainees was much greater, and this would 
also be expected, in keeping with their minimal experience in specimen 
dissection.  
 
Almost half of the cases were staged as pT3 (46.5%), with tumour invasion 
beyond the muscularis propria, but not reaching the serosal surface.  Tumours 
staged as pT2 and pT4 accounted for less than half of those staged as pT3 
(19.5% and 22.5% respectively), with pT1 tumours, limited to the submucosa, 
only reported in 7.5% of cases.  In a further 4.0% of cases the staging was pT0, 
or ypT0.  Some of these cases were in the neoadjuvant arm of the study and 
had shown complete tumour regression in response to long-course neoadjuvant 
therapy, whilst others were polyp cancers where no residual tumour was 
identified at resection.   
 
The two intervention chemicals were used almost equally (50.5% vs 49.5%).  
Due to the characteristic smell, appearance and texture of GEWF the advanced 
practitioner attempted to predict which chemical had been used before 
performing the secondary dissection.  This was checked at the end of the data 
collection period and was found to be accurate in all but two of the 195 cases 
where the prediction was made.  The date and time that specimens were put 
into the intervention chemical was recorded, in order to ensure that secondary 
dissection was performed the day after the intervention chemical was added, 
and as close to 24 hours as possible.  The time in the intervention chemical was 
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never less than 24 hours.  Occasionally it was difficult to perform the secondary 
dissection after 24 hours due to other commitments, but the greatest time a 
specimen was left in an intervention chemical was 32 hours, in a single case 
[109].  In the minority of cases where the specimens were left in the intervention 
chemical for more than one day after primary dissection, the cases were 
excluded [exclusions 1,5,6].  
 
4.6.2 NON- NEOADJUVANT THERAPY GROUP 
The data for the non-neoadjuvant therapy group is similar to that of the entire 
sample (n=173 vs n=200) and can be found in Appendix S. 
 
 
4.6.3 NEOADJUVANT THERAPY GROUP 
Table 4.6 demonstrates the general data for the neoadjuvant therapy group.  In 
this group there were more than three times as many men as women (77.8% vs 
22.2%).  The reasons for this are unclear.  The majority of patients were aged 
between 61 and 90 (77.7%) – a similar proportion to that in the entire sample.   
 
Table 4.6.  General study data for the neoadjuvant therapy group. 
   
Factor (n=27) Variable Number  
(percentage / range) 
 
Sex Male 21/27 (77.8%) 
 Female 6/27 (22.2%) 
Age 41-50 2/27 (7.4%) 
 51-60 4/27 (14.8%) 
 61-70 8/27 (29.6%) 
 71-80 7/27 (25.9%) 
 81-90 6/27 (22.2%) 
Mean age  69.1 years (43-87) 
Screening detected Yes - screening detected 2/27 (7.4%) 
 No - symptomatic 25/27 (92.6%) 
Clinical trial Entered 1/27 (3.7%) 
 Not entered 26/27 (96.3%) 
Site of tumour Rectum 27/27 (100%) 
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All of the tumours in this group were from the rectum.  This is in line with 
national guidance for the use of neoadjuvant therapy in rectal cancer (National 
Institute for Health and Clinical Excellence, 2011).   
 
Table 4.7 demonstrates the pathological data for the neoadjuvant therapy 
group.   
 
Table 4.7.  Pathological study data for the neoadjuvant therapy group. 
   
Factor (n=27) Variable No. 
(% / range) 
 
Mean time from surgery to primary dissection  3 days (2-5) 
Dissector group Consultant (n=4) 11/27 (40.7%) 
 AP (n=1) 13/27 (48.1%) 
 Senior traineea (n=2) 2/27 (7.4%) 
 Junior traineeb (n=1) 1/27 (3.7%) 
Mean time for primary dissection Overall 58 mins (25-136) 
 Consultant (n=4) 38 mins (25-55) 
 AP (n=1) 65 mins (30-90) 
 Senior traineea (n=2) 73 mins (65-80) 
 Junior traineeb (n=1) 136 mins (136) 
Predicted intervention chemical Further fixation 15/27 (55.6%) 
 GEWF 12/27 (44.4%) 
Actual intervention chemical Further fixation 15/27 (55.6%) 
 GEWF 12/27 (44.4%) 
Accuracy of prediction Correct 27/27 (100%) 
Mean time in intervention chemical  25 hours (24-29) 
Mean time for secondary dissection  16.9 mins (1-35) 
ypT stagec ypT0 5/27 (18.5%) 
 ypT1 1/27 (3.7%) 
 ypT2 8/27 (29.6%) 
 ypT3 11/27 (40.7%) 
 ypT4 2/27 (7.4%) 
ain second year or more of histopathology training; bin first year of histopathology training; c‘y’ 
designates long-course neoadjuvant therapy. 
 
The majority of the specimens within this group were dissected primarily by 
consultants or the advanced practitioner (88.8%), with only three out of the 27 
specimens dissected by trainees.  This is due to chance because this group of 
specimens do not arrive according to any particular pattern and the rotas for 
specimen dissection are randomly organised.     
164 
 
The mean time for primary dissection was longer for this group.  This would be 
expected because often there is no macroscopically visible residual tumour.  
This results in the entire tumour site area being sampled.  Lymph nodes are 
often more difficult to identify in specimens after long-course neoadjuvant 
therapy (Marks et al., 2010; Morcos et al., 2010) and therefore this part of the 
dissection may also take longer.  In the one case dissected by an ST1, the 
primary dissection took over two hours (136 minutes).  This extended amount of 
time would be explained by their lack of experience, especially in terms of 
harvesting lymph nodes.  A much higher number of tumours were staged as 
‘ypT0’ within this group in comparison to the non-neoadjuvant group (18.5% vs 
1.7%).  This would be expected because of the effect of complete tumour 
regression in response to long-course neoadjuvant therapy.   
 
4.7 LYMPH NODE RETRIEVAL 
Occult metastatic disease in colorectal cancer has been clearly defined by the 
UICC (Sobin et al., 2009).  Metastases are tumour deposits >2.0mm in 
dimension whilst micrometastases are tumour deposits ≤2.0mm but greater 
than 0.2mm in dimension.  (Sobin et al., 2009). 
 
Isolated tumour cells are single or small numbers of tumour cells ≤0.2mm in 
dimension, however only metastases and micrometastases were considered 
within this study.  In a single case (228160614) two isolated tumour cells were 
identified and confirmed by cytokeratin 8 immunohistochemistry, but this case 
was considered negative due to the size of the deposits (A. Bateman, personal 
communication, June 25, 2014). 
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Table 4.8 demonstrates data relating to the lymph nodes retrieved at primary 
and secondary dissection for the entire sample and in the non-neoadjuvant and 
neoadjuvant groups. 
 
Primary dissection 
The mean and median numbers of lymph nodes identified at primary dissection 
by all groups of staff was 19.3 and 18.0 respectively.  The median figure is 
above the number of 12 recommended by the Royal College of Pathologists 
(The Royal College of Pathologists, 2014).  The median number of lymph nodes 
retrieved at primary dissection for the neoadjuvant group was lower than that of 
the non-neoadjuvant group (13 vs 19).  This would be expected, due to the 
known difficulties in retrieving lymph nodes in neoadjuvant therapy specimens.  
This figure is still above the median of 12, recommended by the Royal College 
of Pathologists for all cases (The Royal College of Pathologists, 2014) and 
demonstrates the high quality of local specimen dissection practice.  In the 
entire sample and the non-neoadjuvant group a similar proportion of cases 
showed metastases within lymph nodes (39.5% vs 42.8%).  The proportion in 
the neoadjuvant group was less than half of that in the other groups (18.5%).  
This could have been due to there being less cases within this group, but also 
because lymph nodes may have been more difficult to find.  Lymph nodes 
within this group may also have contained sterilised tumour or acellular mucin 
pools or may have shown evidence of fibrosis - all of which would have led 
them to be classified as negative for tumour (The Royal College of Pathologists, 
2014).  
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The mean size of lymph nodes retrieved at primary dissection was similar in the 
entire sample and the non-neoadjuvant groups (8.6mm vs 8.8mm).  The mean 
size was greatly reduced in the neoadjuvant group (4.6mm) which was in line 
with existing evidence suggesting that this would be the case (Marks et al., 
2010; Morcos et al., 2010). 
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Table 4.8. Lymph nodes harvested at primary and secondary dissection for the entire sample. 
 
Primary dissection (n=200) 
 
Secondary dissection (n=200) 
Demographic Number (percentage / range) 
 
Demographic Number (percentage / range) 
 
 
Sample 
(n=200) 
 
Non-
neoadjuvant 
(n=173) 
Neoadjuvant 
 
(n=27) 
 
 Sample 
(n=200) 
Non-
neoadjuvant 
(n=173) 
Neoadjuvant 
 
(n=27) 
Total no. of lymph nodes at 
primary dissection 
3850 3471 379 Total no. of lymph nodes 
at secondary dissection 
1555 1384 171 
Mean no. of lymph nodes at 
primary dissection 
19.3  
(3-47) 
20.1  
(4-47) 
14.0  
(3-27) 
Mean no. of lymph nodes 
at secondary dissection 
7.8  
(0-30) 
8  
(0-30) 
6.3  
(0-18) 
Mean size of smallest- 
largest lymph nodes at 
primary dissection 
1.5-8.9mm  
(0.5-28.0) 
1.5-9.4mm  
(0.5-28.0) 
1.3-5.6mm  
(0.5-10.0) 
Mean size of smallest-
largest lymph nodes at 
secondary dissection 
1.2-4.1mm  
(0.5-12.0) 
1.3-4.3mm  
(0.5-12.0) 
0.9-2.9mm  
(0.5-5.0) 
Median no. of lymph nodes 
at primary dissection 
18 
(3-47) 
19 
(4-47) 
13 
(3-27) 
No. of cases with no 
additional lymph nodes at 
secondary dissection 
4  
(2.0%) 
2  
(1.2%) 
2  
(7.4%) 
No. of cases with only 
negative lymph nodes at 
primary dissection 
121/200 
(60.5%) 
99/173 
(57.2%) 
22/27  
(81.5%) 
No. of cases with only 
negative lymph nodes at 
secondary dissection  
177/200  
(90.3%) 
153/173 
(89.5%) 
24/27  
(96%) 
No. of negative lymph 
nodes at primary dissection 
3561 3200 361 No. of negative lymph 
nodes at secondary 
dissection 
1526 1357 169 
No. of cases with positive 
lymph nodes at primary 
dissection 
79/200  
(39.5%) 
74/173 
(42.8%) 
5/27  
(18.5%) 
No. of cases with positive 
lymph nodes at secondary 
dissection  
19/200  
(9.7%) 
18/173 
(10.5%) 
1/27  
(4.0%) 
No. of positive lymph nodes 
at primary dissection  
289 271 18 No. of positive lymph 
nodes at secondary 
dissection  
29 27 2 
Mean size of largest 
positive lymph nodes at 
primary dissection  
8.6mm  
(1.0-28.0) 
8.8mm  
(1.0-28.0) 
4.6mm  
(2.0-9.0) 
Mean size of largest 
positive lymph nodes at 
secondary dissection 
4.4mm  
(1.5-8.0) 
4.4mm  
(1.5-8.0) 
3.5mm  
(3.5-3.5) 
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Secondary dissection  
The total number of additional lymph nodes harvested at secondary dissection 
was 1555.  This equated to a mean of 7.8 nodes per case overall, and an 
additional mean of 8.0 and 6.3 in the non-neoadjuvant and neoadjuvant groups 
respectively.  The mean size of the smallest lymph nodes retrieved at 
secondary dissection was slightly smaller than that in the non-neoadjuvant 
group (0.9mm vs 1.3mm), whilst the mean size of the largest lymph nodes was 
much smaller (2.9mm vs 4.3mm).  This might have been due to the known 
smaller size of lymph nodes in neoadjuvant specimens.  This may have also 
been due to the additional time taken at primary dissection to retrieve the lymph 
nodes in the neoadjuvant group, thus identifying smaller nodes at initial 
examination.   
 
At secondary dissection fewer specimens elicited positive lymph nodes than at 
primary dissection (9.7% vs 39.5%).  This supports the high quality of local 
specimen dissection practice, whereby appropriate lymph node retrieval 
identifying positive lymph nodes is performed at primary dissection.  Only 29 
positive lymph nodes were identified at secondary dissection, the majority of 
which were retrieved in the non-neoadjuvant cases (93.1%).  The mean size of 
positive lymph nodes identified at secondary dissection was smaller in all 
groups, most likely because the larger positive lymph nodes had already been 
identified at primary dissection.   
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4.8 INTERVENTIONS 
 
4.8.1 USE OF GEWF 
Table 4.9 demonstrates that the findings within the GEWF group were similar to 
those within the entire sample.  The total number of additional lymph nodes 
harvested at secondary dissection was 718.  This equated to a mean of 7.3 
nodes per case overall, and a mean of 7.4 and 5.8 additional lymph nodes in 
the non-neoadjuvant and neoadjuvant groups respectively.   The mean size of 
the smallest and largest lymph nodes retrieved at secondary dissection was 
smaller in the neoadjuvant group when compared to the non-neoadjuvant group 
(1.0-2.9mm vs 1.3-4.2mm), as would be expected. 
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Table 4.9.  The effects of GEWF on lymph nodes harvested at primary and secondary dissection. 
 
Primary dissection (n=99) Secondary dissection (n=99) 
 
Demographic Number (percentage / range) 
 
Demographic Number (percentage / range) 
 
 
 
Sample 
 
(n=99) 
Non-
neoadjuvant 
(n=87) 
Neoadjuvant 
 
(n=12) 
 
 Sample 
 
(n=99) 
Non-
neoadjuvant 
(n=87) 
Neoadjuvant 
 
(n=12) 
Total no. of lymph nodes at 
primary dissection 
1877 1693 184 Total no. of lymph nodes at 
secondary dissection 
718 648 70 
Mean no. of lymph nodes at 
primary dissection 
19.0  
(3-43) 
19.5 
(4-43) 
15.3 
(3-27) 
Mean no. of lymph nodes at 
secondary dissection 
7.3  
(0-30) 
7.4 
(0-30) 
5.8 
(0-18) 
Mean size of smallest – 
largest lymph nodes at 
primary dissection (mm) 
1.4-9.0mm 
(0.5-28.0) 
1.5-9.4mm 
(0.5-28.0) 
1.0-5.8mm 
(0.5-10.0) 
Mean size of smallest – 
largest lymph nodes at 
secondary dissection (mm)  
1.3-
4.0mm 
(0.5-9.5) 
1.3-4.2mm 
(0.5-9.5) 
 
1.0-2.9mm 
(0.5-5.0) 
 
    No. of cases with no 
additional lymph nodes at 
secondary dissection 
2/99  
(2.0%) 
1/87  
(1.1%) 
1/12  
(8.3%) 
No. of cases with only 
negative lymph nodes at 
primary dissection 
62/99  
(62.6%) 
51/87  
(58.6%) 
11/12 
(91.7%) 
No. of cases with only 
negative lymph nodes at 
secondary dissection  
88/99  
(88.9%) 
76/87 
(87.4%) 
12/12 
(100%) 
No. of negative lymph 
nodes at primary dissection 
1746 1570 176 No. of negative lymph 
nodes at secondary 
dissection 
698 628 70 
No. of cases with positive 
lymph nodes at primary 
dissection 
37/99  
(37.4%) 
36/87 
(41.4%) 
1/12 
(8.3%) 
No. of cases with positive 
lymph nodes at secondary 
dissection 
11/99  
(11.3%) 
11/87 
(12.6%) 
0/12 
(0%) 
No. of positive lymph nodes 
at primary dissection 
131 123 8 No. of positive lymph nodes 
at secondary dissection 
20 20 0 
Mean size of largest 
positive lymph nodes at 
primary dissection 
8.5mm  
(1.0-28.0) 
8.6mm 
(1.0-28.0) 
4.0mm 
(4.0-4.0) 
Mean size of largest 
positive lymph nodes at 
secondary dissection 
5.2mm  
(1.5-8) 
5.2mm 
(1.5-8) 
- 
171 
 
At secondary dissection fewer specimens elicited positive lymph nodes than at 
primary dissection (11.3% vs 37.4%).  This further supports the high quality of 
local specimen dissection practice.  Only 20 positive lymph nodes were 
identified at secondary dissection, all of which were retrieved in the non-
neoadjuvant cases.  No positive lymph nodes were identified in the neoadjuvant 
group treated with GEWF.  The mean size of positive lymph nodes identified at 
secondary dissection was smaller in all groups, most likely because the larger 
positive lymph nodes had already been identified at primary dissection.   
 
4.8.2 USE OF FURTHER FIXATION 
Table 4.10 demonstrates that the findings within the further fixation group were 
similar to those found in the entire sample.  The total number of additional 
lymph nodes retrieved at secondary dissection in the further fixation group was 
837.  This equated to a mean of 8.3 nodes per case overall, and a mean of 8.6 
and 6.7 additional lymph nodes in the non-neoadjuvant and neoadjuvant groups 
respectively.  The mean size of the smallest lymph nodes retrieved at 
secondary dissection was slightly smaller in the neoadjuvant group than in the 
non-neoadjuvant group (0.9mm vs 1.2mm), whilst the mean size of the largest 
lymph nodes was much smaller (3.0mm vs 4.4mm), for similar reasons as 
suggested for the entire sample.   
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Table 4.10.  The effects of further fixation on lymph nodes harvested at primary and secondary dissection. 
 
Primary dissection (n=101) Secondary dissection (n=101) 
 
Demographic Number (percentage / range) Demographic Number (percentage / range) 
 
 
Sample 
(n=101) 
Non-
neoadjuvant 
(n=86) 
Neoadjuvant 
 
(n=15) 
 
 Sample 
(n=101) 
Non-
neoadjuvant 
(n=86) 
Neoadjuvant 
 
(n=15) 
Total no. of lymph nodes at 
primary dissection 
1973 1778 195 Total no. of lymph nodes 
at secondary dissection 
837 736 101 
Mean no. of lymph nodes at 
primary dissection 
19.5  
(4-47) 
20.7 
(4-47) 
13  
(4-27) 
Mean no. of lymph nodes 
at secondary dissection 
8.3  
(0-28) 
8.6 
(0-28) 
6.7  
(0-13) 
Mean size of smallest – 
largest lymph nodes at 
primary dissection 
1.5-8.7mm  
(0.5-18.0) 
1.5-9.3mm  
(0.5-18.0) 
1.4-5.5mm  
(0.5-9.0) 
Mean size of smallest – 
largest lymph nodes at 
secondary dissection 
1.2-4.2mm  
(0.5-12.0) 
1.2-4.4mm  
(0.5-12.0) 
0.9-3.0mm  
(0.5-5.0) 
    No. of cases with no 
additional lymph nodes at 
secondary dissection 
2/101 
(2.0%) 
1/86  
(1.2%) 
1/15  
(6.7%) 
No. of cases with only 
negative lymph nodes at 
primary dissection 
59/101 
(58.4%) 
48/86  
(55.8) 
11/15  
(73.3%) 
No. of cases with only 
negative lymph nodes at 
secondary dissection  
91/101  
(91.9%) 
78/86  
(91.8%) 
13/15  
(92.9%) 
No. of negative lymph 
nodes at primary dissection 
1815 1630 185 No. of negative lymph 
nodes at secondary 
dissection 
828 729 99 
No. of cases with positive 
lymph nodes at primary 
dissection 
42/101  
(41.6%) 
38/86  
(44.2) 
4/15  
(26.7%) 
No. of cases with positive 
lymph nodes at secondary 
dissection 
8/101  
(8.1%) 
7/86  
(28.0%) 
1/15  
(7.1%) 
No. of positive lymph nodes 
at primary dissection 
158 148 10 No. of positive lymph 
nodes at secondary 
dissection 
9 7 2 
Mean size of largest 
positive lymph nodes at 
primary dissection  
3.8mm  
(1.0-19.0) 
3.9mm 
(1.0-19.0) 
4.8mm  
(2.0-9.0) 
Mean size of largest 
positive lymph nodes at 
secondary dissection 
3.2mm  
(1.5-5.0) 
1.0mm 
(1.0-1.0) 
3.5mm  
(3.5-3.5) 
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At secondary dissection fewer specimens elicited positive lymph nodes than at 
primary dissection (8.1% vs 41.6%), again supporting the high quality of local 
specimen dissection practice.  Only nine positive lymph nodes were identified at 
secondary dissection, the majority of which were retrieved in the non-
neoadjuvant cases (77.8%).  The mean size of positive lymph nodes identified 
at secondary dissection was smaller in all groups, most likely because the 
larger positive lymph nodes had already been identified at primary dissection.   
 
4.8.3 FURTHER FIXATION vs GEWF  
Table 4.11 demonstrates the size of lymph nodes harvested in the entire 
sample and the non-neoadjuvant and neoadjuvant groups according to the 
criteria defined above.  Less lymph nodes were retrieved at secondary 
dissection when GEWF was used (718 vs 837), with the mean number also 
lower (7.3 vs 8.3).  The mean size of the smallest and largest lymph nodes for 
both intervention groups was similar (1.2mm vs 1.3mm and 4.2mm vs 4.0mm).   
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Table 4.11.  The effect of further fixation vs GEWF on the number and size of lymph nodes harvested at secondary 
dissection.  
 
 Sample (n=200) 
 
Non-neoadjuvant (n=173) Neoadjuvant (n=27) 
 Further fixation 
(% / range) 
(n=101) 
GEWF 
(% / range) 
(n=99) 
 
Further fixation  
(% / range) 
(n=86) 
GEWF 
(% / range) 
(n=87) 
Further 
fixation  
(% / range) 
GEWF  
(% / range) 
Total no. of lymph nodes  837 718 736 648 101 70 
Mean no. of lymph nodes  8.3 (0-28) 7.3 (0-30) 8.6 (0-28) 7.4 (0-30) 6.7 (0-13) 5.8 (0-18) 
Mean size of lymph nodes  2.6mm  
(>0.2-12.0mm) 
2.4mm 
(>0.2-9.5mm) 
2.7mm 
(>0.2-12.0mm) 
2.5mm 
(>0.2-9.5mm) 
1.8mm 
(>0.2-5.0mm) 
1.8mm 
(>0.2-5.0mm) 
Negative lymph nodes       
Total no. of negative lymph nodes 828 698 729 628 99 70 
Mean size of negative lymph nodes  2.6mm 
(>0.2-12.0mm) 
2.4mm 
(>0.2-9.5mm) 
2.7mm 
(>0.2-12.0mm) 
2.4mm 
(>0.2-9.5mm) 
1.8mm 
(>0.2-5.0mm) 
1.8mm 
(>0.2-5.0mm) 
No. of lymph nodes ≥5.0mm  81/828 (9.8%) 51/698 (7.3%) 78/729 (10.7%) 50/628 (8.0%) 2/99 (2.0%) 1/70 (1.4%) 
No. of lymph nodes ≥2.0-4.9mm 500/828 (60.4%) 399/698 (57.2%) 447/729 (61.3%) 368/628 (58.6%) 55/99 (55.6%) 31/70 (44.3%) 
No. of lymph nodes >0.2-1.9mm 247/828 (29.8%) 248/698 (35.5%) 204/729 (28.0%) 210/628 (33.4%) 42/99 (42.4%) 38/70 (54.3%) 
Positive lymph nodes       
Total no. of positive lymph nodes 9 20 7 20 2 0 
Mean size of positive lymph nodes  3.0mm  
(1.5-5.0mm) 
4.5mm  
(1.5-8.0mm) 
3.1mm  
(1.5-5.0mm) 
4.5mm 
(1.5-8.0mm) 
2.5mm 
(1.5-3.5mm) 
- 
No. of positive lymph nodes ≥5.0mma  1/9 (11.1%) 9/20 (45.0%) 1/7 (14.3%) 9/20 (45.0%) 0/2 (0%) - 
No. of positive lymph nodes ≥2.0-4.9mmb  6/9 (66.7%) 9/20 (45.0%) 5/7 (71.4%) 9/20 (45.0%) 1/2 (50%) - 
No.of positive lymph nodes >0.2-1.9mmc 2/9 (22.2%) 2/20 (10.0%) 1/7 (14.3%) 2/20 (10.0%) 1/2 (50%) - 
alarge metastases: ≥5.0mm; bsmall metastases: ≥2.0-4.9mm; cmicrometastases:  >0.2mm-1.9mm. 
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A similarly high proportion of cases were negative for metastatic tumour (91.9% 
vs 90.7%), with only eight and 11 cases containing metastatic lymph nodes in 
respective groups.  More than twice as many positive lymph nodes were 
retrieved where GEWF was used (20 vs 9), however no positive lymph nodes 
were retrieved in the neoadjuvant GEWF group.  The reasons for this are 
unclear but as the group was small (n=12), the findings may be due to chance.  
The mean size of positive lymph nodes were smaller in the specimens treated 
with further fixation in comparison to those treated with GEWF (3.2mm vs 
5.2mm).  These differences may also be due to chance as the numbers of 
positive lymph nodes retrieved with both intervention chemicals was small.          
 
4.9 DISSECTION EXPERTISE 
 
Entire sample 
Table 4.12 summarises the effect of dissection expertise on lymph node 
harvesting in the entire sample.  The advanced practitioner retrieved the highest 
mean number of lymph nodes at primary dissection (23.3).  The lowest mean 
number of lymph nodes was retrieved by the consultant group (15.7).  These 
figures are similar to those found in previous departmental audits (Horne & 
Green, 2013; Horne et al., 2011).  When the median number was considered 
the advanced practitioner, consultants and junior trainees all retrieved the same 
number (22).  Only the senior trainees retrieved a lower median number (18.5), 
but this was still in excess of RCPath recommendations (The Royal College of 
Pathologists, 2014).   
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Table 4.12.  The effect of dissection expertise on lymph node harvesting in 
the entire sample.  
 
 Consultants 
 
(%/range) 
Advanced 
practitioner 
(%/range) 
Senior 
trainees 
(%/range) 
Junior 
trainees 
(%/range) 
 
Sample (n=200) (n=66) (n=64) (n=48) (n=22) 
 
Total no. of lymph nodes at primary 
dissection 
1034 1491 929 396 
Mean no. of lymph nodes at 
primary dissection  
15.7  
(3-47) 
23.3  
(4-47) 
19.4  
(4-42) 
18  
(8-37) 
Median no of lymph nodes at 
primary dissection 
22 22 18.5 22 
Mean size of smallest – largest 
lymph nodes at primary dissection 
1.4-8.0mm  
(0.5-24.0) 
1.3-8.3mm  
(0.5-24.0) 
1.5-
10.1mm  
(0.5-28.0) 
1.9-
10.5mm  
(0.5-16.0) 
Mean size of largest positive lymph 
nodes at primary dissection 
7.7mm 
(2.0-24.0) 
7.5mm 
(1.5-24.0) 
10.1mm 
(1.0-28.0) 
10.2mm 
(1.0-16.0) 
Total no. of lymph nodes at 
secondary dissection 
584 283 482 205 
Mean no. of lymph nodes at 
secondary dissection 
8.8 (1-30) 4.7 (0-15) 10 (2-28) 9.3 (1-20) 
Mean size of smallest – largest 
lymph nodes at secondary 
dissection 
1.3-4.7mm  
(0.5-12.0) 
1.3-3.0mm  
(0.5-7.0) 
1.2-
4.6mm  
(0.5-9.0) 
1.1-
4.4mm  
(0.5-7.0) 
Mean size of largest positive lymph 
nodes at secondary dissection  
4.7mm  
(1.5-7.0) 
2.7mm  
(2.0-3.0) 
4.9mm  
(3.0-8.0) 
4.3mm  
(1.5-7.0) 
No. of cases with upstaging (TNM5 
or TNM7) 
2  
(3.0%) 
2 (3.1%)  2  
(4.2%) 
0  
No. of cases with upstaging 
changing treatment 
0  1 (1.6%) 1  
(2.1%) 
0  
No. of cases with no lymph nodes 
harvested at secondary dissection 
0  4 (6.3%) 0  0  
 
Figure 4.4 explains the reasons for the differences in mean and median values 
between groups.  For example, the mean values for advanced practitioner and 
consultant groups varies (23.3 vs 15.7), whilst the median values are the same 
(22).  The higher mean value for the advanced practitioner can be explained by 
the greater range of results, both above and below the median of 22.  For 
consultants the greatest proportion of harvests are below the median of 22, thus 
making the mean value lower. 
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Figure 4.4. Frequency distribution charts to show differences between 
mean and median lymph node harvests at primary dissection by each 
dissector group.  
 
The number of lymph nodes retrieved at secondary dissection was highest in 
the consultant group, which would be expected as this group retrieved the 
lowest number at primary dissection.  The least number of additional lymph 
nodes were retrieved at secondary dissection when the advanced practitioner 
had performed the primary dissection, but this was to be expected as this group 
harvested the most lymph nodes at primary dissection.  All dissector groups 
Advanced Practitioner Consultant 
Junior trainees Senior trainees 
0                              25                           50 
0                              25                           50 0                              25                           50 
0                              25                           50 
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identified lymph nodes as small as 0.5mm or less at primary dissection.  The 
largest lymph nodes identified at primary dissection were up to 28mm.   
 
Positive lymph nodes with a mean size of above 4mm were identified at 
secondary dissection in all of the groups except the advanced practitioner, 
where no positive lymph nodes above 3mm were identified (mean 2.7mm).  In 
the other groups positive lymph nodes up to 8mm were identified at secondary 
dissection, however the largest positive lymph node identified at secondary 
dissection from the advanced practitioner group was 3mm, suggesting that any 
positive lymph nodes above this size were retrieved at primary dissection.   
 
Six cases of upstaging were identified equally across the dissector groups, 
except for the junior trainee group where there were no incidences of upstaging.  
Only two of these cases of upstaging were from pN0 to pN1, leading to the 
potential for change in adjuvant treatment.  These incidences occurred within 
the advanced practitioner and senior trainee groups.  No cases of significant 
upstaging occurred within the consultant dissector group.  It is difficult to identify 
the cause for these two cases of statistical upstaging.  They may have occurred 
by chance because of the low incidence, however they could also be due to 
deficiencies in technique or time spent performing the primary dissection.  The 
primary dissection results for both of these dissector groups fails to support this 
theory, as the quality of practice has been shown to be high.  Therefore chance 
is the most likely reason for the incidence of significant upstaging in these two 
cases.  These findings support the high quality of practice demonstrated by all 
dissector groups.   
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Non-neoadjuvant group 
Table 4.13 summarises the effect of dissection expertise on lymph node 
harvesting in the non-neoadjuvant group.  In keeping with the entire sample, the 
advanced practitioner also retrieved the highest number of lymph nodes at 
primary dissection in the non-neoadjuvant group.  The numbers can only be 
compared to the consultant and senior trainee groups because a similar number 
of specimens were dissected in these three groups.   
 
Table 4.13.  The effect of dissection expertise on lymph node harvesting in 
the non-neoadjuvant group.  
 
 Consultants 
 
(% / range) 
Advanced 
practitioner 
(% / range) 
Senior 
trainees 
(% / range) 
Junior 
trainees 
(% / range) 
 
Sample (n=173) (n=55) (n=51) (n=46) (n=21) 
 
Total no. of lymph nodes at 
primary dissection 
925 1262 909 375 
Mean no. of lymph nodes at 
primary dissection 
16.8  
(4-47) 
24.7  
(4-47) 
19.8  
(7-42) 
17.9  
(8-37) 
Median no. of lymph nodes 
at primary dissection 
23 23 18 17 
Mean size of smallest - 
largest lymph nodes at 
primary dissection  
1.5-8.5mm 
(0.5-24.0) 
1.3-9.0mm 
(0.5-24.0) 
1.5-10.2mm 
(0.5-28.0) 
2.0-10.7mm 
(0.5-16.0) 
Mean size of largest positive 
lymph nodes at primary 
dissection 
8.1mm 
(2.0-24.0) 
7.8mm 
(1.5-24.0) 
10.1mm 
(1.0-28.0) 
10.2mm 
(1.0-16.0) 
Total no. of lymph nodes at 
secondary dissection 
506 230 460 188 
Mean no. of lymph nodes at 
secondary dissection 
9.2  
(1-30) 
4.5  
(0-15) 
10  
(2-28) 
9.0  
(1-20) 
Mean size of smallest – 
largest lymph nodes at 
secondary dissection  
1.3-4.9mm 
(0.5-12.0) 
1.3-3.1mm 
(0.5-7.0) 
1.2-4.7mm 
(0.5-9.0) 
1.1-4.4mm 
(0.5-7.0) 
Mean size of largest positive 
lymph nodes at secondary 
dissection  
4.8mm  
(1.5-7.0) 
2.7mm  
(2.0-3.0) 
 
4.9mm  
(3.0-8.0) 
4.3mm  
(1.5-7.0) 
No. of cases with upstaging 
(TNM5 or TNM7) 
2 (3.6) 2 (3.9%) 2 (4.3%) 0  
No. of cases with upstaging 
changing treatment 
0  1 (2.0%) 1 (2.2%) 0  
No. of cases with no lymph 
nodes harvested at 
secondary dissection 
0 2 (3.9%) 0 0  
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The advanced practitioner retrieved a far higher number of lymph nodes when 
compared to consultant (1262 vs 925) and senior trainee groups (1262 vs 909).  
This may represent the additional time and effort spent on each specimen by 
the advanced practitioner, but also the additional competing demands on 
consultant time.  The difference between the advanced practitioner and senior 
trainee groups may be due to experience as the advanced practitioner dissects 
a greater number of these specimens in routine practice.  The competing 
demands on time for the advanced practitioner and senior trainees are similar 
so this is unlikely to be the underlying cause for the difference.  The mean and 
median number of lymph nodes retrieved at primary dissection by all dissector 
groups was above the recommended median of 12 (The Royal College of 
Pathologists, 2014), further supporting the high quality practice within the 
department.   
 
The least number of lymph nodes were detected at secondary dissection in 
those cases primarily dissected by the advanced practitioner.  The largest 
lymph node identified at secondary dissection was in the consultant group, at 
12mm.  The positive lymph node findings were similar to those within the entire 
sample.  All of the cases of upstaging previously described, were within the 
non-neoadjuvant group of specimens.  Four cases had no further lymph nodes 
detected at secondary dissection, and these were all in cases primarily 
dissected by the advanced practitioner. 
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Neoadjuvant group 
Table 4.14 summarises the effect of dissection expertise on lymph node 
harvesting in the neoadjuvant group.  In keeping with the entire sample, the 
advanced practitioner also retrieved the highest number of lymph nodes at 
primary dissection in the neoadjuvant group.  The numbers can only be 
compared to the consultant group because a similar number of specimens were 
dissected in these two groups.  The advanced practitioner retrieved more than 
twice as many lymph nodes at primary dissection when compared to 
consultants (229 vs 109).  This may represent the additional time and effort 
spent on each specimen by the advanced practitioner and the additional 
competing demands on consultant time.   
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Table 4.14.  The effect of dissection expertise on lymph node harvesting in 
the neoadjuvant group.  
 
 Consultants 
 
(% / range) 
Advanced 
practitioner 
(% / range) 
 
Senior 
trainees 
(% / range) 
Junior 
trainees 
(% / range) 
Neoadjuvant (n=27) (n=11) (n=13) (n=2) (n=1) 
 
Total no. of lymph nodes at 
primary dissection 
109 229 20 21 
Mean no. of lymph nodes at 
primary dissection 
9.9  
(3-15) 
17.7  
(5-27) 
10  
(4-16) 
21  
(21-21) 
Median no. of lymph nodes at 
primary dissection 
19 18 16 21 
 
Mean size of smallest - largest 
lymph nodes at primary 
dissection  
1.1-5.3mm 
(0.5-9.0) 
1.3-5.6mm 
(0.5-10.0) 
2.0-7.5mm 
(1.0-9.0) 
1.0-6.0mm 
(1.0-6.0) 
Mean size of largest positive 
lymph nodes at primary 
dissection 
4.7mm 
(2.0-9.0) 
4.5mm 
(4.0-5.0) 
- - 
Total no. of lymph nodes at 
secondary dissection 
78 53 22 18 
Mean no. of lymph nodes at 
secondary dissection 
7.1  
(2-13) 
4.1  
(0-9) 
11  
(9-13) 
18  
(18-18) 
Mean size of smallest – largest 
lymph nodes at secondary 
dissection  
0.9-3.4mm 
(0.5-5.0) 
1.1-2.3mm 
(0.5-5.0) 
0.8-2.8mm 
(0.5-3.0) 
0.5-4.5mm 
(0.5-4.5) 
Mean size of largest positive 
lymph nodes at secondary 
dissection  
3.5mm  
(3.5-3.5) 
- - - 
No. of cases with upstaging 
(TNM5 or TNM7) 
0 0 0 0 
No. of cases with upstaging 
changing treatment 
0 0 0 0 
No. of cases with no lymph 
nodes harvested at secondary 
dissection 
0 2  
(15.4%) 
0 0 
183 
 
The median number of lymph nodes retrieved at primary dissection by all 
groups met RCPath targets (The Royal College of Pathologists, 2014), however 
the senior and junior trainee groups only contained two and one cases 
respectively and so may not be truly representative.  The mean size of the 
lymph nodes harvested at primary dissection in both of the largest groups 
(consultant and advanced practitioner) was similar.  The total number of lymph 
nodes harvested at secondary dissection was highest in the consultant group as 
might be expected.  However twice as many were not detected in the advanced 
practitioner group, as might have been expected (53 vs 78), suggesting that 
fewer lymph nodes were initially present within the specimens dissected by the 
consultants.  The mean size of lymph nodes retrieved at secondary dissection 
was smallest in the advanced practitioner group, supporting the high quality of 
dissection practice by the individual within this group.  The mean size of largest 
lymph nodes retrieved at primary dissection in the neoadjuvant group were 
smaller than those in the non-neoadjuvant group (7.5mm vs 10.5mm).  This was 
also true for lymph nodes retrieved at secondary dissection however the 
margins were not so large (4.5mm vs 4.7mm).  Only one positive lymph node 
was identified at secondary dissection within the neoadjuvant group and 
therefore it is difficult to comment on any significance in comparison to the non-
neoadjuvant group.  Two cases had no further lymph nodes detected at 
secondary dissection, and these were both in cases primarily dissected by the 
advanced practitioner.  There were no cases of upstaging within the 
neoadjuvant group. 
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4.10 ADDITIONAL FINDINGS 
 
Accuracy and time spent detecting lymph nodes 
Table 4.15 demonstrates the accuracy and time spent detecting lymph nodes at 
secondary dissection for each intervention chemical group.  The accuracy of 
detection of lymph nodes was measured microscopically.  Other structures 
mistaken for lymph nodes and sampled during dissection were blood vessels, 
tumour deposits and fibroadipose tissue.  Table 4.15 shows that the accuracy of 
detection was higher when formalin was used.  This may be related to the 
dehydrating effects of the GEWF which would make the mesenteric tissue 
firmer and the discrimination of lymph nodes from other structures more difficult.  
 
The time taken for secondary dissection was measured at the dissection bench 
and Table 4.15 shows that it was similar, irrespective of the intervention 
chemical that was used.   
 
Table 4.15.  Accuracy and time spent detecting lymph nodes at secondary 
dissection. 
 
 Accuracy 
 
Time for secondary dissection 
(mins) 
 
 Mean % (range) Median % 
(range) 
 
Mean (range) Median (range) 
Formalin (n=101)  64.4 (0-100) 68.8 (0-100) 
 
15.3 15.0 
GEWF (n=99) 55.2 (14.3-100)a 54.9 (14.3-100)a 
 
15.2 15.0 
ain two cases no additional potential lymph nodes were identified (n=97). 
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4.11 STATISTICAL ANALYSIS 
This thesis seeks to answer three research questions: 
 
 
 
 
 
 
 
 
4.11.1 RESEARCH QUESTION 1 
 
 
 
To answer research question 1 and assess the effect of the intervention 
chemical on the number of lymph nodes harvested at secondary dissection, two 
statistical tests were performed - an independent samples t-test and a one-way 
between-subjects (univariate) ANOVA.  The univariate ANOVA test was 
conducted to take into account the variable secondary dissection baseline – i.e. 
the number of lymph nodes available for secondary dissection may differ 
depending on the experience and competence of the primary dissector.     
 
 
 
 
Question 1: 
Does the use of GEWF result in a statistically significant greater lymph node 
harvest in comparison to further fixation in formalin? 
 Question 1:  
Does the use of GEWF result in a statistically significant greater lymph 
node harvest in comparison to further fixation in formalin? 
 
 Question 2:  
Does the use of GEWF identify statistically significant smaller lymph 
nodes at secondary dissection in comparison to further fixation in 
formalin? 
 
 Question 3: 
Does the use of GEWF result in statistically significant upstaging, 
leading to the requirement for adjuvant chemotherapy? 
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Independent samples t-test 
The independent samples t-test was performed using IBM SPSS Statistics, 
version 21 (IBM, 2012).  The results for the entire sample and the non-
neoadjuvant and neoadjuvant groups are summarised below, in Table 4.16.  
The full statistical output for this independent samples t-test can be seen in 
Appendix T.    
 
Table 4.16.  Summary results of the independent samples t-test to 
compare effects of the intervention chemical on numbers of lymph nodes 
harvested at secondary dissection (IBM, 2012).  
 
Group Levene’s Test for Equality of Variance 
 
 F 
 
Sig. (p) 
Sample 1.831 
 
0.178 
Non-
neoadjuvant  
1.897 0.170 
Neoadjuvant  0.060 
 
0.809 
Group t-test for Equality of means 
 
 T df Sig. (p) 
(2 
tailed) 
Mean 
difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
 
      Lower Upper 
Sample 1.256 
 
198 0.211 1.02470 0.81598 -0.58442 2.63382 
Non-
neoadjuvant  
1.231 171 0.220 1.10986 0.90138 -0.66940 2.88913 
Neoadjuvant  0.511 
 
25 0.614 1.76057 0.76057 -2.72596 4.52596 
 
 
The independent samples t-test demonstrated that the difference between the 
intervention chemicals was not statistically significant in the entire sample (t = 
1.256, df = 198, p = 0.211, two-tailed), the non-neoadjuvant group (t = 1.231, df 
= 171, p = 0.220, two-tailed), or the neoadjuvant group (t = 0.511, df = 25, p = 
0.614, two-tailed) (Brace, Kemp & Snelgar, 2012, p. 123).   
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The magnitude of the differences in the means for the whole group (mean 
difference = 1.02470, 95% CI: -0.58 to 2.63) was small (d = 0.18) (Becker, 
2000; Brace et al., 2012, pp. 123-124).  The difference was also small for the 
non-neoadjuvant group (mean difference = 1.10986, 95% CI: -0.67 to 2.89, d = 
0.19) and neoadjuvant group (mean difference = 1.76057, 95% CI: -2.73 to 
4.53, d = 0.20). 
 
Univariate ANOVA 
The univariate ANOVA was performed using IBM SPSS Statistics, version 21 
(IBM, 2012).  The results for the entire sample and non-neoadjuvant and 
neoadjuvant groups are summarised in Table 4.17.  The full statistical output for 
the univariate ANOVA can be seen in Appendix U.    
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Table 4.17.  Summary results of the univariate ANOVA (IBM, 2012). 
 
Group Type III 
Sum of 
Squares 
 
Degrees 
of 
freedom 
Mean 
Square 
F Significance Partial Eta 
Squared 
Sample       
Intervention 51.033 1 51.033 1.528 0.218 0.008 
Error 6580.298 197 33.403    
Non-
neoadjuvant 
      
Intervention 52.214 1 52.214 1.477 0.226 0.009 
Error 6007.863 170 35.340    
Neoadjuvant        
Intervention 7.098 1 7.098 0.333 0.569 0.014 
Error 511.932 24 21.331    
 
 
The univariate ANOVA revealed no statistical significance for the entire sample 
(F(1,197) = 1.528, p = 0.218, partial ƞ2 = 0.008)   the non-neoadjuvant group 
(F(1,170) = 1.477, p = 0.226, partial ƞ2 = 0.009) or the neoadjuvant group 
(F(1,24) = 0.333, p = 0.569, partial ƞ2 = 0.014) (Brace et al., 2012, p. 206).  
 
Research question 1 can therefore be answered as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.11.2 RESEARCH QUESTION 2 
Question 2: 
Does the use of GEWF identify statistically significant smaller lymph nodes 
at secondary dissection in comparison to further fixation in formalin? 
Answer 1: 
The use of GEWF or further fixation in formalin leads to an increased lymph 
node harvest in the entire sample, and non-neoadjuvant and neoadjuvant 
groups.   
 
The use of GEWF does not lead to a statistically significant increase in 
lymph node numbers in the entire sample, non-neoadjuvant or neoadjuvant 
groups, when compared to further fixation in formalin. 
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To answer question 2 and assess the effect of the intervention chemical on the 
size of lymph nodes harvested at secondary dissection, an independent 
samples t-test was performed.   
 
Independent samples t-test 
The independent samples t-test was performed using IBM SPSS Statistics, 
version 21 (IBM, 2012).  The results for the entire sample and the non-
neoadjuvant and neoadjuvant groups are summarised in Table 4.18.  The full 
statistical output for this independent samples t-test can be seen in Appendix V.      
 
Table 4.18.  Summary results of the independent samples t-test to 
compare effects of the intervention chemical on the size of lymph nodes 
harvested at secondary dissection (IBM, 2012).  
 
Group Levene’s Test for Equality of Variance 
 
 F 
 
Sig. (p) 
Sample 0.255 
 
0.614 
Non-
neoadjuvant  
0.779 0.378 
Neoadjuvant  0.436 
 
0.510 
Group t-test for Equality of means 
 
 t df Sig (p) 
(2 
tailed) 
Mean 
difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
 
      Lower Upper 
Sample 1.680 
 
1558 0.093 0.12675 0.07546 -0.02126 0.27476 
Non-
neoadjuvant  
1.936 1382 0.053 0.15773 0.08148 -0.00211 0.31757 
Neoadjuvant  0.345 
 
169 0.730 0.05474 0.15862 -0.25839 0.36787 
 
 
190 
 
The independent samples t-test demonstrated that the difference between the 
size of lymph nodes in the further fixation and GEWF groups was not 
statistically significant in the entire sample (t=1.680, df = 1558, p= 0.093, two-
tailed), the non-neoadjuvant group (t=1.936, df = 1382, p= 0.053, two-tailed), or 
the neoadjuvant group (t=0.345, df= 169, p= 0.730, two-tailed) (Brace et al.,  
2012, p. 123).  The magnitude of the differences in the means for the whole 
group (mean difference = 0.12675, 95% CI: -0.02126 to -0.27476, d= 0.14) was 
small (Brace et al., 2012, pp. 123-124; Becker, 2000).  The difference was also 
small for the non-neoadjuvant group (mean difference = 0.15773, 95% CI: -
0.00211 to 0.31757, d= 0.13) and neoadjuvant group (mean difference = 
0.05474, 95% CI: -0.25839 to 0.36787, d= 0.05).  
 
Research question 2 can therefore be answered as follows: 
 
 
 
 
4.11.3 RESEARCH QUESTION 3 
 
 
 
Summary data for upstaging is shown in Table 4.19.  Upstaging leading to a 
change in treatment was only identified in two of the 200 cases within the study 
(1.0%).  Due to the small size of this group there is not enough data on which to 
apply meaningful statistical analysis in order to identify significance (D. Van 
Laar, personal communication, March 18, 2014; Lang & Secic, 1997).   
Question 3: 
Does the use of GEWF result in statistically significant upstaging, leading to 
the requirement for adjuvant chemotherapy? 
Answer 2: 
The use of GEWF does not find statistically significant smaller lymph nodes 
in the entire sample, non-neoadjuvant or neoadjuvant groups, when 
compared to further fixation in formalin.  
191 
 
Table 4.19.  The effects of further fixation and GEWF use on upstaging.  
 
 Further 
fixation 
 
GEWF 
Sample (n=200) (n=101) (n=99) 
Number of cases with upstaging (TNM5) 1 (1.0%) 1 (1.0%) 
Number of cases with upstaging (TNM5) changing treatment 1 (1.0%) 1 (1.0%) 
Number of cases with upstaging (TNM7)  3 (3.0%) 3 (0.3%) 
Number of cases with upstaging (TNM7) changing treatment 1 (1.0%) 1 (1.0%) 
Non-long course neoadjuvant population (n=173) (n=86) (n=87) 
Number of cases with upstaging (TNM5) 1 (1.2%) 1 (1.1%) 
Number of cases with upstaging (TNM5) changing treatment 1 (1.2%) 1 (1.1%) 
Number of cases with upstaging (TNM7)  3 (3.5%) 3 (3.4%) 
Number of cases with upstaging (TNM7) changing treatment 1 (1.2%) 1 (1.1%) 
Long course neoadjuvant population (n=27) (n=15) (n=12) 
Number of cases with upstaging (TNM5) 0 0 
Number of cases with upstaging (TNM5) changing treatment 0 0 
Number of cases with upstaging (TNM7)  0 0 
Number of cases with upstaging (TNM7) changing treatment 0 0 
 
Therefore the third research question: 
 
 
 
cannot be answered by this study.  However, the implications of these results in 
terms of ‘clinical’, rather than ‘statistical’, significance will be discussed in detail 
in the following chapter. 
 
The following chapter will discuss the results of the study in depth, putting them 
into context with respect to the existing body of evidence, procedure and policy. 
 
 
 
 
 
 
 
 
 
 
Question 3: 
Does the use of GEWF result in statistically significant upstaging, leading to 
the requirement for adjuvant chemotherapy? 
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5. DISCUSSION 
This chapter will consider achievement of the primary objective of this thesis, 
and contains an in-depth discussion of the results, with comparison of the two 
intervention chemicals.  The impact of neoadjuvant therapy, the BCSP and 
potential confounding factors on the findings are also considered in detail.   
 
5.1 OBJECTIVES 
The primary objective of this thesis is as follows: 
 
 
 
 
The proposed outcomes of the primary objective can be summarised as the 
following three research questions: 
 
 
 
 
 
 
 
 
 
 
 
Primary research objective: 
To compare the effects of further fixation in formalin and GEWF on the lymph 
node harvest of patients with colorectal cancer, with or without neoadjuvant 
therapy via a diagnostic test study. 
 Question 1:  
Does the use of GEWF result in a statistically significant greater lymph 
node harvest in comparison to further fixation in formalin? 
 
 Question 2:  
Does the use of GEWF identify statistically significant smaller lymph 
nodes at secondary dissection in comparison to further fixation in 
formalin? 
 
 Question 3: 
Does the use of GEWF result in statistically significant upstaging, 
leading to the requirement for adjuvant chemotherapy? 
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5.2 METHODOLOGY / DATA COLLECTION 
Careful design of this study sought to meet the required ethical demands and 
minimise bias.  This was achieved by anonymisation, randomisation and 
stratification of cases on entrance into the study.  These controls were put in 
place to improve the robustness of the study design and were often absent in 
existing studies, with the Iversen et al. (2008) the only study to employ 
randomisation.  Although Tasi et al. (2012), Lindboe (2011), Storli et al. (2011), 
Kelder et al. (2008) and Švec et al. (2006) considered the variation between 
colonic and rectal specimens or non-neoadjuvant versus neoadjuvant therapy, 
none of the existing studies stratified non-neoadjuvant colorectal specimens 
from neoadjuvant specimens within the same research study.  This study is the 
therefore the first to truly compare the effects of further fixation in formalin and 
GEWF in groups of non-neoadjuvant and neoadjuvant specimens within the 
same study. 
 
The stringent planning performed in this research study was followed by the 
data collection period, which ran from June 2012 until July 2014 (26 months).  
Figure 5.1 shows that there was an equal distribution of cases with pre-analysis 
exclusions throughout the study, due to the continual rotation of staff within the 
dissection room who needed to be reminded of the study guidelines whenever 
they worked in the area.  Post-analysis exclusions were distributed throughout 
the study, however the cluster towards the end of the study was due to slides 
not being returned to the filing system in a timely manner.   
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Figure 5.1.  Timeline of pre-analysis and post-analysis exclusions. 
 
Data collection was predicted to take 24 months, but in reality took 26 months.  
In the first half of the study too many cases were excluded as secondary 
dissections were not being performed on Saturdays.  On realisation that the 
expected numbers of cases were not being entered into the study the 
methodology was altered to allow for Saturday dissections.  If this had not been 
changed then the data collection period would have been extended even 
further.   
   
5.3 DEMOGRAPHIC DATA  
A comparison of demographic data between existing studies and this thesis are 
demonstrated in Table 5.1.     
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Table 5.1.  Comparison of demographic data between existing studies and this thesis.  
 
Author, year Cases  Mean age  Gender  Site of tumour  
 
 Control Intervention Control Intervention Male Female Colon Rectum 
       Right sided Left sided  
Koren et al., 1997 - 100%  
(n=30) 
- - - - 100%  
(n=30) 
0% 
Newell et al., 2001 47.8% 
(n=32) 
52.2% 
(n=35) 
73 71 47.8% 
(n=32) 
52.2% 
(n=35) 
52.2% 
(n=35) 
40.3% 
(n=27) 
7.5% 
(n=5) 
Saleki and Haeri, 2002 - 100%  
(n=35) 
- 54.2 - - 100% 
(n=35) 
0% 
Švec et al., 2006a 
 
36.6% 
(n=34) 
63.4% 
(n=59) 
- - - - - - 
Iversen et al., 2008a 49.2% 
(n=59) 
50.8% 
(n=61) 
71.1b / 
66.5b 
69.7c / 64.0c 55% 
(n=66) 
45% 
(n=54) 
14.8% 
(n=17) 
33.9% 
(n=39) 
51.3% 
(n=59) 
Kelder et al., 2008 48.3% 
(n=117) 
51.7% 
(n=125) 
74 72 56.6% 
(n=137) 
43.4% 
(n=105) 
54.1% 
(n=131) 
45.9% 
(n=111) 
0% 
Gregurek and Wu, 2009a 47.1% 
(n=40) 
52.9% 
(n=45) 
- - 51.2% 
(n=44) 
48.8% 
(n=42) 
59.5% 
(n=50) 
39.3% 
(n=33) 
1.2% 
(n=1) 
Lindboe, 2011a,d - 100% 
(n=8) 
- 71 50% 
(n=4) 
50% 
(n=4) 
37.5% 
(n=3) 
62.5% 
(n=5) 
- 
Lindboe, 2011e - 100% 
(n=423) 
- 70.7f / 73.5g 49.6% 
(n=210) 
50.4% 
(n=213) 
44.7% 
(n=189) 
30.4% 
(n=129) 
24.9% 
(n=105) 
Storli et al., 2011a 48.5% 
(n=204) 
51.5% 
(n=217) 
71.36 72.32 47.7% 
(n=201) 
52.3% 
(n=220) 
61.5% 
(n=259) 
38.5% 
(n=162) 
- 
Tasi et al., 2012 - 100% 
(n=8) 
- 64.5 37.5% 
(n=3) 
62.5% 
(n=5) 
0% 
(n=0) 
75.0% 
(n=6) 
25.0% 
(n=2) 
This thesis, 2014 50.5% 
(n=101) 
49.5% 
(n=99) 
70.7 70.3 59.5% 
(n=119) 
40.5% 
(n=81) 
37.0% 
(n=74) 
31.0% 
(n=62) 
32.0% 
(n=64) 
asome cases had no site specified; bcolonic cancer; crectal cancer; dpilot study; emain study; fmale; gfemale. 
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Number of cases within each group 
Where there were control and intervention groups, the distribution of cases 
between groups was well balanced in all studies, apart from Švec et al. (2006) 
(control group = 36.6%; intervention group = 63.4%).  However, this thesis 
contains the most balanced groups of all studies (control group = 50.5%; 
intervention group = 49.5%). 
 
Mean age of patients within each group 
The mean age range of patients was similar (64-74 years) in the five studies 
where it was stated (Tasi et al., 2012; Lindboe, 2011; Storli et al., 2011; Iversen 
et al., 2008; Kelder et al., 2008; Newell et al., 2001).  The mean age of patients 
in this thesis was 70.5 years, demonstrating the similarity of age at diagnosis to 
that in previous studies.  This is also in keeping with UK statistics, where 26% of 
colorectal cancers occur in 60-69 year olds, whilst 43% occur in those 75 years 
and over (Cancer Research UK, 2014o).  Refer to Figure 5.2 for Cancer 
Research UK figures showing age at diagnosis.     
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Figure 5.2.  Average number of new cases of colorectal cancer per year 
and age-specific incidence rates (Cancer Research UK, 2014o). 
 
The patients in the study by Saleki and Haeri (2002) had a lower mean age 
(54.2 years), however there were only 35 patients within the study and this was 
most likely due to chance, but it may also have been specific to the Iranian 
population within the study, e.g. differences in the Iranian healthcare system 
leading to earlier diagnosis.  According to a 2012 study by Salimzadeh, Delavari 
& Mirzazadeh, Iran does not have any national guidelines for colorectal cancer 
screening.  Salimzadeh et al. (2012) also note that although colorectal cancer is 
more prevalent in those of 50 years of age, it does also occur in younger 
populations in rates similar to those in the west.  The true prevalence and 
relation to age at diagnosis is unclear due to a lack of data (Salimzadeh et al., 
2012; Kolahdoozan, Sadjadi, Radmard & Khademi, 2010). 
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Distribution of sexes  
The distribution of cases between the sexes differed between previous studies, 
with some studies having a greater proportion of men to women (Gregurek & 
Wu, 2009; Iversen et al., 2008; Kelder et al., 2008), whereas others had a 
greater proportion of women to men (Tasi et al., 2012; Lindboe, 2011; Storli et 
al., 2011; Newell et al., 2001).  In this thesis there were a greater proportion of 
men (59.5%) to women (40.5%).  The variation in all of these studies was most 
probably due to chance as there was no stated preferred selection of men or 
women in any of the studies (Tasi et al., 2012; Newell et al., 2001; Lindboe, 
2011; Storli et al., 2011; Gregurek & Wu, 2009; Iversen et al., 2008; Kelder et 
al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Koren et al., 1997), nor within 
this thesis. 
 
Site of tumour 
There is a large amount of variability in terms of the site of tumours included 
within existing studies.  In some studies tumours were all grouped as being from 
one major site, e.g. colon, rectum or colorectum, with no distinction between 
those from anatomical sites with a known variation in lymph node numbers 
(Storli et al., 2011, Švec et al., 2006; Saleki & Haeri, 2002; Koren et al., 1997).  
For those studies which did stratify cases into anatomical groups (Tasi et al., 
2012; Lindboe, 2011; Gregurek & Wu, 2009; Kelder et al., 2008; Iversen et al., 
2008; Newell et al., 2001), none of the studies had completely balanced study 
groups.  This may have been due to a lack of good study design, i.e. no sample 
size calculation.   Although the study by Iversen et al. (2008) included a power 
calculation and randomisation within its design, it still included a much higher 
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proportion of rectal cancers in comparison to right sided tumours (59 vs 17), 
showing limitations in the study design.  In this thesis there was an almost equal 
distribution between right sided (37%), left sided (31%) and rectal tumours 
(32%).  The distribution is due to chance as cases were randomly entered into 
the study, however the balanced distribution may be helped by the large sample 
size (n=200). 
 
Overall, the demographic data relating to age, sex and distribution of cases 
between study groups within this thesis is similar to that within earlier literature.  
There is a difference in the variation of cases between anatomical sites 
amongst all studies, due to chance or exclusion of cases from certain 
anatomical sites (e.g. rectum), which makes direct comparison difficult. 
 
5.4 THE USE OF ADJUNCT TECHNIQUES 
This section of the discussion relates to the following research question:  
 
 
 
Statistical analysis by independent samples t-test and univariate ANOVA (see 
section 4.11.1) showed that: 
 
 
 
 
 
Question 1 
Does the use of GEWF result in a statistically significant greater lymph node 
harvest in comparison to further fixation in formalin? 
Answer 1: 
The use of GEWF does not lead to a statistically significant increase in 
lymph node numbers in the entire sample, non-neoadjuvant or neoadjuvant 
groups, when compared to further fixation in formalin. 
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In this thesis the use of both further fixation with formalin and GEWF resulted in 
the detection of more lymph nodes at secondary dissection, as would be 
expected.  This was in keeping with existing studies where additional lymph 
nodes were also identified in all cases (Tasi et al., 2012; Lindboe, 2011; Storli et 
al,. 2011; Gregurek & Wu, 2009; Iversen et al., 2008; Kelder et al., 2008; Švec 
et al., 2006; Saleki & Haeri., 2002; Newell et al., 2001; Koren et al., 1997).  
However this thesis is based upon a much greater sample size (n=200) than 
most of the existing studies, with only three of the existing studies containing 
more than 100 patients (Lindboe, 2011; Storli et al., 2011; Kelder et al., 2008).  
None of these three studies appear to have used a power calculation to define 
required numbers, and they are open to other study design bias (Lindboe, 2011; 
Storli et al., 2011; Kelder et al., 2008).  Therefore the results within this thesis 
are more robust than those within all of the existing studies.   
 
5.4.1 THE USE OF GEWF 
In the existing literature Kelder et al. (2008) demonstrated the biggest difference 
in study and intervention groups, harvesting 160% more lymph nodes in the 
GEWF group, with a mean of 5 lymph nodes at primary dissection increasing to 
a mean of 13 after intervention.  In this thesis, there was an increase from a 
mean of 19.0 lymph nodes at primary dissection to 27.3 after secondary 
dissection in the GEWF group, representing a 43.7% increase in the number of 
lymph nodes harvested.  In the formalin group the increase was very similar at 
42.6% (mean 19.5 at primary dissection to mean 27.8 after secondary 
dissection).  In this thesis the increases in lymph nodes were similar when using 
either adjunct technique.  The increase was much smaller than that identified by 
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Kelder et al. (2008) (43.7%/42.6% vs 160%).  The difference between the two 
studies can be explained by considering underlying primary dissection practice 
and study design.   
 
The greatest failure of the study by Kelder et al. (2008) was the poor underlying 
dissection practice, with only a mean number of five lymph nodes retrieved in 
the 117 colonic specimens sampled.  In contrast there is good local practice 
with lymph node retrieval at primary dissection in clear excess of the minimum 
numbers recommended by the The Royal College of Pathologists (2014).  This 
good local practice demonstrates a high level of training and competence and 
demonstrates that staff are meeting General Medical Council (GMC) Good 
Medical Practice standards for medically qualified histopathologists (General 
Medical Council, 2014) and HCPC standards of proficiency for Biomedical 
Scientists (Health and Care Professions Council, 2012a).   
 
In the study by Kelder et al. (2008) there was also potential for the introduction 
of bias because the effects of staging variation and variation in time spent 
harvesting lymph nodes was not considered.  There was also no power 
calculation, although the study size was bigger than in many of the other 
existing studies (Tasi et al., 2012; Gregurek & Wu, 2009; Iversen et al., 2008; 
Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 1997).  
This thesis has attempted to address the errors within earlier studies, by 
performing a power calculation to estimate the appropriate sample size, and by 
minimising bias, e.g. by the use of randomisation.  The application of 
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appropriate statistical analysis to these data has produced the most reliable and 
believable results of any study to date. 
 
5.4.2 THE USE OF FURTHER FIXATION 
In this thesis fewer lymph nodes were retrieved at secondary dissection when 
GEWF was used in comparison to formalin (718 vs 837), with the mean number 
also lower (7.3 vs 8.3).  One might expect GEWF to retrieve a greater number 
of lymph nodes than further fixation as many of the existing studies have 
focused on the use of GEWF rather than simply further fixing specimens (Tasi 
et al., 2012; Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; Iversen et 
al., 2008; Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et 
al., 2001; Koren et al., 1997).   
 
The only study to specifically consider further fixation by Poller (2000) showed 
an increase in the numbers of lymph nodes retrieved when 24 hours further 
fixation was compared to primary manual dissection, but it was not statistically 
significant.  However, the design of Poller’s study differed because there was 
only one dissection, and there was no power calculation to identify whether the 
100 cases included were adequate (Poller, 2000).  It is therefore unclear 
whether the findings of this study are real or whether underlying dissection 
practice or other potentially confounding factors, e.g. anatomical site or TNM 
stage, are at least partly responsible for the findings.  Cases for each group 
were also selected, rather than randomly assigned, although the author admits 
that it was a confounding factor within his study.  Although there is potential bias 
within the study by Poller (2000), it does conclude that “the removal and 
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additional fixation of pericolic or perirectal fat for 24 h or more seems to provide 
a compromise between laborious lymph-node clearance techniques and the 
requirement in routine laboratory practice for a rapid reporting of the pathology 
specimen”.   
 
The findings of this single study by Poller (2000) correlate with the findings of 
this thesis, where further fixation in formalin has been shown to retrieve a 
greater number of lymph nodes at secondary dissection in comparison to 
GEWF.  However, this thesis has the additional benefits in that it has corrected 
the failure of the Poller (2000) study, by using a power calculation to create an 
appropriate sample size and account for any potential bias (such as anatomical 
site, staging variation).   
 
None of the existing studies involving the use of GEWF compared the 
difference between further fixation in formalin vs GEWF (Tasi et al., 2012; 
Lindboe, 2011; Storli et al,. 2011;Gregurek & Wu, 2009; Iversen et al., 2008; 
Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001; 
Koren et al., 1997), so no other direct comparison to the findings of this thesis 
can be made, however this sample is large enough to provide valid results. 
 
5.4.3 POSITIVE LYMPH NODES 
In this study only 9 out of 837 (1.1%) of the additional lymph nodes found with 
further fixation in formalin contained metastatic tumour deposits.  In the GEWF 
group this number was higher at 20 out of 718 (2.8%), however both of these 
figures were lower than was expected at the start of the study.  It is not clear 
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why the number is more than double in the cases where GEWF was used, but it 
is most likely due to chance.  It is clear that the small number of positive lymph 
nodes detected at secondary dissection is a reflection of the high quality of 
underlying primary dissection practice, whereby positive lymph nodes are being 
appropriately identified at primary dissection.  
 
5.4.4 SIZE OF LYMPH NODES 
This section of the discussion relates to the following research question:  
 
 
 
Statistical analysis by independent samples t-test (see section 4.11.2) showed 
that: 
 
 
 
 
Table 5.2 shows how this thesis agreed with the findings of existing studies 
which described smaller lymph nodes being retrieved in the specimens of 
patients who had received neoadjuvant therapy (McDonald et al., 2012; Miller et 
al., 2012; Latkauskas et al., 2010; Baxter et al., 2005; Topor et al., 2003).   
 
 
 
 
Question 2 
Does the use of GEWF identify statistically significant smaller lymph nodes 
at secondary dissection in comparison to further fixation in formalin? 
Answer 2: 
The use of GEWF does not find statistically significant smaller lymph nodes 
in the entire sample, non-neoadjuvant or neoadjuvant groups, when 
compared to further fixation in formalin. 
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Table 5.2.  Lymph node size in existing studies and this thesis. 
 
Author, year 
 
Node size after 
manual 
dissection (mm) 
 
Node size after 
intervention 
(mm) 
Statistically significant 
difference in node size 
(p value) 
Koren et al., 1997 - 0.5-7.0 - 
Newell et al., 2001 7.0a 5.0a Yes (0.046)b 
Saleki and Haeri, 2002 0.429 
0.568a 
0.268 
0.35a 
Yes (<0.0000001)b 
Yes (0.00572)a,b 
Švec et al., 2006 - - - 
Iversen et al., 2008 - - - 
Kelder et al., 2008 6.0c 
9.0a 
4.0c 
6.0a 
Yes (<0.001)b 
Yes (<0.001)b 
Gregurek and Wu, 2009 - - - 
Lindboe, 2011d 
Lindboe, 2011e 
Lindboe, 2011f 
4.3 
4.3 
- 
3.8 
2.5 
- 
- 
- 
- 
Storli et al., 2011 - - - 
Tasi et al., 2012 2.6 2.1 No (>0.11) 
This thesis, 2014 1.5-9.4mm 
1.3-5.6mm 
2.5g 
1.8h 
No (0.053)i 
No (0.730)i 
ametastatic lymph node; bsignificance = p≤.005; cadditional lymph nodes; dpilot study - further 
fixation; epilot study – GEWF; fmain study – GEWF; gnon-neoadjuvant group; hneoadjuvant 
group; icomparison of intervention groups. 
 
At primary dissection, in the non-neoadjuvant group (n=173) the mean size of 
lymph nodes retrieved was 1.5mm–9.4mm, whilst in the neoadjuvant group 
(n=27) the mean size was much smaller at 1.3mm–5.6mm.  Even with this 
reduction in mean size in the neoadjuvant group, the mean number retrieved at 
primary dissection achieved recommended targets.  This contradicts the 
suggestion that the retrieval of 12 lymph nodes is unrealistic in these specimens 
(Miller et al., 2012; Marks et al., 2010), as this thesis has clearly shown that it is 
achievable without the need for adjunct techniques.  Achievement of the target 
does however rely upon high quality underlying dissection practice, which is 
present locally but is lacking in previous studies (Tasi et al., 2012; Lindboe, 
2011; Storli et al., 2011; Kelder et al., 2008; Iversen et al., 2008; Švec et al., 
2006; Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 1997). 
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In this thesis GEWF was not shown to find statistically significantly smaller 
lymph nodes when compared to further fixation in formalin, including in the 
neoadjuvant group (p=0.730).  However as an appropriate number of lymph 
nodes were identified at primary dissection, the use of adjunct techniques and 
secondary dissection was not necessary as it did not lead to statistically 
significant upstaging.   
 
This thesis provides a greater amount of detail relating to the size of lymph 
nodes retrieved at primary and secondary dissection, in comparison to existing 
studies (Tasi et al., 2012; Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 
2009; Kelder et al., 2008; Iversen et al.,2008; Švec et al., 2006; Saleki & Haeri, 
2002; Newell et al., 2001; Koren et al., 1997), some of which do not consider 
the potential importance of lymph node size (Storli et al., 2011; Gregurek & Wu, 
2009; Iversen et al., 2008; Švec et al., 2006; Koren et al., 1997).  In this thesis, 
for every case, the mean size of the smallest and largest harvested lymph node 
was measured.  This gave a range of sizes rather than just one average size, 
which would not account for the potentially large amounts of variation between 
small and large lymph nodes.  This demonstrates another benefit of this thesis 
over existing studies, whereby the variation in size of lymph nodes retrieved can 
be clearly demonstrated. 
 
In this thesis the mean size of lymph nodes ranged from 1.5mm–8.9mm (range 
0.5mm–28.0mm) at primary dissection, with the mean size of positive lymph 
nodes at primary dissection 8.6mm (range 1.0mm-28.0mm). This demonstrates 
that with adequate manual dissection practice, tiny lymph nodes may be 
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identified at primary dissection and although these may contain metastatic 
tumour deposits (Bilchik & Compton, 2007; Brown, Luckasevic, Medich, 
Celebrezze & Jones, 2004), on average metastases are often identified in larger 
lymph nodes.  Secondary dissection showed that there was no difference 
between further fixation and GEWF in terms of identifying smaller lymph nodes.  
In fact, the mean size of positive lymph nodes identified at secondary dissection 
was 4.4mm (range 1.5mm-8.0mm), suggesting that they were simply missed at 
primary dissection due to dissector error.  In the neoadjuvant group the mean 
size of lymph nodes at primary dissection was much smaller, with a mean size 
of 4.6mm (range 2.0-9.0mm).  At secondary dissection the mean size of 
detected lymph nodes reduced to 3.5mm, which was only marginally smaller 
than in the non-neoadjuvant group (4.4mm).  This suggests that lymph nodes 
are being adequately detected at primary dissection, with no need to use 
adjunct techniques to search for even smaller lymph nodes. 
 
5.4.5 UPSTAGING 
This section of the discussion relates to the following research question:  
 
 
 
The above research question could not be answered (see section 4.11.3), 
because in this study significant upstaging leading to a potential change in 
patient treatment (pN0 to pN1/pN2) was only identified in two cases out of 200 
(1.0%).  This is unsurprising as only 29 positive lymph nodes were found at 
secondary dissection in the 200 cases. 
Question 3 
Does the use of GEWF result in statistically significant upstaging, leading to 
the requirement for adjuvant chemotherapy? 
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The fact that only two cases of upstaging were identified in 1.0% of cases 
demonstrates that the size of lymph nodes identified at primary dissection or 
after the use of an adjunct chemical is not important, as the key positive lymph 
nodes are being retrieved, resulting in the correct staging and the patient going 
on to receive the appropriate adjuvant treatment. 
 
In the existing literature significant upstaging prompting adjuvant therapy was 
claimed in two studies (Saleki & Haeri, 2002; Koren et al., 1997).  Saleki and 
Haeri (2002) identified upstaging in 3/35 (8.6%) of cases whilst the figure was 
even higher in the study by Koren et al. (1997) at 8/30 (26.7%).  These figures 
are much greater than those identified in this thesis which prompts a challenge 
to the validity of these claims.  Both of these studies were small, with no power 
calculation performed beforehand.  Koren et al. (1997) claimed statistically 
significant upstaging but did not describe any associated statistics so it is 
unclear how this conclusion was reached, especially with a small sample size of 
30.  Although Saleki and Haeri (2002) commented that statistics had been used, 
they failed to describe them.  Neither of these studies considered other 
potentially confounding factors such as the underlying quality of manual 
dissection practice, anatomical or staging variations or time spent in GEWF.   
The presence of significant upstaging in any existing studies must therefore be 
questioned.  In this thesis there was an appropriately large sample size, 
randomisation and stratification was used, and yet potentially significant 
upstaging was still only identified in one percent of cases.  This low figure is due 
to the high quality of underlying primary dissection practice and minimisation of 
209 
 
potential confounding factors - which was not evident in previous studies, 
including those by Saleki and Haeri (2002) and Koren et al. (1997).  
 
5.4.6 STATISTICAL VS CLINICAL SIGNIFICANCE 
In this thesis only two cases of upstaging, leading to a potential change in 
patient treatment, were identified after secondary dissection.  The incidence of 
upstaging was so small that it was not possible to determine potential statistical 
significance.  The p value of statistical significance is the standard measure 
used to determine differences between groups in clinical research (Houle & 
Stump, 2008).  However, it is also known that any difference may be found to 
be statistically significant if the sample size is large enough (Houle & Stump, 
2008).  In contrast, clinical significance is defined as “the practical or applied 
value of a treatment effect” (Kazdin, 1999).  Houle & Stump (2008) argue that 
clinical significance is more realistic, depending on the “real-world effect of a 
treatment, and most importantly, whether it is perceived to be beneficial by the 
patient.”  The value of clinical significance should therefore always be 
considered in addition to statistical significance because statistical significance 
does not inform about the effect size or clinical relevance, because “a large 
sample size study may have a statistically significant result but a small effect 
size” (FreshBiostats, n.d.). 
 
Although the results related to upstaging within this thesis may not be 
statistically significant, when considering future practice and policy, they should 
be considered as clinically significant, because just one case of upwards stage 
migration from pN0 to pN1 or pN2 may result in the patient being offered 
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adjuvant chemotherapy (Sommariva et al., 2010).  Therefore the size of the 
effect may be large (especially for the two affected patients), although a much 
larger sample size would be required to demonstrate the effect with a p value of 
less than 0.05.  Again, this demonstrates the high quality of local primary 
dissection practice. In these two cases with upstaging it should also be 
considered that the positivity of these lymph nodes at secondary dissection 
could also be due to other sources of bias, e.g. due to poor fixation or 
underlying inexperience or lack of time spent by the primary dissector, rather 
than being truly undetectable by manual dissection.   
 
Overall, when assessing the effectiveness and efficacy of new techniques, 
whether it be a new drug or an adjunct technique, not only should the p value 
be considered, but also how meaningful the benefit may be (FreshBiostats, 
n.d.).  This would include the magnitude of benefit of the treatment in terms of 
quality of life and survival for the patient, plus any other costs, benefits or 
limitations associated with it (Mariani & Pêgo-Fernandes, 2014). 
 
5.5. THE IMPACT OF NEOADJUVANT THERAPY 
Only three of the previous studies have discussed the impact of long-course 
neoadjuvant therapy on lymph node retrieval in rectal cancer (Tasi et al., 2012; 
Kelder et al., 2008, Švec et al., 2006), although others did exclude rectal 
specimens without explaining the reasons behind it (Lindboe, 2011; Storli et al., 
2011; Koren et al., 1997).  Long-course neoadjuvant therapy has been shown to 
reduce the size of lymph nodes in an anatomical region with an already known 
paucity (McDonald et al., 2012; Miller et al., 2012; Latkauskas et al., 2010; 
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Baxter et al., 2005; Topor et al., 2003).  The resulting difficulty in identifying 
lymph nodes in these specimens has led to some authors suggesting that a 
target of 12 lymph nodes may be unrealistic (Miller et al., 2012; Marks et al., 
2010).  This thesis agreed with these previous findings, whereby fewer lymph 
nodes were identified in the specimens of patients who had received 
neoadjuvant therapy.  In the neoadjuvant group (n=27) a mean of 14 and 
median of 13 lymph nodes were found at primary dissection.  Not only does this 
number meet the recommended number of 12, but it also exceeds the mean 
number in the majority of earlier studies (Tasi et al., 2012; Lindboe, 2011; Storli 
et al., 2011; Iversen et al., 2008; Kelder et al., 2008; Švec et al., 2006; Saleki & 
Haeri, 2002; Newell et al., 2001; Koren et al., 1997), as demonstrated in Table 
5.3.   
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Table 5.3.  Numbers of lymph nodes retrieved before and after GEWF in 
previous studies. 
 
Author, year 
 
Mean number of 
nodes after 
manual dissection 
Mean number of 
nodes after 
intervention 
Statistically 
significant difference 
in number of nodes                               
(p value) 
 
Koren et al., 1997 2.94 8.6a - 
Newell et al., 2001 6.8 10.2 Yes (0.002)b 
Saleki and Haeri, 2002 6.26 13.0a - 
Švec et al., 2006 5.9 14.7 Yes (0.05)b 
Iversen et al., 2008 9.5 16.5 Yes (<0.001)b 
Kelder et al., 2008 5.0 13.0 Yes (<0.001)b 
Gregurek and Wu, 2009 18.3 19.96 No (0.53)b 
Lindboe, 2011c 
Lindboe, 2011d 
Lindboe, 2011e 
11.4 
11.4 
- 
5.9a 
6.0f 
16.8 
- 
- 
- 
Storli et al., 2011 10.98g 15.61g Yes (<0.01) 
Tasi et al., 2012 7.6 4.7a Yes (<0.05) 
This thesis, 2014 14.0h 
20.1i 
6.3a 
8.0a 
No (0.569)j 
No (0.226)j 
aadditional lymph nodes; bsignificance = p ≤0.005; cpilot study - further fixation; dpilot study – 
GEWF; emain study – GEWF; fthird dissection; gthree sites with differing interventions; 
hneoadjuvant group; inon-neoadjuvant group; jdifference between further fixation and GEWF. 
 
The 10 studies in Table 5.3 also included non-rectal cases (Tasi et al., 2012; 
Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; Kelder et al., 2008; 
Iversen et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001; 
Koren et al., 1997) and so the findings of this thesis confirm the high quality of 
local dissection practice and the questionable quality of manual dissection 
practice in 90 percent of earlier studies (Tasi et al., 2012; Lindboe, 2011; Storli 
et al., 2011; Kelder et al., 2008; Iversen et al., 2008; Švec et al., 2006; Saleki & 
Haeri, 2002; Newell et al., 2001; Koren et al., 1997).   
 
In this thesis, a mean of 20.1 and median of 19 lymph nodes were identified at 
primary dissection in the non-neoadjuvant group (n=173).  Table 5.4 
demonstrates how this clearly exceeds all of the earlier published research, 
including the study by Gregurek and Wu (2009) which has the highest quality 
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dissection practice and is the only previous study to exceed the recommended 
numbers.  Secondary dissection further to the use of GEWF showed an 
increase in the number of lymph nodes, but this did not have statistical 
significance when compared to the use of further fixation, in either the 
neoadjuvant group (p=0.569) or non-neoadjuvant group (p=0.226).   
 
The robust nature of the data within this thesis is due to the power calculation, 
randomisation, stratification and minimisation of bias employed during study 
design.  This is at least partially absent from all of the existing studies (Tasi et 
al., 2012; Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; Iversen et 
al., 2008; Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et 
al., 2001; Koren et al., 1997).  Appropriate study design within this thesis has 
enabled demonstration of a true absence of statistical significance, because the 
quality of underlying dissection practice is known to be good.  This is the first 
study to provide accurate results because the data within previous studies 
precludes assessment of true statistical significance due to poor design and the 
influence of potential bias, e.g. poor underlying dissection practice (Tasi et al., 
2012; Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; Iversen et al., 
2008; Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 
2001; Koren et al., 1997).   
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5.6 THE IMPACT OF THE BOWEL CANCER SCREENING PROGRAMME 
Despite the introduction of the BCSP locally in 2008 (NHS Southampton City, 
2011), ten and a half percent of cases within this study (21/200) were 
diagnosed via this pathway.  There is no clear data available as yet to say 
whether this is representative of the diagnostic rate following screening within 
the UK (NHS Cancer Screening Programmes, 2014a; Cancer Research UK, 
2009b).   
 
Outcome data from the second round of the NHS BCSP pilot showed a cancer 
detection rate of 0.94 per 1000 people (62/66264) (Weller, 2009), whilst Blanks 
and Moss (2012, p. 72) state that the “for the prevalent (first) round, prevalent 
screen and incident screens the calculated targets for the cancer detection rate 
are 2.3, 1.3 and 1.7 per 1000 people respectively.”  However, both of these 
figures are an estimate of cancer incidence within the screening population, 
rather than an assessment of the proportion of screening detected resection 
specimens received within a histopathology department. 
 
In this thesis tumours detected via the BCSP arose in both sides of the colon 
(42.9% right sided vs 57.1% left sided).  The T stage was also equally 
distributed, with 19.0% pT1, 23.8% pT2 and 38.1% and 19% pT4.  This is 
surprising as the aim of the BCSP is to detect dysplastic polyps and early 
tumours, as has been demonstrated in studies from Denmark, Nottingham and 
Wolverhampton, where higher proportions of Dukes A cancers than Dukes C 
cancers were identified within screened populations (Anand, Gwinnett & 
Phillips, 2012; Logan et al., 2012; McClements et al., 2012; Ellul et al., 2010).     
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The obvious benefit of this, and of the screening programme overall, is the 
associated reduction in mortality (Anand et al., 2012).  However, as 
McClements et al. (2012) point out, these changes in stage distribution could 
also “reflect advances in surgery and/or pathology (for example, an increase in 
the numbers of regional lymph nodes harvested) and imaging.” 
 
It is likely that in this thesis the sample size is too small to show an accurate 
spread of tumour stages detected by the screening programme.  Future 
research could be performed with a larger cohort of specimens to assess 
whether screening successfully detects earlier pre-invasive and invasive lesions 
in the local population.       
 
5.7 DISSECTION EXPERTISE 
This study confirms the high quality of local underlying primary dissection 
practice.  Guidelines for retrieving a median of 12 lymph nodes were met by all 
dissector groups, and even in the neoadjuvant group where there is a known 
paucity of lymph nodes.  Only 29 positive lymph nodes were identified at 
secondary dissection in all 200 cases.  This led to upstaging (pN0 to pN1/2) in 
just two cases.  In the other 27 cases the patient was already node positive 
(pN1/2) and this would not have led to any change in patient treatment.  The 
results of this thesis demonstrate the questionable results of previous studies, 
where underlying manual primary dissection practice was poor, leading to a 
larger number of lymph nodes being identified at secondary dissection after the 
use of adjunct techniques.  Six of these studies attributed statistical significance 
to these findings (Tasi et al., 2012; Storli et al., 2011; Iversen et al., 2008; 
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Kelder et al., 2008; Švec et al., 2006; Newell et al., 2001), which is 
inappropriate considering the potential bias within these studies.  It is likely that 
the study findings would have been different if the underlying dissection practice 
had been adequate.  The reason for the inadequacies relating to primary 
dissection within these studies is not clear, however their conclusions should 
have been to improve training and expertise in primary dissection rather than to 
recommend the routine use of GEWF (Tasi et al., 2012; Lindboe, 2011; Saleki & 
Haeri, 2002; Koren et al., 1997).  
 
5.7 ADDITIONAL FINDINGS 
 
Detection of the intervention chemical 
There was a clear detectable difference between the two chemicals, 
demonstrated by the 99% predictive accuracy before secondary dissection.  Not 
only was there a clear distinction between the two chemicals before dissection, 
but there was a notable difference during dissection.  When GEWF was used, 
the fat became nodular and hard, likely due to the effects of dehydration by the 
alcohol based compound.  This made it more difficult to palpate any lymph 
nodes within the fat, however it improved the visibility of lymph nodes as they 
became white in colour.  See Figure 5.3, which identifies the lymph nodes as 
white rounded structures (LN), versus yellow adipose tissue (A) and grey/black 
blood vessels (BV). 
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Figure 5.3.  Characteristic white colour of lymph nodes after GEWF use. 
 
The findings in this thesis are the same as those in the two other studies which 
describe the inability to blind due to the easy detection of GEWF (Iversen et al., 
2008; Newell et al., 2001).  Both of these studies describe the detection bias 
caused by GEWF, which Iversen et al. (2008, p. 1207) describe as having “its 
own characteristic macroscopic appearance, which is impossible to hide”.  In 
both of these studies multiple dissectors performed the secondary dissection, 
which may have led to bias as they could choose to alter their practice and thus 
affect the results (Iversen et al., 2008; Newell et al., 2001).  This thesis 
attempted to minimise this potential bias, by ensuring that the secondary 
dissection was performed by only one dissector - however the risk of detection 
bias could not be removed completely as there was still the potential for altered 
practice by the single dissector. 
 
LN 
BV 
LN 
A 
LN 
LN 
A 
A 
A 
BV 
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The time spent detecting lymph nodes and the accuracy of detection within this 
thesis was also checked microscopically, and is shown in Table 5.4.  
 
Table 5.4.  Accuracy and time spent detecting lymph nodes at secondary 
dissection. 
 
 Accuracy 
 
Time for secondary dissection 
 Mean %  
(range) 
Median % 
(range) 
 
Mean minutes 
(range) 
Median minutes 
(range) 
Formalin (n=101)  64.4 (0-100) 68.8 (0-100) 15.3 
 
15.0 
GEWF (n=99) 55.2 (14.3-100)a 54.9 (14.3-100)a 15.2 
 
15.0 
ain two cases no additional potential lymph nodes were identified (n=97). 
 
 
Table 5.4 shows that there was a greater accuracy of detecting lymph nodes 
when further fixation with formalin was used as the adjunct chemical.  
Structures often mistaken for lymph nodes were nodules of fat or blood vessels 
(which sometimes contained tumour), or tumour deposits (not within lymph 
nodes or vessels).  These were more difficult to distinguish from lymph nodes 
when GEWF was used, due to the nodularity caused by dehydration. 
 
In contrast, formalin is water-based and so the fat remained soft and more 
easily palpable.  Lymph nodes may not have been so easily visible, but as only 
small lymph nodes remained in the fat at this point, the ability to palpate smaller 
lymph nodes was more important.  The secondary dissections were all 
performed by an experienced dissector, who relied equally upon palpation and 
vision.  It is therefore unsurprising that a greater number of lymph nodes were 
detected with formalin than with GEWF, as the smaller lymph nodes were more 
likely identified by palpation than vision at secondary dissection. 
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The ability to detect small lymph nodes is partly based upon experience and 
therefore dissectors with limited experience may find GEWF to be a useful 
adjunct chemical.  In this study the dissector found it easier using further fixation 
with formalin, however the median time spent performing the secondary 
dissection was identical for both techniques (15 minutes).  This demonstrates 
that in terms of time cost there is no difference between formalin or GEWF 
when applied to specimens.  The only time difference occurs when making up 
the GEWF compound, which takes approximately 10 minutes for each batch of 
5 litres.  Formalin has to be diluted to make the working solution, however on a 
daily basis it is always available at the correct dilution for immediate use. 
 
The following chapter will consider achievement of the primary and secondary 
objectives of this thesis, discussing the key conclusions, but also the limitations 
of the research study.  The implications for local practice, profession and policy 
will be considered, and recommendations for future practice will also be made.   
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6. CONCLUSION 
This chapter will consider achievement of the primary and secondary objectives 
of this thesis, discussing the key conclusions, but also the limitations of the 
research study.  The implications for local practice, profession and policy will be 
considered.  Finally, there will be an assessment of the original objectives set 
out in the research proposal, with some recommendations for future practice 
also made.   
 
6.1 OBJECTIVES 
The objectives of this thesis are as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
Achievement of objectives 1 and 2 is discussed in sections 6.2, 6.3 and 6.4, 
whilst achievement of objectives 3 and 4 is discussed in section 6.5 and 6.6. 
 
 Objective 1: 
Compare two methods of adjunct preparatory techniques – GEWF vs 
further fixation – via a randomised controlled trial designed study. 
 
 Objective 2: 
Critically analyse results to determine whether either GEWF or further 
fixation leads to a statistically significant increase in lymph node 
harvest and/or upstaging from pN0 to pN1/pN2. 
 
 Objective 3: 
Develop a new departmental protocol for the macroscopic handling of 
colorectal cancer specimens based on the findings.  This will involve 
either no change, treatment with GEWF either before or after primary 
dissection, or further fixation of specimens before secondary 
dissection. 
 
 Objective 4: 
Disseminate findings via publication in appropriate journals and 
presentation of key findings, locally, nationally and internationally. 
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6.2 KEY CONCLUSIONS 
The key conclusions from this thesis are as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3 LIMITATIONS OF THIS THESIS 
When compared to previous studies this thesis provides reliable statistically 
significant findings.   This is because of the strict study design, with a large 
sample size supported by a power calculation, and the attempt to minimise bias 
and potential confounding factors, and to provide objectivity, despite the study 
being performed in a busy routine histopathology laboratory.  However, a 
number of limitations do remain due to the type of research being performed, 
and carrying it out within a busy clinical working environment. 
 
 
 The use of GEWF or further fixation in formalin leads to an increased 
lymph node harvest. 
 
 The use of GEWF does not lead to a statistically significant increase 
in lymph node numbers when compared to further fixation in formalin. 
 
 The use of GEWF does not find statistically significantly smaller 
lymph nodes when compared to further fixation in formalin. 
 
 The use of adjunct techniques only leads to upstaging in a small 
percentage of cases, but in these it may be clinically significant. 
 
 Adjunct techniques are not required in the majority of cases if an 
appropriate primary dissection has been performed on an adequately 
fixed specimen by an appropriately trained person. 
 
 The key to adequate lymph node retrieval is high quality training, 
effort and time spent at primary dissection. 
 
 In difficult cases adjunct techniques may be useful, and further 
fixation in formalin is recommended as it is cheaper, more readily 
available and more efficient at detecting lymph nodes. 
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Study design limitations 
This study attempted to remove and minimise bias wherever possible, 
correcting the mistakes of previous studies conducted in clinical practice 
settings.  However, it was not entirely possible to remove all types of potential 
bias (Hartman et al., 2002).  The main issue with this study was the ability to 
instantly detect the adjunct chemical which had been applied to each specimen, 
due to the distinctive smell and texture of GEWF which would make it instantly 
recognisable (see Figure 5.3).  This was an unavoidable and unmanageable 
problem and was also identified in existing studies by Iversen et al. (2008) and 
Newell et al. (2001).  As management of this issue was not possible, it had to 
be accepted that it might potentially introduce bias from the secondary 
dissector, who could if they choose, place more effort into retrieving lymph 
nodes when GEWF had been used in order to demonstrate its efficacy in 
comparison to further fixation.  However, the large sample size and 
demonstrable equivalence in the time spent on the secondary dissection for 
each adjunct chemical, has shown how there has been some attempted control 
over this potential confounding factor. 
 
Professional limitations 
Optimal practice would have been to completely exclude the secondary 
dissector from the primary dissection process, as they could have chosen to 
use more or less effort to detect secondary lymph nodes if the secondary 
dissector remembered the specimen from the previous primary dissection.  
Unfortunately it was neither feasible nor desirable to exclude the secondary 
dissector from primary dissections as this formed a major part of the secondary 
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dissector’s routine clinical workload.  Participation in the research also ensured 
that the requirements of the professional doctorate programme were met 
(University of Portsmouth, 2014).  The requirements related to participation in 
the practical research are summarised below:   
 
 
 
 
 
 
 
 
 
 
 
 
(University of Portsmouth, 2014) 
 
The previous limitations were all predicted and minimised accordingly via robust 
study design, which included a large sample size.  However, there was also an 
unexpected limitation due to non-compliance from some histopathologist 
colleagues with reference to collecting data and identifying non-filed slides.  At 
the outset of the research options for collection of data were discussed and 
agreed with histopathologist colleagues, however once the research was 
ongoing that there was an almost complete lack of compliance to the agreed 
protocol.  There may have been numerous reasons for non-compliance, but the 
majority of histopathologist colleagues attributed it to their busy schedules, 
 Provide authoritative solutions when presented with practical, 
managerial, business, ethical and research problems within a 
professional context (requirement C4). 
 
 Manage dilemmas and value conflicts in a way which takes forward 
professional practice (requirement C8). 
 
 Plan a research/professional development protocol and prepare an 
application for approval and demonstrate the likely relevance of the 
work to the area of practice (requirement C11). 
 
 Manage and make professional use of resources (e.g. human, 
financial and physical) where appropriate (requirement D2). 
 
 Manage information and research data (requirement D3). 
 
 Manage change effectively, prioritise time and workloads and 
respond to changing professional demands (requirement D4).  
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saying that they did not have the time to do it.  This problem was fully realised 
half way through the data collection period and the necessary adjustments were 
made in order to ensure the adequate data was retrieved and recorded.  
Although this created large amounts of extra work for the chief investigator it 
was achieved without causing a significant delay.  The only delay encountered 
at the end of the data collection period was due to slides not being placed into 
the departmental filing system in a timely manner.  This was also attributed to 
the busy schedules of histopathologist colleagues, who sent slides for filing in 
large batches, rather than immediately after reporting.         
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6.4 IMPLICATIONS OF THIS THESIS 
Figure 6.1 shows the possible outcomes of this thesis, described at the 
research proposal stage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1.  Possible outcomes of this thesis, described at the research 
proposal stage. 
 
The following section will discuss the implications of this thesis in terms of local, 
national and international clinical practice.  It will also consider the implications 
for professions and policy.  These implications will then be related back to an 
amended version of the above flowchart shown in Figure 6.1.     
 
 
 
 
Change in working practice No change in working practice 
Sharing of evidence 
publication and presentation 
Change in working practice elsewhere  
Time / cost savings 
Improved treatment for patients 
One or more intervention is shown to be 
statistically significantly better than the 
standard method  
(improved retrieval of lymph 
nodes/upstaging) 
No intervention is shown to be 
statistically significantly better than the 
standard method                            
 (no improved retrieval of lymph 
nodes/no upstaging)  
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6.4.1 IMPLICATIONS FOR CLINICAL PRACTICE 
 
Implications for local clinical practice 
The results of this study have shown that the use of adjunct techniques leads to 
the retrieval of a greater number of lymph nodes at secondary dissection.  
Unsurprisingly this is in keeping with the findings of previous studies (Tasi et al., 
2012; Lindboe, 2011; Gregurek & Wu, 2009; Iversen et al., 2008; Kelder et al., 
2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 
1997).  The difference between this thesis and existing studies is the baseline of 
good primary dissection practice.  In previous studies primary dissection 
practice was generally shown to be inadequate (Tasi et al., 2012; Lindboe, 
2011; Storli et al., 2011; Iversen et al., 2008; Kelder et al., 2008; Švec et al., 
2006; Saleki & Haeri, 2002; Newell et al., 2001; Koren et al., 1997), leading to 
the retrieval of a greater proportion of lymph nodes at secondary dissection, 
with some authors attributing statistical significance (Tasi et al., 2012; Storli et 
al., 2011; Iversen et al., 2008; Kelder et al., 2008; Švec et al., 2006; Newell et 
al., 2001) and recommending the routine use of GEWF (Tasi et al., 2012; 
Lindboe, 2011; Saleki & Haeri, 2002; Koren et al., 1997).   
 
The results of this thesis dispute the previous findings and the conclusions 
made by Tasi et al. (2012), Lindboe (2011), Saleki and Haeri (2002) and Koren 
et al. (1997).  This thesis has shown that the application of adjunct techniques is 
not necessary if there is good underlying primary dissection practice, because it 
does not lead to statistically significant upstaging and a resulting change in 
patient treatment.   
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The major implication for practice within the department is to continue with 
existing manual dissection practice which has been shown to be excellent.  This 
study was performed in a large teaching hospital with a range of dissector 
groups, from novices to highly experienced.  All dissector groups have been 
shown to meet national standards for minimum number of lymph nodes 
retrieved, even in specimens where neoadjuvant therapy was given prior to 
surgery.  Although experience improves lymph node retrieval rates, high quality 
training and spending an appropriate amount of time on each specimen also 
provides adequate results, removing the need for secondary dissection in most 
cases.  
 
Professional and policy aspects 
The findings within this thesis further support the use of non-medically qualified 
staff as team contributors to provision of the clinical service.  Previous studies 
have repeatedly shown the high quality of practice by healthcare scientists 
(Horne & Green, 2013; Haynes & Lindley, 2012; Sanders et al., 2012; Shaw et 
al., 2008; Duthie et al., 2004; Ashworth, 1994; Biggart & Allen, 1994) who have 
been shown to outperform their medically trained counterparts (Horne et al., 
2011).  This thesis corroborates the findings of the study by Horne et al. (2011) 
because the underlying manual dissection practice by the advanced practitioner 
in this thesis outperformed that of medical colleagues, with retrieval of the 
highest mean number of lymph nodes at primary dissection (23.3).  This was 
almost double the minimum required number required by RCPath guidelines 
(The Royal College of Pathologists, 2014).  The advanced practitioner also 
retrieved a greater proportion of smaller positive lymph nodes at primary 
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dissection in comparison to medically qualified colleagues.  These findings 
clearly demonstrate that advanced practitioners should contribute to provision of 
the clinical histopathology service, and may also provide training and guidance 
to less experienced colleagues, whether medically or scientifically qualified.  
This role should replace that previously performed by consultant 
histopathologists as this thesis has shown that the advanced practitioner 
outperforms not just trainees, but also consultants.   
 
This would support the recommendations of the NHS Plan, by breaking down 
barriers between services and extended roles (Great Britain. Department of 
Health, 2000), Modernising Pathology Services, by re-profiling the pathology 
workforce (Great Britain. Department of Health, 2004) and the Report of the 
Review of NHS Pathology Services in England (Great Britain. Department of 
Health, 2006) by achieving the following recommendations set out in the 
document: 
 
 
 
 
 
 
 
 
 
 
 
(Great Britain. Department of Health, 2006)  
 Recommendation 1: 
The need to review the roles and structures of the workforce to ensure 
that it is equipped to deliver modernised, affordable high quality 
pathology services for the future. 
 
 Recommendation 2: 
Achievement of productivity gains and improvements in efficiency and 
effectiveness, requiring an integrated pathology service model with 
inputs matched to skill and knowledge requirements with development 
of a workforce profile to optimise the desired service outputs (different 
from the workforce that has evolved to date). 
 
 Recommendation 3: 
Clear opportunities for the extension of roles beyond traditional 
delivery boundaries. 
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These extended roles are beneficial to the service user, the productivity of the 
department and the healthcare scientists who have the ability to develop a 
clinical career, but also to consultant histopathologists who will have training 
and dissection time released for them to perform other roles within their job 
plan. 
 
Technical aspects 
 As well as good training it is important that specimens are adequately prepared 
and fixed in formalin before primary dissection is performed (The Royal College 
of Pathologists, 2014).  Locally, specimens are not dissected until 24 hours after 
they have been prepared, and this is usually 24 hours after initial placement in 
formalin fixative within theatres.  This is in accordance with departmental 
protocols for preparing luminal gastrointestinal specimens and RCPath 
guidelines (The Royal College of Pathologists, 2014).    
 
The use of adjunct techniques has been shown to increase the lymph node 
yield and in difficult cases where inadequate lymph nodes are retrieved at 
primary dissection the techniques have been shown to be of use.  This thesis 
has shown that further fixation in formalin retrieves more lymph nodes, and the 
chief investigator anecdotally noted that lymph node detection was easier with 
this technique as the fat was less nodular.  However, GEWF has been shown 
by this thesis to identify a greater number of positive lymph nodes (20 vs 9) and 
so this technique may be equally useful, especially for less experienced 
dissectors where lymph nodes become more visible due to the change in colour 
from grey to white.  In routine practice this thesis recommends the use of further 
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fixation in formalin in difficult cases – not only because it yields more lymph 
nodes, but also because it is cheaper, easier to prepare and more readily 
available within laboratories.  The textural properties of formalin on mesenteric 
adipose tissue are also already familiar to dissectors.  In this thesis the 
advanced practitioner found it more challenging to identify lymph nodes after 
GEWF was applied because the experienced technique used to identify lymph 
nodes relied on palpation as well as vision.  It is entirely possible that more 
experienced dissectors would also find the textural changes caused by GEWF 
challenging when retrieving lymph nodes from mesenteric adipose tissue.  In 
contrast, GEWF might be of benefit to less experienced dissectors who might 
rely more heavily on vision than palpation in earlier stages of training.  
 
Implications for national and international clinical practice 
Numerous suggestions have been put forward in order to identify a greater 
number of lymph nodes in colorectal cancer.  Although GEWF was suggested 
to be the most applicable of these methods in terms of cost, time and ease of 
use (Tasi et al., 2012; Lindboe, 2011; Gregurek & Wu, 2009; Iversen et al., 
2008; Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 
2001; Koren et al., 1997), this thesis has been shown it to be an unnecessary 
step in the majority of cases.  The question of its use in other cancer specimens 
remains unanswered and there is little existing evidence to assess its efficacy.  
Satyanarayana, Chaturvedi, Mani and Subramanya (2003), commenting on the 
study by Newell et al. (2001), note an improved yield of lymph nodes less than 
1.0mm when GEWF is primarily used in breast cancer, prompting them to 
recommend its use.  However, their study was based on 11 specimens and was 
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open to numerous potential confounding factors, e.g. poor study design, small 
sample size and with no statistics used (Satyanarayana et al., 2003).  There are 
no studies within the literature investigating the effects of further fixation or 
GEWF on upper gastrointestinal cancers, such as oesophageal cancer or 
gastric cancer, which is another area where lymph nodes may be difficult to 
detect (Hanna et al., 2013; Chen, Schultheiss, Wong & Kernstine, 2009; Twine 
et al., 2009).  A recent study by Lavy et al. (2014) concluded that an acetone 
clearing technique enables evaluation of a larger number of lymph nodes in a 
group of gastric cancers (n=124).  An increase in positive lymph nodes was 
identified within the acetone group (n=63), however it was not statistically 
significant (Lavy et al., 2014).  In 2005 a small study (n=11) compared the use 
of a lymph node revealing solution to immunohistochemistry in gastric cancer 
(Luebke et al., 2005).  This study did not recommend the use of the lymph node 
revealing solution, yet it was too small to make an appropriate judgement on its 
efficacy.  A similarly small study by Koren et al. (1998) did recommend the use 
of a lymph node revealing solution in cases of gastric cancer where less than 10 
lymph nodes were identified at primary dissection, however this conclusion was 
based on 10 problematic cases and was open to numerous potential 
confounding factors (e.g. small sample size, no statistics, suspicious underlying 
dissection practice). 
 
Implications for national and international practice should be the same as those 
suggested locally.  That is, if there is good education, training and attention to 
detail, adjunct techniques such as further fixation in formalin or GEWF are not 
necessary.  Although there was detection bias within their study, with dissectors 
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being allowed to choose which adjunct technique they wished to use, the 
findings of Gregurek and Wu (2009) are partially in agreement with this thesis, 
concluding that the education of histopathologists in appropriate manual 
dissection practice gives more powerful results than the use of lymph node 
retrieval solutions.   
 
6.4.2 IMPLICATIONS FOR PROFESSIONS AND POLICY 
The findings of this thesis have local, national and international implications for 
professions and policy. 
 
Local implications for professions and policy 
This thesis demonstrates the high quality of local histopathological dissection 
practice.  Adequate primary dissection has been demonstrated by all dissector 
groups, including the advanced practitioner healthcare scientist.  The findings of 
this thesis support the previous audit of practice performed by the advanced 
practitioner (Horne et al., 2011) and meet professional standards of proficiency 
(Health and Care Professions Council, 2012a) and the professional 
requirements of the RCPath Continuing Professional Development (CPD) 
scheme (The Royal College of Pathologists, 2013c).  
 
This thesis clearly shows that the educational background of the dissector is 
irrelevant, provided that they are appropriately trained to perform the task, take 
an appropriate amount of time to perform it, and understand the need for 
adequate fixation and preparation of the specimen beforehand.  No change to 
departmental policy is required as a result of this thesis, however it does 
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reinforce the fact that specimens need to be adequately fixed in formalin before 
dissection to ensure high quality lymph node retrieval.     
 
National implications for professions and policy 
This thesis increases the body of evidence supporting the value of extended 
roles for healthcare scientists within histopathology (Sanders et al., 2012; Horne 
et al., 2011; Duthie et al., 2004; Joint RCPath/IBMS Working Group, 2004; 
Ashworth, 1994; Biggart & Allen, 1994).  During the last decade the roles for 
healthcare scientists in specimen dissection have been developed, with 
advanced practitioners, holding the IBMS Diploma of Expert Practice in 
Histological Dissection (Joint RCPath/IBMS Working Group, 2004), now 
commonplace in histopathology laboratories all over the UK.  The results of this 
thesis should not be interpreted as a threat to the role of histopathologists, 
either to those at consultant level or to those in training.  Instead the results add 
to the body of evidence which suggests that a high quality clinical service is 
best provided by a shared medical and scientific workforce (Sanders et al., 
2012; Horne et al., 2011; Great Britain. Department of Health, 2008; Great 
Britain. Department of Health, 2006; Duthie et al., 2004; Joint RCPath/IBMS 
Working Group, 2004; Ashworth, 1994; Biggart & Allen, 1994, van Schalkwyk, 
n.d.).   The findings of this thesis are in keeping with the key recommendations 
of the Carter Report, which supports transformation of the roles of healthcare 
scientists via workforce review and recommends productivity gains with 
improved efficiency and effectiveness (Great Britain. Department of Health, 
2006). 
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International implications for professions and policy 
This thesis does not agree with the findings of other studies who advocate the 
routine use of GEWF in lymph node retrieval in colorectal cancer (Tasi et al., 
2012; Lindboe, 2011; Saleki & Haeri, 2002; Koren et al., 1997).  None of these 
studies were from the UK, but were performed in Asia (Tasi et al., 2012; Saleki 
& Haeri, 2002; Koren et al., 1997) and Scandinavia (Lindboe, 2011).  In fact, 
none of the previous studies related to GEWF originated in the UK (Tasi et al., 
2012; Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; Iversen et al., 
2008; Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 
2001; Koren et al., 1997).  In all but one of the studies, a recommended 
minimum lymph node harvest target of 12 was recommended (Tasi et al., 2012; 
Lindboe, 2011; Storli et al., 2011; Gregurek & Wu, 2009; Iversen et al., 2008; 
Kelder et al., 2008; Švec et al., 2006; Saleki & Haeri, 2002; Newell et al., 2001) 
– a primary dissection target which was only achieved by Gregurek and Wu 
(2009).  Therefore, the international implications of this thesis should be to 
encourage appropriate training in the dissection of colorectal cancer specimens, 
combined with adequate fixation of the specimen beforehand.  The findings of 
this thesis argue that although the use of adjunct techniques will lead to an 
increased number of retrieved lymph nodes, they will not improve patient 
outcomes, and are unnecessary in routine practice.   
 
In countries where specimen dissection is only performed by medically qualified 
histopathologists, a change in workforce configuration might also be 
considered.  This thesis has added to the body of the evidence which advocates 
the provision of a high quality histopathology service by a combined medical 
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and scientific workforce.  Not only does this improve the quality of specimen 
dissection, it also delivers productivity gains for histopathology departments as 
well as increasing the job satisfaction for healthcare scientists.   
 
6.5 RECOMMENDATIONS 
Objectives 
The objectives of this thesis are summarised below:  
 
 
 
 
 
 
 
 
 
 
 
Objective 3 has been met as a result of the work performed for this thesis.  A 
new departmental protocol for the macroscopic handling of colorectal cancer 
specimens is unwarranted because underlying primary dissection practice has 
been shown to be excellent, with no requirement for the routine use of adjunct 
techniques.  GEWF has not been shown to be advantageous over further 
fixation, and so the practice of secondary dissection after further fixation should 
 Objective 1: 
Compare two methods of adjunct preparatory techniques – GEWF vs 
further fixation – via a randomised controlled trial designed study. 
 
 Objective 2: 
Critically analyse results to determine whether either GEWF or further 
fixation leads to a statistically significant increase in lymph node 
harvest and/or upstaging from pN0 to pN1/pN2. 
 
 Objective 3: 
Develop a new departmental protocol for the macroscopic handling of 
colorectal cancer specimens based on the findings.  This will involve 
either no change, treatment with GEWF either before or after primary 
dissection, or further fixation of specimens before secondary 
dissection. 
 
 Objective 4: 
Disseminate findings via publication in appropriate journals and 
presentation of key findings, locally, nationally and internationally. 
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continue in cases where lymph nodes are difficult to retrieve at primary 
dissection. 
 
Key recommendations for histopathology departments are as follows: 
 
 
 
 
 
 
 
 
 
Key recommendations for local and national policy are as follows:  
 
 
 
 
 
 
 
 
 
 
 
 
 Specimens should be adequately fixed before primary dissection. 
 
 An appropriate amount of time should be spent retrieving lymph 
nodes. 
 
 Existing training and dissection practice is of high quality and should 
continue with minimal change to local protocols (see below). 
 
 Adjunct techniques may be useful in cases where lymph nodes are 
difficult to retrieve, however further fixation may be a more appropriate 
alternative. 
 
 Secondary dissections should be performed in a more timely manner 
in cases where lymph nodes are difficult to retrieve at primary 
dissection, in order to minimise turnaround time delays. 
 There should be a focus on training and educating dissectors to an 
adequate standard, using direct and indirect supervision before 
independent practice is permitted. 
 
 Specimens should be adequately fixed in formalin before primary 
dissection. 
 
 Dissectors should be encouraged to spend an appropriate time 
harvesting lymph nodes, with outcomes focused on accuracy rather 
than time spent. 
 
 The commission of a combined medical and scientific workforce 
should be encouraged and actioned, with appropriately trained and 
supervised advanced practitioners and histopathologists performing 
specimen dissections to ensure provision of a high quality service. 
 
 Adjunct techniques may be useful, however further fixation may be a 
more appropriate alternative. 
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Key recommendations for future research are as follows: 
 
 
 
 
 
 
Key recommendations for professions are as follows:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Adjunct techniques may be useful in other upper gastrointestinal 
cancers where lymph nodes are difficult to identify and this could be 
examined with further studies, e.g. in other upper gastrointestinal 
cancers. 
 
 A further study could be performed to assess whether the BCSP is 
successfully detecting early cancers locally. 
 
 The provision of a combined medical and scientific workforce to 
provide a high quality histopathology service should be encouraged 
and developed. 
 
 Further opportunities for development of the scientific workforce into 
clinical roles previously only performed by medically qualified 
histopathologists should be sought, e.g. reporting. 
 
 The body of evidence for workforce review in histopathology should 
be increased further with more audits, research studies and evidence 
of good clinical practice. 
 
 The provision of appropriate training programmes and qualifications 
for extended or new roles for the scientific workforce should be 
ensured. 
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Figure 6.2 compares the proposed versus actual outcomes and 
recommendations of this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.  Proposed vs actual outcomes and recommendations of this 
thesis. 
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Working practices 
The findings of this thesis support the further development of a joint medical 
and scientific workforce to provide the clinical histopathology service.  This is in 
keeping with national policy (Great Britain. Department of Health, 2006; Great 
Britain. Department of Health, 2004; Great Britain. Department of Health, 2000) 
and would ensure provision of a service which is focused on quality as well as 
productivity and efficiency gains.  This will ensure that histopathology is 
equipped to deliver a modernised, affordable high quality service fit for the 
future (Great Britain. Department of Health, 2006).   
 
Time and cost savings 
The originally proposed outcomes of this thesis were for a possible change in 
working practice with associated time and cost savings.  These potential 
savings could be due to histopathologists not having to return to specimens to 
perform secondary dissections because adequate lymph nodes for staging 
would have been detected at primary dissection.  Although no change is 
required to the dissection protocol, the findings of this thesis may still be 
associated with time and cost savings because local primary dissection practice 
has been shown to be adequate.  The actual time and cost saving identified by 
this thesis relates to the timeliness of performing secondary dissections in 
cases where lymph nodes are difficult to detect at primary dissection.  In these 
cases it is recommended that specimens are placed in fresh formalin solution 
after primary dissection, with secondary dissection of the mesenteric adipose 
tissue performed 24 hours later.  This would minimise current delays due to 
inadequate lymph node harvests, whereby secondary dissections are 
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performed after initial slide review, which may be days after the primary 
dissection.  Performing a secondary dissection at this point would therefore add 
days to the turnaround time, potentially delaying the final histopathological 
report.  Performing more timely secondary dissections would reduce turnaround 
time delays and ensure that service users received appropriate complete 
reports in a timely manner.  
 
Sharing of evidence 
Objective 4 has been partially met and will be further explored and addressed in 
the future.  An article based upon the literature review in this thesis, challenging 
the claims of the previous literature, has been successfully published in the 
Journal of Clinical Pathology (see Appendix W) (Horne, Bateman, Carr, & 
Ryder, 2014b).  Early research findings have also been disseminated by poster 
presentation at the European Congress of Pathology in London (see Appendix 
X) (Horne, Carr, Ryder & Green, 2014c) which prompted interesting discussion 
and debate between UK and European colleagues.  The conclusion of the 
published literature review included recommendation for the carrying out of 
appropriately designed research to truly assess the efficacy of GEWF in 
colorectal cancer.  The final findings of this thesis will be published in the future 
as a response to this recommendation.  
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6.6 ACHIEVEMENT OF DOCTORAL LEARNING OUTCOMES 
This section will consider the achievement of the required learning outcomes for 
the professional doctorate in health science.  Table 6.1 shows the required 
learning outcomes of the doctoral programme and evidence of their 
achievement.   
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Table 6.1.  Achievement of learning outcomes of the doctoral programme. 
  
Category 
 
Achieved Evidence of 
achievement 
 
A Knowledge and understanding   
A1 Current professional developments within their area of practice Yes Thesis 
A2 Models of evidence based practice, evaluation and audit used to inform and innovate practice within their professional 
area 
Yes Thesis 
Dissemination 
A3 The theory and practice of qualitative and quantitative research methodologies and techniques appropriate to health 
and social care 
Yes Study design 
Thesis 
A4 The ethical and governance frameworks applicable to research within their chosen area of study Yes Study design 
A5 Critical reflection for own learning and professional practise Yes Thesis  
A6 Styles of scientific writing and publication processes within the health and social care fields and specifically within their 
own professional domain 
Yes Thesis 
Dissemination 
B Cognitive (intellectual or thinking) skills   
B1 Integrate knowledge of science and or social theory to analyse problems or opportunities related to practice and justify 
strategies to inform practice 
Yes Thesis 
B2 Formulate questions, critically appraise, synthesise and evaluate evidence so as to transfer theoretical, research and 
professional understanding into areas of practice 
Yes Thesis 
B3 Critically discuss the methodological, ethical and financial limitations of their proposed plan of investigation and be 
aware of the implications of such constraints 
Yes Study design 
Thesis 
B4 Critically appraise the value of theoretical perspectives and research evidence collected and use it to effectively and 
logically challenge current concepts, thinking and approaches 
Yes Thesis 
Dissemination 
C Practical (professional or subject) skills   
C1 Outline changing professional context and manage the processes of change to enable solving of problematic situations 
as they arise 
Yes Thesis 
C2 Use appropriate and well-reasoned methodology, and make a significant and original contribution to professional 
practice 
Yes Thesis 
C3 Independently, critically challenge current assumptions relevant to the profession Yes Thesis 
Dissemination 
C4 Provide authoritative solutions when presented with practical, managerial, business, ethical and research problems 
within a professional context 
Yes Study design 
Thesis 
C5 Evaluate the various sources of information such as relevant library databases and conduct rigorous 
library/information-based searches 
Yes Thesis 
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C6 Select appropriate qualitative and quantitative methodologies and techniques to conduct research and professional 
development within their profession 
Yes Study design 
C7 Demonstrate the relevance and innovative approaches of their research and professional development to their area of 
practice 
Yes Study design 
Thesis 
C8 Manage dilemmas and value conflicts in a way which takes forward professional practice Yes Study design 
Thesis 
C9 Attain critical and creative mastery of the latest available knowledge within their area of professional practice Yes Thesis 
Dissemination 
C10 Take responsibility as a leading practitioner, innovator and manager of others in a community of practice and beyond Partial Study design 
Thesis 
C11 Plan a research/professional development protocol and prepare an application for approval and demonstrate the likely 
relevance of the work to the area of practice 
Yes Study design 
Thesis 
D Transferable (graduate and employability) skills   
D1 Disseminate theoretical, research and professional understanding and recommendations to critical communities using 
a variety of formats 
Partial Dissemination 
D2 Manage and make professional use of resources (e.g. human, financial and physical) where appropriate Yes Study design 
Thesis 
D3 Manage information and research data Yes Thesis 
Dissemination 
D4 Manage change effectively, prioritise time and workloads and respond to changing professional demands Yes Study design 
Thesis 
D5 Command the attention and respect of others in providing professional and intellectual leadership, inspiration and 
motivation 
Partial Dissemination 
D6 Present articles for publication in a scientific or professional journal or other media Partial Dissemination 
D7 Interact and network within a multidisciplinary team to conduct research and develop professionally Partial Dissemination 
D8 Identify learning needs and be autonomous in the planning and management of their own learning Yes Study design 
Thesis 
D9 Demonstrate a reflective and thoughtful approach to their research and professional development Yes Thesis 
D10 Demonstrate a reflective and self-critical approach to the application of their learning to their professional practice Yes Thesis 
 
(University of Portsmouth, 2014) 
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Table 6.1 demonstrates that the majority of learning outcomes have been met 
via designing the research study, writing the thesis and dissemination of the 
research findings.  Those outcomes which have only been partially met require 
further publication and dissemination and sharing of evidence, which will occur 
after completion of the doctoral programme. 
 
Many of the learning outcomes are continuous, and should be seen as part of 
good CPD for a healthcare scientist (Institute of Biomedical Science, 2014e; 
The Royal College of Pathologists, 2013c; Health and Care Professions 
Council, 2012b). 
 
The following final chapter contains personal reflection on the body of work 
which has made up this thesis.  
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7. REFLECTION 
 
7.1 RESEARCH AND PROFESSIONAL OBJECTIVES 
Whilst working towards the Professional Doctorate qualification I have had two 
sets of objectives.  The first are the primary and secondary research objectives 
set out within the thesis, as described below: 
 
 
 
 
 
 
 
 
 
 
As described in chapter 5 I have successfully met the primary objectives.  I 
have partly met the secondary objectives, but there is still work to do within this 
area, which will follow completion of the doctoral programme. 
 
The second set of objectives are those set for my own professional and 
personal development at the end of part one of the doctoral programme, within 
my critical reflection portfolio.  These were written as an Identified Programme 
of Learning (IPL) in 2011 and are summarised, with comments on achievement, 
in Table 7.1. 
Primary research objective: 
 
 To compare the effects of further fixation in formalin and GEWF on the 
lymph node harvest of patients with colorectal cancer, with or without 
neoadjuvant therapy via a controlled trial. 
Secondary research objectives: 
 
 Development of a new departmental protocol for the macroscopic 
handling of colorectal cancer specimens based upon the findings of 
the research study. 
 
 Dissemination of study findings via publication in appropriate journals, 
with key conclusions presented locally, nationally and internationally. 
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Table 7.1.  My professional and personal development objectives, as set out in my IPL.  
 
Key objectives  
 
Achieved Evidence 
Become fully competent and experienced as an Advanced Practitioner in 
Histopathology 
Yes Completed competence portfolio 
Experience of teaching and training others 
Continue to develop skills in the reading, writing and publishing of retrospective 
and prospective research to tie in with teaching and training as well as doctoral 
studies 
Yes Three publications to date 
Now performing peer reviews 
Success in the course with the skills, experience, confidence, thesis and doctorate 
as evidence 
Partially Confidence still requires some building 
Study objectives   
Continued training in all aspects of dissection, including an understanding of the 
theory behind the practice 
Yes Attending courses and amendment of protocols 
dependent upon best practice 
Completing the higher level RCPath/IBMS qualification in Lower GI Histological 
Dissection 
No Studying a new and more useful reporting qualification 
Keeping up to date with relevant literature surrounding developments in colorectal 
histopathology, especially related to my thesis subject  
Yes Continuous reading of new literature 
Developing my writing and presenting skills further, by attempting to conduct, 
publish and present relevant audits 
Yes Published and disseminated numerous audits at regional 
and national meetings 
Developing my writing and presenting skills further by undertaking training 
provided by the University of Portsmouth, e.g. dissertation writing, viva voce skills 
Yes Writing practice gained by publishing articles and 
attending courses 
Other objectives    
Develop and encourage evidence based practice within my department Yes Training and teaching based upon evidence based 
practice 
Develop my leadership skills further and in other colleagues  
 
Partially Mentoring opportunities taken 
Further develop skills and confidence to use in lecturing post and in development 
of teaching role 
Yes Experience teaching and training and speaking in public 
Share examples of good practice with others in order to help advertise improved 
career prospects for Biomedical Scientists within Histopathology  
Yes Publication and dissemination; participation in 
histopathology reporting pilot for healthcare scientists 
Network, share and use experience and knowledge with peers and lecturers in 
order to improve my own practice 
Yes Publication and dissemination; participation in 
histopathology reporting pilot for healthcare scientists 
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Specific, time related objectives   
Completion of thesis 
 
Yes Thesis 
Achieve complete competency in dissection and dissection teaching skills, 
measured by feedback and audit  
Yes Competence portfolio complete 
Have examples of good / changed practice which are shareable with other Trusts 
etc., measured by public speaking, publications, networking 
Yes Participation in histopathology reporting pilot for 
healthcare scientists 
Publish and disseminate a variety of examples of advanced practice / research  Partially Publication and dissemination of audits, a case study, a 
literature review.  More to follow on completion of 
doctorate 
Workplace objectives   
Achieve absolute competency in dissection of all specimens, measured by 
feedback and audit  
Yes Competence portfolio complete 
Publish appropriate dissection protocols within the department and encourage 
their use during training and practice  
Yes New and updated dissection protocols all published  
Achieve knowledge and understanding in order to teach / advise others in the 
dissection of all specimens, measured by personal competence, confidence, 
feedback and audit  
Yes Competence portfolio complete; teaching and training of 
others; independent practice 
Train a pool of Biomedical Scientist colleagues to a competent level in appropriate 
histological dissection, measured by feedback and audit  
Partially Some training provided, but mostly by consultants in 
accordance with department agendas 
Drive a lean management project within the cut up laboratory to achieve the 
highest levels of possible efficiency  
Partially Some progress made but work taken over by others 
Help to advertise SUHT as a gold standard site for extended training of 
Biomedical Scientists in order to improve career progression within 
Histopathology, measured by public speaking, publications, networking  
Partially Directly linked to objective above; participation in the 
histopathology reporting pilot for healthcare scientists 
Improve the teaching and training within the department, measured by audit, 
feedback, networking  
Partially Directly linked to objective above; teaching and training 
of others 
Support objectives    
University thesis supervisor - to drive direction of project and work out how to 
measure outcomes  
Yes Achievement of thesis 
Workplace thesis supervisor – to help plan finer details of project, drive the 
process and work out how to measure outcomes 
Yes Achievement of thesis 
University statistician – to help me analyse the results No No university statistician available, but sought help from 
another statistical expert within the graduate school 
GI Histopathology Consultants – I need them to record all data appropriately and No Non-compliance from some  
249 
 
to support the process as they are responsible for authorisation of cases (mostly)  
Trainee Histopathologists – I need them to record all data appropriately No 
(mostly) 
Directly associated with objective above 
New professional department manager – I need to gain their support Yes 
 
Financial support given throughout 
Time – organisation of time essential as study leave currently only given to 
medical staff.  Need to get study leave built into my new job description  
Yes  All requested study leave given 
Money – funding required for equipment, consumables and statistician No Three funding applications rejected 
Department funded consumables 
University statistician resigned and not replaced 
 
I am satisfied to have met the majority of my objectives, with good reasons given for those where I failed to meet them. 
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7.2 TIMELINE OF RESEARCH AND PROFESSIONAL DEVELOPMENT 
Figure 7.1 shows the predicted and actual timeline of my research and 
professional development through part two of the doctoral programme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1.  Timeline of research and professional development. 
ACTUAL TIMELINE PREDICTED TIMELINE 
Completion of part 
one of the doctoral 
programme 
2011 
Submission of 
research proposal 
Apr 2012 
Start data 
collection 
Finish data 
collection 
Jun 2012 
Jun 2014 
Completion of part one of the 
doctoral programme 
Submission of research 
proposal 
Start data collection 
Finish data collection July 2014 
Informed of potential histopathology 
reporting pilot for healthcare scientists 
May 2012 
Sep 2012 Successful application onto year 1 of 
histopathology reporting pilot 
Passed end of year 1 histopathology 
reporting pilot exam 
Sep 2013 
Publication of literature review Mar 2014 
Histopathology reporting pilot exit exam 
and viva voce 
Dec 2014 
Feb 2015 
Sep 2015 
Exit presentation and viva voce 
Submit thesis Submit thesis 
Exit presentation 
and viva voce 
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7.3 REFLECTION ON RESEARCH AND PROFESSIONAL 
DEVELOPMENT 
 
Adherence to predicted timeline 
I have generally kept to the predicted timeline, finishing data collection just one 
month later than expected.  On reflection, if I had performed secondary 
dissections on Saturdays from the start of the study then I would have probably 
finished data collection in less than the predicted two years.  The problems with 
data collection were overcome by a period of intense hard work to enable timely 
completion of this part of the research without a long delay. 
 
Statistics 
My other concern was with regard to statistical analysis.  As described within 
my 2011 critical reflection portfolio “I am fully aware of my limitations in terms of 
performing statistics and I know that I must seek support from the university 
statistician when analysing data within my project.”  Soon after the university 
statistician performed a power calculation and generated a randomised number 
sample for me he left the organisation and was not replaced.  This concerned 
me greatly as I had little confidence in my statistical expertise.  Whilst waiting 
for the data collection period to be completed I decided to try and address my 
own issues, by signing up to two remedial statistics courses organised by the 
university Graduate School Development Programme (GSDP) and by 
downloading SPSS onto my home PC to practice entering and analysing data.  
At the second course I took some of my preliminary research data with me and 
asked for specific advice from the course leader, which I was given.  These 
252 
 
courses were invaluable, as not only did I realise that I could do statistics, albeit 
with some guidance before performing the calculations, but I also had 
confirmation of the statistical tests required for my own research.  I returned 
from these courses with a new found confidence and soon after performed all of 
my own statistical analyses – something which I thought would have been 
impossible at the start of the programme.   
 
As demonstrated in my critical reflection portfolio I favour Gibbs model of 
reflection when considering and organising my reflective practice.  Applying 
theories of critical reflection can to help understand the incident.  Gibbs (1988) 
uses a cyclical model based on consideration of each step of the incident.  An 
applied Gibbs model of reflection is shown in Figure 7.2, and then Figure 7.3 
shows the model reflecting on my ability to perform statistical analysis. 
 
 
 
 
 
 
 
 
Figure 7.2.  Applied Gibbs model of reflection (Gibbs, 1988). 
Description 
What happened? 
Conclusion 
What else could have been done? 
Action Plan 
If it happened again what would 
you do? 
Feelings 
What were you feeling? 
Evaluation 
What was good / bad? 
Analysis 
What sense can you make of it? 
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Figure 7.3.  Applied Gibbs model reflecting on my ability to perform 
statistical analysis (Gibbs, 1988). 
 
 
 
 
 
Description 
 
Lack of competence in 
understanding and 
performing statistical 
analysis  
 
Conclusion 
There should still be easier access 
to a university statistician 
I could have worried about 
statistics less during part two of 
the programme 
My confidence has been boosted 
Action Plan 
 
Attend remedial statistics courses 
Download SPSS for my home PC 
Seek advice from statistics course 
leader 
Feelings 
Fear; worry; uncertainty; doubt 
Evaluation 
Good – remedial courses are useful if 
lacking confidence; statistical advice 
was available and all that was needed 
Bad – I will always lack some 
confidence when talking to others with 
more statistical knowledge than me 
Analysis 
My concerns about statistics 
were slightly unfounded and 
forced to be challenged with 
no formal statistical support 
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Publication and dissemination 
I am pleased with the development of my writing skills and the transference of 
those skills into publications and presentations.  My publication and 
dissemination experience can be found as a prefix chapter at the beginning of 
the thesis.  My progress in this area has been fully supported by my consultant 
colleagues and university supervisor, and I am very proud of my literature 
review article which was published in the Journal of Clinical Pathology in March 
2014, following very minor revisions (Horne et al., 2014b) (see Appendix W).  
As a result of this publication I have been asked to perform a number of peer 
reviews, I have been contacted by pathologists in Perth, Australia for advice 
about using adjunct histopathological techniques, and I have been interviewed 
by a new publication called ‘The Pathologist’ for an upcoming issue (Texere 
Publishing Ltd, 2014).  I am most proud that my literature review is referenced 
in the newly updated ‘Dataset for colorectal cancer histopathology reports’, 
which is used by histopathologists throughout the UK (The Royal College of 
Pathologists, 2014, p. 36). 
 
7.4 OPPORTUNITIES AND CHALLENGES 
I have faced a number of opportunities and challenges during the doctoral 
programme.  These will be discussed in the following section.  
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7.4.1 HISTOPATHOLOGY REPORTING PILOT 
Quite unexpectedly, the opportunity to take part in a national histopathology 
reporting pilot came in 2012.  Given the chance to plan my professional and 
educational development I would never have considered doing more than one 
doctoral level qualification at a time.  However, this was a dream opportunity 
and one which I had to take and be at the forefront of.  I successfully joined the 
inaugural year of the histopathology reporting pilot for healthcare scientists, 
developed and run by a working group from the Royal College of Pathologists in 
September 2012.  Doing this qualification alone would be difficult enough, but to 
do it in conjunction with the second part of my doctoral programme was, and 
continues to be, incredibly challenging.  However, the opportunities for myself 
and my peers are too great to allow to pass by, and so I have studied for both 
qualifications concurrently.  If successful at exit examination and viva voce I will 
receive a diploma giving me privileges to independently report gastrointestinal 
histopathology specimens.  Independent reporting by a healthcare scientist 
would have been unheard of within my profession just ten years ago, and is still 
not supported by some histopathologists who feel that this represents a threat 
to their dominance.  However, it should be noted that the pilot for specimen 
dissection is only a decade old (Joint RCPath/IBMS Working Group, 2004) and 
although seen as a threat in 2004, the employment of advanced practitioners in 
histological dissection is now commonplace within the UK (C. Ward, personal 
communication, October 23, 2014).  These changes are also entirely in keeping 
with national policy and strategy (Great Britain. Department of Health, 2010; 
Great Britain. Department of Health, 2006; Great Britain. Department of Health, 
2004; Great Britain. Department of Health, 2000).  I am immensely proud to be 
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at the forefront of this new development within histopathology which I believe 
will enable histopathology services to be fit for the future challenges which no 
doubt lie ahead, with a highly trained and knowledgeable combined workforce 
of doctors and scientists – a change which is long overdue. 
 
7.4.2 SUPPORT FROM COLLEAGUES 
One of the steepest learning curves during this research has been the varying 
amount of support that I received from my colleagues.  Whilst designing the 
study I was careful to involve all staff groups by discussing potential protocols.  
The greatest input was to have been from the gastrointestinal specialist 
consultant histopathologists, all of whom said that they were happy to follow the 
protocol and assist me with microscopic data collection.  Naively I had no 
doubts as to the support that I thought would be forthcoming.  This opinion had 
not altered since writing my critical reflection portfolio, which contained the 
following paragraph:        
 
 
 
However, once data collection began I soon realised that there were problems 
due to non-compliance with the research protocol.  I spent a large amount of 
time attempting to retrieve data collection sheets from consultants, and when I 
did they were often incomplete.  When I politely challenged my colleagues, the 
response that I received varied, but included apologetic, embarrassed and 
laissez faire.  In hindsight I had been very naïve – I simply thought that my close 
working relationship to the consultants would have led to compliance with 
“…I made the decision to change my project idea.  I knew that I had to develop a project that 
I had more control over, involving less input from scientific staff who were controlled by the 
section manager, and greater input from the medical staff, who were fully supportive…” 
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agreed research protocols.  As a result as I had to redesign my data collection 
strategy for the second half of the data collection period, creating a large 
amount of additional work for me, and minor amounts of additional work for 
those consultants who were able to help me.  At the time I found the experience 
stressful and frustrating because I didn’t feel that my expectations of support 
were unrealistic.  In many ways I felt let down and isolated.  I reflected heavily 
on this experience afterwards, wondering what, if anything, I could have done 
differently.  This is summarised in Figure 7.4. 
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Figure 7.4.  Applied Gibbs model reflecting on challenges I faced due to a 
lack of consultant support during the data collection period (Gibbs, 1988). 
 
 
 
 
Description 
 
Lack of promised support 
collecting microscopic data 
by consultant colleagues  
 
 
Conclusion 
The consultants could have been 
upfront about their ability to 
support my research during the 
study design stage 
I could have amended my study 
design earlier, when I first realised 
there was a problem 
Action Plan 
 
Design studies to minimise 
involvement from others who in 
reality may not be able to comply 
Feelings 
Stress; disappointment; isolation; 
frustration; annoyance 
Evaluation 
Good – I realised that I was able to be 
proactive and rethink study protocols, 
thus not putting my research at risk 
Bad – the failure of the process led to 
an increased amount of work and 
stress 
Analysis 
I was naïve to expect 
everything to go to plan 
despite initial detailed 
protocol design and 
agreement with staff groups 
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I also faced a number of other challenges during the data collection period.  I 
was convinced that enough specimens would be entered into the study by only 
working Monday to Friday.  In fact, during the first 12 months of data collection I 
lost numerous cases because of my reluctance to go into work on a Saturday, 
mainly because it was the only day I had that remained free from work or study 
each week.  This decision was challenged by a peer at a review meeting in May 
2013 and I realised that I needed to address the problem and begin to attend 
work on Saturdays as well.  I did not enjoy driving a 46 mile round trip to do a 
10-15 minute dissection on most Saturdays, but the knowledge that data 
collection would finish more quickly gave me the drive to carry on.   
 
Throughout the data collection period I had problems collecting microscopic 
data, however I had complete support from my laboratory colleagues who 
ensured that protocols were strictly adhered to and entered specimens into the 
study in a timely and appropriate manner (apart from a few occasional errors).  
This was driven by the dissection room lead scientist who I very much enjoyed 
working with and was reliant upon.  Sadly she resigned half way through the 
data collection period, to my absolute dismay.  This was one of the lowest 
points of my research, because where I was experiencing problems with 
microscopic data collection, I felt that I could always rely on the macroscopic 
part of the study to be organised due to the commitment of my colleague.  I was 
very concerned that this part of the study would also fall down with her 
resignation.  Fortunately the role was taken over by a new member of staff who 
was equally as supportive and helpful.  As a result no detrimental effects were 
seen with regard to entering of specimens into the study. 
260 
 
7.5 THE FUTURE 
As part of my critical reflection portfolio I described my hoped future 
professional development and practice as follows.  These are summarised, with 
comments on achievement, in Table 7.2. 
 
Table 7.2.  Future professional development and practice, described in 
2011. 
 
Publication and dissemination 
I am very pleased with the progress in my professional development and 
practice, and am especially happy in terms of my increasing amounts of 
publication and dissemination.  Although I am an early career researcher, with 
only one literature review, one case study and one letter published in the 
literature as of October 2014, I have already seen the opportunities that this 
experience can deliver.  As a result of these publications I have been invited to 
perform a number of peer reviews and have spoken to numerous UK and 
international colleagues about the use of adjunct techniques in histopathology.  
I have also presented a number of audits and early research findings at national 
Key objectives  Achieved Evidence 
 
Perform audits to share good 
practice 
Yes Numerous audits performed and 
presented locally and nationally 
Publish more research in addition to 
my thesis subject 
Yes Case study on gallbladder adenomas 
published in 2013 
Use evidence based practice and 
encourage others to do so 
Yes Experiential 
Carry out project and achieve thesis Yes Thesis 
Develop and improve role of 
scientists to a more appropriate level 
Partially Influencing ongoing, but many 
challenges ahead 
Improve the way Biomedical 
Scientists are viewed by the medical 
profession 
Partially Improving with more clinical input, but 
many challenges ahead to change 
attitudes and hierarchical behaviour 
inside and outside of department 
Improve the education of Biomedical 
Scientists in line with MSC 
Partially One trainee employed on the Scientific 
Training Programme, but many 
challenges ahead 
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and European conferences (refer to page ix – dissemination list).  I look forward 
to the future opportunities that will arise as a result of further publications 
related to this thesis. 
 
Overall, the doctoral programme has provided me with the tools which have 
completely changed my professional outlook.  I have changed the way that I 
plan, time manage, and react to the challenges that I have met, during both 
parts of the doctoral programme.  The work that I have undertaken will help me 
deal with the challenges that I will certainly face in the future.   
 
Professions and policy 
The main challenges that lie ahead are those related to policy, where a large 
amount of work is required to replace historical, out of date working practices 
with those fit for future service provision, whilst also giving professional 
satisfaction for all.  These challenges will no doubt be difficult and stressful, but 
I feel that carrying out this doctoral research has given me a much greater 
chance of success.   
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Appendix A.  Summary of the Report of the review of NHS pathology 
services in England (The Carter Report).  
 
Theme 
 
Description 
Professional 
demarcations 
Introduction of greater service/workforce flexibility is not being exploited 
 Complementarity of skills within a common service/competence framework is 
required 
Workforce 
planning 
Any workforce planning model must not preserve current professional silos 
 Needs to be set in context of the whole career pathway/workforce, with 
provision of extended roles put onto a footing similar to that of medical 
training 
 More clarity regarding non-medical role expansion across the pathology 
workforce is required 
Recruitment 
and retention 
Significant recruitment and retention issues remain 
 A lack of resources has led to freezing/loss of posts and restricted provision of 
basic and higher specialist training 
 An ageing workforce provides scope for introducing new staff/skill mix into 
pathology, refreshing the workforce and developing attractive career 
pathways which should prevent future recruitment and retention issues 
Career 
pathways 
Career pathways in pathology need to be clearly defined, based on the skills 
and competences required for modernised services and transferable roles 
 There should be coherence between medical and non-medical career 
pathway strands so that a truly competence-based workforce can be 
introduced 
 The Healthcare Scientist career framework needs to be fully implemented, 
with specialist and higher specialist training requirements clearly identified 
and resourced and common approaches to education and training adopted, 
with prevention of stand-alone qualifications by individual professional groups 
Skill mix There is an increasing divergence between the skill mix of the current 
workforce and the functions required by a modern pathology service 
 A more ‘business orientated’ management of the service is required, with 
strong leadership and development of local champions 
 Large scale workforce change is difficult to deliver and national support will be 
required to assist and direct the process 
 Delineation of roles based on skill- and knowledge-based competences are 
required from support worker, to consultant-level practitioner to clinical 
director  
 Identification and development of common education and training pathways is 
required 
Training A training model driven by delivered standards and equivalent academic 
levels is required, perhaps modelled on the training schools for 
histopathology, where all pathology service providers including the 
independent sector participate in the provision of training 
 Full funding for the non-medical workforce is essential for more advanced 
roles to be taken on.  This needs to be lined to the introduction of designated 
training numbers to support future more intelligent workforce planning and 
commissioning of supporting educational programmes 
 A sustainable academic base for promoting research and development in 
pathology needs to be created in order to develop evidence-based pathology 
services 
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The 
professions 
The number of disciplines, professional grouping and bodies within pathology 
promote and impression of professional fragmentation which makes provision 
of integrated leadership and representation more difficult 
 Barriers between different disciplines should be diminished with a more united 
professional face for pathology being promoted 
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Appendix B. Types of scientific bias.  
 
 
Type 
 
 
Subtype 
 
Definition 
Publication bias Bias of rhetoric Arguments presented in a compelling manner 
but with conclusions based on opinion rather 
than evidence 
 Reference bias Authors cite more references that support their 
position than contradict it, skewing 
understanding of the topic 
 Positive results bias Investigators and publishers are more likely to 
submit and accept manuscripts with positive 
results 
 
Selection bias 
Wrong sample size 
bias 
Too small a sample might miss significant 
differences whilst too large a sample might 
establish significant differences that are not 
clinically relevant 
 Non-contemporaneous 
control bias 
Over time, changes in definitions, exposures, 
diagnostic abilities, and treatments render 
historical controls incomparable 
 Starting time bias Failing to identify the start of exposure or 
disease may lead to errant stratification 
 Allocation bias Non-random assignment to a specific study 
group can create incomparable groups 
Exposure bias Compliance bias The measured efficacy of an intervention can 
be confounded by non-adherence to the 
regimen 
 Therapeutic 
personality bias 
An unblinded intervention allows the 
practitioner to influence the perception of 
benefit 
 Bogus control bias Reallocation of subjects to a control group or 
omission due to withdrawal leaves the 
intervention and control groups no longer 
matched, with differences possibly biased 
towards the intervention group 
 Proficiency bias Experimental manoeuvres of treatments may 
not be equally administered to subjects 
Detection bias 
 
Attention bias Practitioners may alter their behaviour when 
they know they are under scrutiny thereby 
altering outcomes 
Analysis bias Tidying up bias Excluding outlying data that seems implausible 
cannot be statistically justified and 
contaminates the analysis 
Interpretation bias Significance bias Confusing statistical significance with clinical 
significance may result in pointless 
conclusions 
 
 
Under-exhaustion bias Failure to reject the null hypothesis because of 
a limited investigation may lead to authoritarian 
speculation rather than truthful conclusions 
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Appendix C. United States ‘stage grouping’ system for colorectal cancer. 
 
Group 
 
Stage Description 
0 Tis N0 M0 Tumour has not invaded beyond the mucosa 
I T1-T2 N0 M0 Tumour has invaded through the muscularis mucosa into the 
submucosa (T1) or it may also have invaded into the 
muscularis propria (T2).  It has not spread to nearby lymph 
nodes or distant sites 
IIA T3 N0 M0 Tumour has invaded through the muscularis propria but has not 
breached the serosal surface (T3).  It has not reached nearby 
organs.  It has not yet spread to the nearby lymph nodes or 
distant sites 
IIB T4a N0 M0 Tumour has breached the serosal surface but has not invaded 
nearby tissues or organs (T4a).  It has not yet spread to the 
nearby lymph nodes or distant sites 
IIC T4b N0 M0 Tumour has breached the serosal surface and is attached to or 
has invaded into other nearby tissues or organs (T4b).  It has 
not yet spread to the nearby lymph nodes or distant sites 
IIIA T1-T2 N1 M0 Tumour has invaded into either submucosa (T1) or muscularis 
propria (T2).  It has spread to 1-3 regional lymph nodes 
(N1a/N1b) or into areas of fat near the lymph nodes but not the 
nodes themselves (N1c).  It has not spread to distant sites 
 T1 N2a M0 Tumour has invaded into submucosa (T1).  It has spread to 4-6 
regional lymph nodes (N2a).  It has not spread to distant sites 
IIIB T3-T4a N1 M0 Tumour has invaded through the muscularis propria (T3) or 
breached the serosa (T4a) but has not reached nearby organs.  
It has spread to 1-3 regional lymph nodes (N1a/N1b) or into 
areas of fat near the lymph nodes but not the nodes 
themselves (N1c).  It has not spread to distant sites.  
 T2-T3 N2a M0 Tumour has invaded into or through the muscularis propria (T2-
T3).  It has spread to 4-6 regional lymph nodes (N2a).  It has 
not spread to distant sites 
 T1-T2 N2b M0 Tumour has invaded into the submucosa (T1) or the muscularis 
propria (T2).  It has spread to 7 or more nearby lymph nodes 
(N2b).  It has not spread to distant sites 
IIIC T4a N2a M0 Tumour has breached the serosa (T4a) but has not reached 
nearby organs (T4b).  It has spread to 4-6 regional lymph 
nodes (N2a).  It has not spread to distant sites 
 T3-T4a N2b M0 Tumour has invaded through the muscularis propria (T3) or 
breached the serosal surface (T4a) but has not reached nearby 
organs.  It has spread to 7 or more regional lymph nodes 
(N2b).  It has not spread to distant sites 
 T4b N1-N2 M0 Tumour has become attached to or has invaded into other 
nearby tissues or organs (T4b).  It has spread to at least one 
nearby lymph node or into areas of fat near the lymph nodes 
(N1 or N2).  It has not spread to distant sites 
IVA Any T, any N, M1a Tumour may or may not have breached the serosa, and it may 
or may not have spread to regional lymph nodes.  It has spread 
to 1 distant organ, e.g. liver or lung, or set of distant lymph 
nodes (M1a). 
IVB Any T, any N, M1b Tumour may or may not have breached the serosa, and it may 
or may not have spread to regional lymph nodes.  It has spread 
to more than 1 distant organ, e.g. liver or lung, or set of distant 
lymph nodes, or distant parts of the peritoneum (M1b) 
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For staff use only: Ref: Form1_adults_010702  
Appendix D.  Example of a local consent form. 
Consent Form 1         
  
Patient agreement to       
investigation or treatment 
Staff Use only: 
  
Special patient requirements...................................   Responsible healthcare professional ............................... 
(e.g. other language/other communication method)         Job Title: ...............................................                                                                                     
 Side/site: ...................... 
 (as appropriate) 
(include brief explanation if medical term not clear)       
.............................................................................................................................................................
............................................................................................................................................................. 
 
 
(To be filled in by a health professional with an appropriate knowledge of the proposed procedure, as 
specified in the Trust’s Consent Policy) 
 
I have explained the procedure to the patient. In particular, I have explained: 
 The intended benefits of the procedure……………………………………………………..……….……… 
……………………………………………………………………………………………………………………………
…………………………………………..…………………………..……………..................................................... 
 Any serious or frequently occurring risks from the procedure…………...……………….................. 
...………………………………………………………………………………………….……………………
……………………….………………………………………………..……………………............................ 
 Any extra procedures which may become necessary during the procedure 
 Blood product transfusion  Radiological procedure  Other procedure (please specify) ......................... 
........................................................................................................................................................................... 
I have discussed what the treatment procedure is likely to involve, the benefits and risks of any available 
alternative treatments (including no treatment) and any particular concerns of this patient. 
 The following information leaflet/tape has been provided …………………………..…................ 
(include version number/date as appropriate) 
This procedure will involve: 
  general and/or regional anaesthesia    local anaesthesia   sedation 
 
Health professional’s signature .....................................................      Date: ............................ 
Name (PRINT): ..........................................................      Job Title: .............................................. 
Contact details (if patient wishes to discuss options later)   …..……………….……………............ 
 I have offered the patient information about the procedure but s/he has refused information. 
 
 
I have interpreted the information above to the patient to the best of my ability and in a way in which I 
believe s/he can understand. 
Interpreter’s signature...........................................................  Date ................................................ 
Name (PRINT) …………………..……………………………… 
                                       Copy accepted by patient: yes/no (please ring)                                     Page 1 of 2 
 
 
For staff use only: 
Surname: 
First names: 
Date of birth: 
Hospital no: 
Male/Female: 
(Use Hospital Identification label) 
 
Statement of Health Professional 
Statement of the Interpreter (if appropriate) 
GOLD COPY: CASE NOTES       WHITE COPY: PATHOLOGY         PINK COPY: PATIENT 
(send to Pathology Business Unit SGH MP 8)  
Name of proposed procedure or course of treatment 
Appendix D. Example of a local consent form. 
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Please read this form carefully. If your treatment has been planned in advance, you should already have your own 
copy, which describes the benefits & risks of the proposed treatment. If not, you will be offered a copy now. Do ask if 
you have any further questions - we are here to help you. You have the right to change your mind at any time 
before the procedure is undertaken, including after you have signed this form. You may ask for a relative, or 
friend, or a nurse to be present whilst the procedure is being explained and consent is obtained. 
The training of doctors and other health professionals is essential to the continuation of the Health Service and 
improving the quality of care. Your treatment may provide an important opportunity for such training, where necessary 
under the careful supervision of a senior doctor. You may, however, decline to be involved in the formal training of 
medical and other students without this adversely affecting your care and treatment. 
Please initial the boxes to indicate you have understood and agree to the statements below.     
 I agree to the procedure (or course of treatment) described on this form. 
 I understand that you cannot give me a guarantee that a particular person will perform the procedure. The person 
will, however, have appropriate experience. 
 I understand that any tissue removed as part of the procedure or treatment may be used for diagnostic and 
therapeutic purposes as part of my care and may subsequently be stored as part of my Medical Records and may 
be of benefit to my subsequent care management.  
 I understand that any surplus tissue may also be used for quality control/monitoring and/or public health 
surveillance purposes, where at the point of use my identity would not be known. The disposal of any surplus tissue 
would be done in a manner regulated by appropriate, ethical, legal and professional standards.  
 I agree that any tissue removed as part of the procedure or treatment, which is then surplus to my own care, may 
be used for audit, teaching, and/or research. Any sample used for such purposes would be done in an anonymous 
way so that my identity at the point of use would not be known. All research studies would be subject to Research 
Ethics Approval and would be subject to national standards of practice. 
 I agree to the use of photographs/video for the purpose of diagnosis and treatment. 
 I understand that I will have the opportunity to discuss the details of anaesthesia with an anaesthetist before the 
    procedure, unless the urgency of my situation prevents this. (This only applies to patients having general or regional   
    anaesthesia.) 
Female Patients only (when applicable); I understand my care may involve X-rays and that radiation should be     
    limited during pregnancy. There is a chance I may be pregnant.   Yes    No   
 I understand that any procedure in addition to those described on this form will only be carried out if it is necessary    
    to save my life or to prevent serious harm to my health.  
 I have been told about additional procedures, which may become necessary during my treatment. I have listed    
    below any procedures that I do not wish to be carried out, without further discussion with me 
…………………………………………………………………………………………………………………
………………………………………………………………………………………………………………… 
Patient’s own signature ………………………………………….. Date………………………….. 
Name (PRINT) ……………………………………………………………………………………… 
If the patient is unable to sign but has indicated his/her consent, a witness should sign below. Young people/children 
may also like a parent to sign here (see notes) 
Signed: ...............................................................  Date: ...................................... 
Name (PRINT) ………………………………………………………………………………….… 
 
 
  
On behalf of the team treating the patient, I have confirmed with the patient that s/he has no further questions and 
wishes the procedure to go ahead. 
Signed:…….……………………………………....................................  Date .. …………………….… 
Name (PRINT) ………………………. ………..............   Job title …….. …………………......… 
Important notes: (tick if applicable)                                                                             
Statement of Patient 
Confirmation of consent: to be completed by a health professional when the patient is admitted for 
the procedure, if the patient has signed the form in advance)   
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Appendix E.  Cut up data collection sheet A. 
 
 
 
Colorectal cancer lymph node harvest research project 
Cut up data collection sheet A 
 
This sheet should be attached to each resection for colorectal cancer where patients 
have consented to the use of their specimen for teaching, audit and research. 
 
Please could all details be completed at the time of dissection by laboratory or medical 
staff. 
 
Once dissection is complete specimens will be entered into the study and allocated a 
research number.  This form must remain with the anonymised specimen. 
 
Jody Adams should be contacted with any initial queries.  Any further queries should 
be directed to Dr Norman Carr, or in his absence Dr Adrian Bateman, Dr Ele Jaynes or 
one of the other GI consultant histopathologists. 
 
Under no circumstances should any patient identifiable details, including 
specimen number, be written on this sheet. 
 
 
Research number……………………………………………. 
 
Please complete the following information at time of dissection: 
  
Site of tumour:  
Neo-adjuvant therapy: Yes / No 
Course of neo-adjuvant therapy: Long / Short 
Size of mesentery:          mm x         mm 
Date of receipt:  
Length of fixation before dissection (days):  
Date of dissection:  
Dissector (initials):  
Time taken to perform dissection (minutes):  
 
 
Many thanks for your assistance - Jo Horne / Dr Norman Carr 
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Appendix F.  Cut up data collection sheet B. 
 
 
 
 
Colorectal cancer lymph node harvest research project 
Cut up data collection sheet B 
 
This sheet should be attached to each resection for colorectal cancer where patients 
have consented to the use of their specimen for teaching, audit and research. 
 
This sheet is to be completed by the primary researcher when performing secondary 
lymph node harvest. 
 
Under no circumstances should any patient identifiable details, including 
specimen number, be written on this sheet. 
 
 
Research number……………………………………………. 
 
Please complete the following information at time of dissection: 
  
 
Date solution (formalin or GEWF) added to specimen:  
Time solution (formalin or GEWF) added to specimen:  
Date of secondary lymph node harvest:  
Time of secondary lymph node harvest:  
Time taken to perform secondary LN harvest (minutes):  
 
Many thanks for your assistance – Jo Horne / Dr Norman Carr 
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Appendix G.  Microscopy data collection sheet C. 
 
 
 
Colorectal cancer lymph node harvest research project 
Microscopy data collection sheet C 
 
This form should be completed by the Histopathologist when microscopically assessing 
and reporting each case of colorectal cancer enrolled in the study.  The form should 
then be given to the appropriate Consultant GI Histopathologist who will complete the 
final TNM staging information after receiving any further lymph nodes harvested at 
secondary dissection.  
 
Once this form has been completed please return to Jo Horne.  Any queries should be 
directed to Dr Norman Carr, or in his absence Dr Adrian Bateman, Dr Ele Jaynes or 
one of the other GI Consultant Histopathologists.    
 
Under no circumstances should any patient identifiable details, including 
specimen number, be written on this sheet or discussed with Jo Horne. 
 
 
Research number……………………………………………. 
 
Please complete the following information at time of reporting: 
  
 
Number of lymph nodes harvested at primary dissection 
 
 
Range in size of lymph nodes negative for tumour at 
primary dissection  
       mm  -           mm 
 
Range in size of lymph nodes positive for tumour at 
primary dissection 
        mm  -           mm 
 
TNM5 staging – before secondary lymph node harvest 
 
pT      pN      pM      
 
Final TNM5 staging 
 
pT      pN      pM 
 
TNM7 staging – before secondary lymph node harvest 
 
pT      pN           
 
Final TNM7 staging 
 
pT      pN 
 
Many thanks for your assistance - Jo Horne / Dr Norman Carr 
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Appendix H.  Microscopy data collection sheet D. 
 
 
 
Colorectal cancer lymph node harvest research project 
Microscopy data collection sheet D 
 
This form should be completed by the primary researcher when microscopically 
assessing the secondary lymph nodes harvest.   
 
 
 
Research number……………………………………………. 
 
 
Number of lymph nodes harvested at secondary 
dissection 
 
Number of lymph nodes negative for tumour at 
secondary dissection 
 
Number of lymph nodes positive for tumour at secondary 
dissection 
 
Size of lymph nodes negative for tumour at secondary 
dissection  
       
 
 
 
 
 
 
 
 
 
Size of lymph nodes positive for tumour at secondary 
dissection 
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Specimen type:   Choose an item:   Total colectomy  Anterior resection 
     Right hemicolectomy Abdominoperineal resection 
     Left hemicolectomy ELAPE resection 
     Sigmoid colectomy Other 
Neoadjuvant therapy given: Choose an item:    Yes 
                              No                
Course of neoadjuvant therapy: Choose an item:    Short course 
                              Long course 
                              n/a 
Length of specimen:                . 
Site of tumour Choose an item:    Caecum           Descending colon 
                              Ascending colon  Sigmoid colon 
                              Hepatic flexure     Rectum 
                              Transverse colon  Other 
                              Splenic flexure 
Maximum diameter of tumour:                . 
Distance of tumour to nearer cut end:                . 
Tumour perforation: Choose an item:     Yes 
                               No 
If yes, perforation is: Choose an item:     Serosal 
                               Retro/infraperitoneal      n/a 
Appearance of tumour: Choose an item:     Exophytic 
                               Ulcerated 
                               Stenosing 
For rectal tumours – relationship to peritoneal reflection: Choose an item:     Above 
                               Astride 
                               Below 
                               n/a 
For rectal tumours – plane of surgical excision: Choose an item:     Mesorectal fascia 
                               Intramesorectal 
                               Muscularis propria 
                               n/a  
For rectal tumours – position of tumour within rectum: Choose an item:     Anterior             Left lateral 
                               Posterior           Circumferential 
                               Right lateral 
For AP resections – distance from dentate line:  
For ELAPE resections – levator muscle identified:  Choose an item:    Yes 
                               No 
For ELAPE resections – coccyx identified:  Choose an item:    Yes  
                               No 
For ELAPE resections – distance of tumour from coccyx:                 . 
For AP / ELAPE resections – photograph taken: Choose an item:    Yes 
                               No 
For right hemicolectomies – appendix: Choose an item:     Present 
                               Absent 
                               n/a 
Highest lymph node: Choose an item:     Identified 
                               Not identified 
Background abnormalities:  
Tumour invasion beyond muscularis propria:  
 
Choose an item:     Yes 
                               No 
If yes, how far:  
Distance of tumour from circumferential margin:  
Block descriptions:  
Macroscopic proforma - before study. 
Appendix I. Examples of reporting proformas used before and during the study. 
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Specimen type:   Choose an item:   Total colectomy  Anterior resection 
     Right hemicolectomy Abdominoperineal resection 
     Left hemicolectomy ELAPE resection 
     Sigmoid colectomy Other    
Neoadjuvant therapy given: Choose an item:    Yes 
                              No                
Course of neoadjuvant therapy: Choose an item:    Short course 
                              Long course 
                              n/a 
Length of specimen:                . 
Size of mesentery (high tie to distal margin x maximum depth)                . 
Site of tumour Choose an item:    Caecum           Descending colon 
                              Ascending colon   Sigmoid colon 
                              Hepatic flexure     Rectum 
                              Transverse colon  Other 
                              Splenic flexure 
Maximum diameter of tumour:                . 
Distance of tumour to nearer cut end:                . 
Tumour perforation: Choose an item:     Yes 
                               No 
If yes, perforation is: Choose an item:     Serosal 
                               Retro/infraperitoneal 
                               n/a 
Appearance of tumour: Choose an item:     Exophytic 
                               Ulcerated 
                               Stenosing 
For rectal tumours – relationship to peritoneal reflection: Choose an item:     Above 
                               Astride 
                               Below        n/a 
For rectal tumours – plane of surgical excision: Choose an item:     Mesorectal fascia 
                               Intramesorectal 
                               Muscularis propria            n/a 
For rectal tumours – position of tumour within rectum: Choose an item:     Anterior             Left lateral 
                               Posterior           Circumferential 
                               Right lateral 
For AP resections – distance from dentate line:  
For ELAPE resections – levator muscle identified:  Choose an item:    Yes 
                               No 
For ELAPE resections – coccyx identified:  Choose an item:    Yes  
                               No 
For ELAPE resections – distance of tumour from coccyx:                 . 
For AP / ELAPE resections – photograph taken: Choose an item:    Yes 
                               No 
For right hemicolectomies – appendix: Choose an item:     Present 
                               Absent 
                               n/a 
Highest lymph node: Choose an item:     Identified 
                               Not identified 
Background abnormalities:  
Tumour invasion beyond muscularis propria:  
 
Choose an item:     Yes 
                               No 
If yes, how far:  
Distance of tumour from circumferential margin:  
Block descriptions:  
Macroscopic proforma - during study. 
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TUMOUR: 
Type:   
Differentiation by predominant area:   
Local invasion:   
Distance beyond muscularis propria:   
Neoadjuvant therapy given:   
Response to neoadjuvant therapy:   
 
TUMOUR INVOLVEMENT OF MARGINS: 
Donuts:   
Margin (cut end):   
Non-peritonealised circumferential margin:   
Distance of tumour from non-peritonealised margin:   
 
METASTATIC SPREAD: 
Number of lymph nodes present:   
Number of involved lymph nodes:   
Highest node involved (Dukes’ C2):   
Extramural venous invasion:   
Histologically confirmed distant metastases:   
If yes, site:   
 
BACKGROUND ABNORMALITIES:  
 
PATHOLOGICAL STAGING: 
Complete resection at all surgical margins:   
TNM (5th edition):   
TNM (7th edition):  
Dukes’:   
 
 
Representative tumour block:    
 
 
COMMENTS:  
 
Pathologist: 
 
 
 
 
 
 
 
 
 
Microscopic proforma – before study. 
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TUMOUR: 
Type:   
Differentiation by predominant area:   
Local invasion:   
Distance beyond muscularis propria:   
Neoadjuvant therapy given:   
Response to neoadjuvant therapy:   
 
TUMOUR INVOLVEMENT OF MARGINS: 
Donuts:   
Margin (cut end):   
Non-peritonealised circumferential margin:   
Distance of tumour from non-peritonealised margin:   
 
METASTATIC SPREAD: 
Number of lymph nodes present (1ry dissection):   
Number of lymph nodes present (2ry dissection):  
Total number of lymph nodes present:  
Number of involved lymph nodes:   
Highest node involved (Dukes’ C2):   
Extramural venous invasion:   
Histologically confirmed distant metastases:   
If yes, site:   
 
BACKGROUND ABNORMALITIES:  
 
PATHOLOGICAL STAGING: 
Complete resection at all surgical margins:   
TNM (5th edition):   
TNM (7th edition):  
Dukes’:   
 
 
Representative tumour block:    
 
 
COMMENTS:  
 
Pathologist: 
 
 
 
 
Microscopic proforma - during study. 
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Colorectal cancer lymph node harvest research project 
 
Protocol for consultant histopathologists 
 
 
1.  Staff involved in study  
 
Primary researcher     Jo Horne 
 
Histopathologist team 
 
Primary educational supervisor   Dr Norman Carr 
Secondary educational supervisor   Dr Adrian Bateman 
Nominated additional histopathologist  Dr Ele Jaynes 
 
Laboratory team 
 
Cut up team leader biomedical scientist  Jody Adams 
Nominated additional laboratory staff 1  Hollie Guy  
Nominated additional laboratory staff 2  Tiffany Jones 
 
IMPORTANT: Under no circumstances should any patient identifiable details, 
including specimen number, be discussed with the primary researcher (JH) in 
relation to the study. 
 
 
 
 
 
 
 
 
Appendix J.  Protocol for consultant histopathologists. 
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2.  Primary dissection 
  
Colorectal cancer specimens will be received into cut up as per routine practice.  
Specimens should be treated as per standard dissection protocols. 
 
Please complete cut up data collection sheet A during specimen dissection.  Cut up 
data collection sheet B is for the primary researcher to complete at secondary lymph 
node harvest and should be ignored. 
 
After specimen dissection please give data collection sheet A and the specimen pot to 
cut up staff.  The specimen will then be enrolled into the study if it fits appropriate 
criteria as outlined below: 
 
 
 
Inclusion criteria for the study are as follows: 
 
1. Colorectal cancer specimens received for curative resection of  
adenocarcinoma at Southampton General Hospital 
 
2. Informed consent given to use the sample for teaching, audit and research 
 
Exclusion criteria for the study are as follows: 
 
1.  Colorectal specimens received without informed patient consent  
 
2. Colorectal specimens received for primary resection of non-
adenocarcinoma  
 
3. Colorectal specimens received for resection of recurrent disease with 
previous primary resection 
 
4. Colorectal specimens received for resection of non-malignant disease 
 
5. Colorectal specimens received for resection of non-malignant disease 
where unexpected tumour is found but an appropriate (cancer) mesenteric 
resection has not been performed 
 
 
3.  Communication with educational supervisor / laboratory team 
 
After primary dissection specimens will be entered into the study and will be given a 
research number by one of the nominated laboratory team.  At this point the specimen 
will be transferred into a new pot which only bears the research number.  The original 
pot will bear the specimen number and the research number and will be stored by one 
of the nominated laboratory team.  The team member will then e-mail the primary and 
secondary educational supervisors the specimen number, linked research number and 
study group and this will be entered onto the spreadsheet stored on the G drive at:  
G:/cellularpathology/colorectalstudy.  If you need to return to the specimen you will 
need to use the research number rather than specimen number.  To retrieve the 
specimen please speak to one of the nominated laboratory team.   
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4.  Reporting 
 
Slides will be sent out as per routine practice to either yourselves or the trainee 
histopathologist.  The microscopy data collection sheet C will be attached to the 
specimen request form within an envelope. 
 
Specimens will receive either the intervention or control solution for 24 hours after 
primary dissection.  Secondary lymph node harvest will be performed after a minimum 
of 24 hours has passed and anonymised slides will be sent to the primary researcher 
for data collection in collaboration with the educational supervisor.  These slides will 
then be passed to you, with completed data collection sheet D, by the educational 
supervisor for amendment of the final report. 
 
4a.  Reporting with a trainee histopathologist 
 
The trainee histopathologist will have completed the data items within microscopy data 
collection sheet C.  Please retain the data sheet until slides from the secondary lymph 
node harvest have been interpreted.  Once data sheet C is complete please return it to 
its envelope and return to the primary researcher.   
 
IMPORTANT: Please do not write the specimen number or any other patient 
identifiable details on the data collection sheet.    
 
4b.  Reporting with the advanced practitioner 
 
The advanced practitioner will not be able to complete microscopy data sheet C 
because it may compromise anonymisation of the specimen.  The advanced 
practitioner will collect the appropriate data and bring it to you with the slides and 
proforma sheet.  Data collection sheet C will also be provided, blank, within its 
envelope, attached to the request form.  In the absence of the advanced practitioner 
please transfer the data provided before completing the sheet once slides from the 
secondary lymph node harvest have been interpreted.  Please return microscopic data 
collection sheets C and D to their envelopes and return to the primary researcher.     
 
IMPORTANT: Please do not write the specimen number or any other patient 
identifiable details on the data collection sheet.    
 
 
5.  Return of sheets, slides and blocks   
   
Please return the anonymised slides from the secondary lymph node harvest to the 
primary researcher who will give to a member of the laboratory team for relabeling with 
the original specimen number. 
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Figure 1J.  Colorectal cancer specimen pathway during the study. 
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Figure J1. Colorectal cancer specimen pathway during the study. 
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Figure 2J.  Data collection sheet pathways during study. 
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Figure J2. Data collection sheet pa hways during the study. 
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Colorectal cancer lymph node harvest research project 
 
Protocol for trainee histopathologists 
 
 
1.  Staff involved in study  
 
Chief investigator     Jo Horne 
 
Histopathologist team 
 
Primary educational supervisor   Dr Norman Carr 
Secondary educational supervisor   Dr Adrian Bateman 
Nominated additional histopathologist  Dr Ele Jaynes 
 
Laboratory team 
 
Cut up team leader biomedical scientist  Jody Adams 
Nominated additional laboratory staff 1  Hollie Guy  
Nominated additional laboratory staff 2  Tiffany Jones 
 
IMPORTANT: Under no circumstances should any patient identifiable details, 
including specimen number, be discussed with the chief investigator (JH) in 
relation to the study 
 
 
2.  Primary dissection 
  
Colorectal cancer specimens will be received into cut up as per routine practice.  
Specimens should be treated as per standard dissection protocols. 
 
 
Appendix K. Laboratory protocol for trainee histopathologists. 
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Please complete cut up data collection sheet A during specimen dissection.  Cut up 
data collection sheet B is for the chief investigator to complete during secondary lymph 
node harvesting and should be ignored. 
 
After specimen dissection please give data collection sheet A and the specimen pot to 
cut up staff.  The specimen will then be enrolled into the study if it fits appropriate 
criteria as follows: 
 
Inclusion criteria for the study are as follows: 
 
3. Colorectal cancer specimens received for curative resection of  
adenocarcinoma at Southampton General Hospital 
 
4. Informed consent given to use the sample for teaching, audit and research 
 
Exclusion criteria for the study are as follows: 
 
1.  Colorectal specimens received without informed patient consent  
 
6. Colorectal specimens received for primary resection of non-
adenocarcinoma  
 
7. Colorectal specimens received for resection of recurrent disease with 
previous primary resection 
 
8. Colorectal specimens received for resection of non-malignant disease 
 
9. Colorectal specimens received for resection of non-malignant disease 
where unexpected tumour is found but an appropriate (cancer) mesenteric 
resection has not been performed 
 
3.  Communication with educational supervisor / laboratory team 
 
After primary dissection specimens will be entered into the study and will be given a 
research number by one of the nominated laboratory team.  At this point the specimen 
will be transferred into a new pot which only bears the research number.  The original 
pot will bear the specimen number and the research number and will be stored by one 
of the nominated laboratory team.  The team member will then e-mail the primary and 
secondary educational supervisors the specimen number, linked research number and 
study group and this will be entered onto the spreadsheet stored on the G drive at:  
G:/cellularpathology/colorectalstudy.  If you need to return to the specimen you will 
need to use the research number rather than specimen number.  To retrieve the 
specimen please speak to one of the nominated laboratory team.   
 
4.  Reporting 
 
Slides will be sent out as per routine practice.  The microscopy data collection sheet C 
will be attached to the specimen request form within an envelope.  Please complete the 
information on data sheet C and give to the consultant histopathologist when you report 
the case. 
 
IMPORTANT: Please do not write the specimen number or any other patient 
identifiable details on the data collection sheet.    
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Specimens will receive either the intervention or control solution for 24 hours after 
primary dissection.  Secondary lymph node harvest will be performed after a minimum 
of 24 hours has passed and anonymised slides will be sent to the chief investigator for 
data collection in collaboration with the educational supervisor.  These slides will then 
be passed to the consultant histopathologist by the educational supervisor for 
amendment of the final report. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure K1.  Colorectal cancer specimen pathway during the study. 
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Figure K1. Colorectal cancer speci en pathway during the study. 
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Figure K2. Data collection sheets pathway during study. Figure K2. Data collection sheet pathways during the study. 
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Colorectal cancer lymph node harvest research project 
 
Protocol for laboratory team 
 
 
1.  Staff involved in study  
 
Primary researcher     Jo Horne 
 
Histopathologist team 
 
Primary educational supervisor   Dr Norman Carr 
Secondary educational supervisor   Dr Adrian Bateman 
Nominated additional histopathologist  Dr Ele Jaynes 
 
Laboratory team 
 
Cut up team leader biomedical scientist  Jody Adams 
Nominated additional laboratory staff 1  Hollie Guy  
Nominated additional laboratory staff 2  Tiffany Jones 
 
IMPORTANT: Under no circumstances should any patient identifiable details, 
including specimen number, be discussed with the primary researcher (JH) in 
relation to the study 
 
Research materials required 
 
The following is required when enrolling specimens into the study: 
 
Randomisation list 
Access to e-mail 
Research number labels x 2 
Cut up data collection sheet A with an envelope 
Cut up data collection sheet B  
 
Appendix L. Protocol for laboratory team. 
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Microscopy data collection sheet C within an envelope 
 
2.  Primary dissection 
  
Colorectal cancer specimens will be received into cut up as per routine practice.  
Specimens should be treated as per standard dissection protocols. 
 
i. Attach data collection sheets A, B and C to the specimen request form.   
 
ii. Complete cut up data collection sheet A only with the dissector during  
specimen dissection.  At this point the sheets will not have a research number, 
but please do not write any patient identifiable details on them.  Please attach a 
post it note which bears the specimen number and name until it can be entered 
into the study. 
 
After specimen dissection please enrol the specimen into the study if it fits the 
appropriate criteria described below – if unsure please contact the primary educational 
supervisor.  In their absence please contact the secondary educational supervisor or 
the nominated additional consultant histopathologist.  In their absence ask advice from 
another GI consultant histopathologist or consultant colleague. 
 
Inclusion criteria for the study are as follows: 
 
5. Colorectal cancer specimens received for curative resection of  
adenocarcinoma at Southampton General Hospital (i.e. with an appropriate 
excision of the mesentery to harvest lymph nodes) 
 
6. Informed consent given to use the sample for teaching, audit and research 
 
Exclusion criteria for the study are as follows: 
 
1.  Colorectal specimens received without informed patient consent  
 
10. Colorectal specimens received for primary resection of non-
adenocarcinoma  
 
11. Colorectal specimens received for resection of recurrent disease with 
previous primary resection 
 
12. Colorectal specimens received for resection of non-malignant disease 
 
13. Colorectal specimens received for resection of non-malignant disease 
where unexpected tumour is found but an appropriate (cancer) mesenteric 
resection has not been performed 
 
 
3.  Enrolling the specimen in the study 
 
The study has two arms.  It is important that specimens are entered into the 
appropriate arm before being enrolled into either group A or B. 
 
Arm A contains colonic specimens which have not received long-course neoadjuvant 
therapy 
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Arm B contains rectal (anterior resection (AR) abdominoperineal (AP) or ELAPE) 
specimens which have received long-course neoadjuvant therapy 
 
This information should be gained either from the request form or e-docs at primary 
dissection and will be included on cut up data collection form A.   
 
In total the study will have four groups: 
 
Group 1A: 24 hours GEWF                 non-neoadjuvant cases 
Group 1B: 24 hours further fixation     non-neoadjuvant cases  
 
Group 2A: 24 hours GEWF                 neoadjuvant cases 
Group 2B: 24 hours further fixation     neoadjuvant cases 
 
Research numbers will follow this pattern: 
 
JH1-010312 
JH2-010312 
JH3-020312 
JH4-040312 
 
Where, taking the first example: ‘JH’ is the primary researcher’s initials 
     ‘1’ is the allocated number 
     ‘010312’ is the date of enrolment  
 
Whether the specimens are enrolled into arm 1 or arm 2, they should still receive 
subsequent research numbers as demonstrated above. 
 
i. Identify the appropriate arm and then enrol the specimen into the study with  
the next available research number using the randomisation list provided.  Do 
not allow the primary researcher to see this list. 
ii. Once enrolled and assigned, the research number should be written on the  
label.  One research label should be stuck onto the original specimen pot.   
iii. Transfer the specimen into a clean pot with a second copy of the research  
label stuck to the pot only.   
iv. Place either formalin or GEWF solution into the specimen pot as 
appropriately  
assigned by the automated randomisation program.   
v. Write the research number, time and date that the solution was added to cut  
up data collection sheet B.   
vi. Leave data collection sheet B with the specimen for the primary researcher 
to  
perform secondary lymph node harvest on the following day.  
 
IMPORTANT: There must be no patient identifiable details on the specimen pot 
bearing the research number only.   
 
vii. Store the original pot away from view of the primary researcher.   
viii. Write the research number onto cut up data collection sheet A, place in an  
envelope and place in the tray provided for the primary researcher to collect. 
ix. Write the research number onto microscopy data collection sheet C, place 
in  
an envelope and place in the pigeon hole of the dissector for completion at 
microscopy. 
x. E-mail the primary and secondary education supervisors and give them the  
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following information: 
 
Original specimen number 
Patient name 
Arm of study (non-neoadjuvant or neoadjuvant) 
Research number 
Study group (GEWF or formalin) 
 
 
 
5.  Relabelling slides and blocks   
   
Anonymised blocks and slides will be returned to you by the primary researcher.   
 
For blocks:  
 
i. Identify the specimen number from the g drive spreadsheet 
ii. Print the appropriate number of cassettes from the back copy of the request  
form 
iii. Melt down the blocks and reblock in appropriately labelled blocks 
iv. Put the blocks for filing 
 
For slides: 
 
i. Identify the specimen number from the g drive spreadsheet 
ii. Relabel the slides with the original specimen number   
iii. Put the slides for filing 
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Figure L1.  Colorectal cancer specimen pathway during the study. 
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Figure L1. Colorectal ncer s imen pathway during the study. 
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Figure L2. Data collection sheets pathway during study. Figure L2. Data collection sheet pathways during the study. 
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Appendix M.  Example of secondary lymph node dissection information e-
mailed to consultant histopathologists. 
 
Subject: Results of secondary lymph node harvests 
 
Dear [consultant], 
 
The following colorectal cancer cases are yours and have been entered into my study.  Second 
checks done by [consultant].  I have put the slides in your pigeon hole as requested.  Can you 
please return them to me as soon as you are able. 
 
Research no  No LN harvested No positive LN  Size of negative LN 
183161213  6   0   1.5mm – 2.0mm 
184181213  11   0   1.0mm – 3.0mm 
 
Best wishes, 
Jo 
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Appendix N.  Example of e-mail flagging potential upstaging to the 
relevant consultant histopathologist. 
 
Subject: Research case 171071113 - FLAG - PLEASE READ BEFORE THE COLORECTAL 
MDT  
 
Dear [consultant], 
 
The above research case 171071113 may be on the MDT meeting as it is quite 
recent.  Obviously I cannot check, and also there may already be positive nodes in the primary 
dissection.  It was cut up on 7th November [trainee/consultant]: 
 
There is a tiny focus of tumour in a lymphatic in one of the 16 lymph nodes harvested at 
secondary dissection. 
 
Best wishes, 
Jo 
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Appendix O.  Letter of favourable opinion from the North West 
Research Ethics Committee. 
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Appendix P. Letter of sponsorship from local Trust. 
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Appendix Q.  Letter of SSI approval from local Trust. 
326 
 
Appendix R. COSHH sheets for glacial acetic acid, ethanol and 
formaldehyde. 
 
 
 
 
DEPARTMENT:              CELLULAR PATHOLOGY                               DEPARTMENT RECORD NUMBER:      002 
LOCATION:                   
SUBSTANCE NAME: PHYSICAL FORM: CLASSIFIED AS:  NATURE OF HAZARD: 
 
 
 
 
ACETIC ACID, GLACIAL 
 
 
 
0.2% - 10% ACETIC ACID IN USE ON 
BENCH AND FOR SOLUTION 
PREPARATION 
 
 
 
 
COLOURLESS LIQUID 
 
 
 
 
 
VERY TOXIC 
 
TOXIC 
 
CORROSIVE 
 
HARMFUL 
 
IRRITANT 
 
DANGER TO 
ENVIRONMENT 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
CAUSES SEVERE BURNS. 
 
FLAMMABLE. 
NATURE OF PROCESS OR METHOD OF WORK: 
COMPONENT OF FROZEN SECTION FIXATIVE, STAIN DIFFERENTIATOR AND STAINING REAGENTS. 
Is there a less hazardous substance?     NO. 
If so, why not use it? 
CONTROL MEASURES REQUIRED: 
(Local exhaust, ventilation, personal protection etc) 
 
WEAR PROTECTIVE CLOTHING, GLOVES AND EYE PROTECTION. 
WHEN DECANTING CONCENTRATED ACID USE A FUME CUPBOARD. 
ENSURE ADEQUATE VENTILATION. DO NOT INHALE VAPOUR. 
AVOID PROLONGED OR REPEATED EXPOSURES. 
 
IS HEALTH SURVEILLANCE 
REQUIRED? 
 
 
 
  YES                          NO 
 
 
If YES contact Occupational 
Health. 
 
 
 
X  
METHOD OF DISPOSAL:   
SMALL AMOUNTS MAY BE WASHED DOWN THE SINK WITH COPIOUS RUNNING WATER. LARGE AMOUNTS TO BE REMOVED BY A CONTRACTOR. 
EMERGENCY ARRANGEMENTS: 
EYES – IRRIGATE THOROUGHLY WITH WATER FOR AT LEAST15 MINUTES. SEEK MEDICAL ATTENTION. 
INHALATION – REMOVE PERSON TO FRESH AIR. IN SEVERE CASES SEEK MEDICAL ATTENTION. 
SKIN – WASH AREA THOROUGHLY WITH WATER FOR 10 MINUTES. REMOVE CONTAMINATED CLOTHING.UNLESS MINOR SEEK MEDICAL 
ATTENTION. 
INGESTION – WASH OUT MOUTH THOROUGHLY AND GIVE PLENTY OF WATER TO DRINK. DO NOT INDUCE VOMITING. SEEK MEDICAL 
ATTENTION. 
SPILLAGE: 
SMALL AMOUNTS MAY BE MOPPED UP WITH PLENTY OF WATER. ALL WASTE TO BE DISCARDED IN A CLINICAL WASTE BIN. 
LARGE AMOUNTS TO ABSORBED BY SPILLAGE GRANULES. ALL WASTE TO BE DISCARDED IN A CLINICAL WASTE BIN.  
WASH SITE OF SPILLAGE THOROUGHLY WITH WATER AND DETERGENT. 
WEAR PPE WHEN DEALING WITH SPILLAGES AND VENTILATE AREA TO DISPEL RESIDUAL VAPOUR. 
FIRE HAZARD: 
FLAMMABLE. 
VAPOURS HEAVIER THAN AIR VAPOUR/AIR MIXTURE EXPLOSIVE. 
EXTINGUISH WITH WATER SPRAY/FOAM OR CARBON DIOXIDE. 
 
STORAGE: 
AVOID EXPOSURE TO MOISTURE. STORE IN TIGHTLY CLOSED CONTAINERS 
IN A COOL DRY PLACE ABOVE FREEEZING POINT. PROTECT FROM 
SOURCES OF IGNITION. SECURE CHEMICALS FROM UNATHOURISED USE. 
AVOID ALDEHYDES, METALS AND OXIDISING AGENTS. 
FAILURE CONTROL METHODS: 
IF PPE OR FUME CUPBOARD UNAVAILABLE DO NOT HANDLE CONENTRATED ACID. 
 
DECLARATION:  IF HANDLED CORRECTLY THE RISKS ARE RELATIVELY SMALL AND THE CONTROLS ARE ADEQUATE. 
 
Name of assessor:    
 
Status:                        
 
Signed: 
 
Date: 
 
 
IMPORTANT ! 
 
THIS FORM AND THE PRODUCT SAFETY DATA SHEET MUST 
BE HELD IN THE DEPARTMENT/WARD C.O.S.H.H. FILE OR 
HEALTH & SAFETY FILE, AND A COPY SENT TO THE 
DIRECTORATE HEALTH & SAFETY CO-ORDINATOR. 
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DEPARTMENT:              CELLULAR PATHOLOGY DEPARTMENT RECORD NUMBER:     099 
LOCATION:                   
SUBSTANCE NAME: PHYSICAL FORM: CLASSIFIED AS:  NATURE OF HAZARD: 
 
 
 
 
ETHANOL 
 
 
  
 
 
 
 
COLOURLESS LIQUID 
 
 
 
ALCOHOL ODOUR 
 
 
 
 
 
VERY TOXIC 
 
TOXIC 
 
CORROSIVE 
 
HARMFUL 
 
IRRITANT 
 
DANGER TO 
ENVIRONMENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIGHLY FLAMMABLE. 
 
IRRITATING TO EYES, SKIN, RESPIRATORY 
TRACT AND BY INGESTION. 
 
INHALATION OF HIGH CONCENTRATIONS 
MAY CAUSE HEADACHE, DIZZINESS, 
UNCONCIOUSNESS AND COMA. 
 
 
NATURE OF PROCESS OR METHOD OF WORK: 
DEHYDRATING AGENT. 
Is there a less hazardous substance?     NO. 
If so, why not use it? 
CONTROL MEASURES REQUIRED: 
(Local exhaust, ventilation, personal protection etc) 
 
WEAR PROTECTIVE CLOTHING, GLOVES AND EYE PROTECTION WHERE NECESSARY. 
ENSURE ADEQUATE VENTILATION. 
DO NOT INHALE VAPOURS. 
 
IS HEALTH SURVEILLANCE 
REQUIRED? 
 
 
 
  YES                          NO 
 
 
If YES contact Occupational 
Health. 
 
X  
METHOD OF DISPOSAL:   
SMALL AMOUNTS MAY BE WASHED DOWN THE SINK WITH COPIOUS RUNNING WATER. LARGE AMOUNTS TO BE REMOVED BY A CONTRACTOR. 
EMERGENCY ARRANGEMENTS: 
EYES – IRRIGATE THOROUGHLY WITH WATER FOR AT LEAST15 MINUTES. OBTAIN MEDICAL ATTENTION. 
INHALATION – REMOVE PERSON TO FRESH AIR. IF BREATHING IS DIFFICULT SEEK MEDICAL ATTENTION.  
SKIN – WASH AREA THOROUGHLY WITH SOAP AND WATER. REMOVE CONTAMINATED CLOTHING. IN SEVERE CASES SEEK MEDICAL 
ATTENTION. 
INGESTION – WASH OUT MOUTH THOROUGHLY AND GIVE PLENTY OF WATER TO DRINK. OBTAIN MEDICAL ATTENTION. 
SPILLAGE: 
SMALL AMOUNTS MAY BE MOPPED UP WITH PLENTY OF WATER. ALL WASTE TO BE DISCARDED IN A CLINICAL WASTE BIN. 
LARGE AMOUNTS TO ABSORBED BY AN INERT ABSORBENT. ALL WASTE TO BE DISCARDED IN A CLINICAL WASTE BIN.  
WASH SITE OF SPILLAGE THOROUGHLY WITH WATER AND DETERGENT. 
WEAR PPE WHEN DEALING WITH SPILLAGES AND VENTILATE AREA TO DISPEL RESIDUAL VAPOUR. 
FIRE HAZARD: 
 
HIGHLY FLAMMABLE. 
EXTINGUISH WITH FOAM, DRY POWDER OR CARBON DIOXIDE. 
 
STORAGE: 
 
AVOID EXPOSURE TO MOISTURE AND DIRECT SUNLIGHT. STORE IN 
TIGHTLY CLOSED CONTAINER AT ROOM TEMPERATURE. STORE LARGE 
QUANTITIES IN FLAMMABLE CABINETS. SMALLER QUANTITIES ON THE 
BENCH MUST BE STORED AWAY FROM IGNITION SOURCES. AVOID 
OXIDISING AGENTS. 
FAILURE CONTROL METHODS: 
NONE APPLICABLE. RISK IS MINIMAL. 
 
DECLARATION:  IF HANDLED CORRECTLY THE RISKS ARE SMALL AND THE CONTROLS ARE ADEQUATE. 
 
Name of assessor:    
 
Status:                        
 
Signed: 
 
Date: 
 
 
IMPORTANT ! 
 
THIS FORM AND THE PRODUCT SAFETY DATA SHEET MUST 
BE HELD IN THE DEPARTMENT/WARD C.O.S.H.H. FILE OR 
HEALTH & SAFETY FILE, AND A COPY SENT TO THE 
DIRECTORATE HEALTH & SAFETY CO-ORDINATOR. 
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DEPARTMENT:              CELLULAR PATHOLOGY DEPARTMENT RECORD NUMBER:     108 
LOCATION:                  
SUBSTANCE NAME: PHYSICAL FORM: CLASSIFIED AS:  NATURE OF HAZARD: 
 
 
 
 
FORMALDEHYDE 
(FORMALIN) 
 
 
10% SOLUTION USED ON 
BENCH  
 
 
 
 
COLOURLESS LIQUID 
 
 
 
PUNGENT ODOUR 
 
 
 
 
 
VERY TOXIC 
 
TOXIC 
 
CORROSIVE 
 
HARMFUL 
 
IRRITANT 
 
DANGER TO 
ENVIRONMENT 
 
 
 
X 
 
 
 
X 
 
 
 
 
 
 
 
TOXIC BY INHALATION, IN CONTACT WITH 
SKIN AND IF SWALLOWED. 
 
DANGER OF SERIOUS IRREVERSIBLE 
EFFECTS. 
 
MAY CAUSE SENSITISATION BY SKIN 
CONTACT. 
 
POSSIBLE CARCINOGENIC EFFECT. 
 
NATURE OF PROCESS OR METHOD OF WORK: 
ROUTINE HISTOLOGICAL FIXATIVE. COMPONENT OF STAINING PROCEDURE. 
Is there a less hazardous substance?     NO. 
If so, why not use it? 
CONTROL MEASURES REQUIRED: 
(Local exhaust, ventilation, personal protection etc) 
 
WEAR PROTECTIVE CLOTHING, RESPIRATOR, GLOVES AND EYE PROTECTION WHERE NECESSARY. 
ENSURE ADEQUATE VENTILATION. USE AFOS BENCHES WHEN HANDLING FIXED SPECIMENS. 
DO NOT INHALE VAPOUR. 
 
 
IS HEALTH SURVEILLANCE 
REQUIRED? 
 
 
 
  YES                          NO 
 
 
If YES contact Occupational 
Health. 
 
 X 
METHOD OF DISPOSAL:   
SMALL AMOUNTS MAY BE WASHED DOWN THE SINK WITH COPIOUS RUNNING WATER. LARGE AMOUNTS TO BE REMOVED BY A CONTRACTOR. 
EMERGENCY ARRANGEMENTS: 
EYES – IRRIGATE THOROUGHLY WITH WATER FOR AT LEAST15 MINUTES. IF DISCOMFORT PERSISTS OBTAIN MEDICAL ATTENTION. 
INHALATION – REMOVE PERSON TO FRESH AIR. IN EXTREME CASES SEEK MEDICAL ATTENTION.  
SKIN – WASH AREA THOROUGHLY WITH SOAP AND WATER. REMOVE CONTAMINATED CLOTHING. IN SEVERE CASES SEEK MEDICAL 
ATTENTION. 
INGESTION – WASH OUT MOUTH THOROUGHLY AND GIVE PLENTY OF WATER TO DRINK. OBTAIN MEDICAL ATTENTION. 
SPILLAGE: 
SMALL AMOUNTS MAY BE MOPPED UP WITH PLENTY OF WATER. ALL WASTE TO BE DISCARDED IN A CLINICAL WASTE BIN. 
LARGE AMOUNTS TO BE ABSORBED BY AN INERT ABSORBENT. ALL WASTE TO BE DISCARDED IN A CLINICAL WASTE BIN.  
WASH SITE OF SPILLAGE THOROUGHLY WITH WATER AND DETERGENT. 
WEAR PPE INCLUDING A RESPIRATOR WHEN DEALING WITH SPILLAGES AND VENTILATE AREA TO DISPEL RESIDUAL VAPOUR. 
FIRE HAZARD: 
 
COMBUSTIBLE. MAY EMIT TOXIC FUMES. 
EXTINGUISH WITH FOAM DRY POWDER OR CARBON DIOXIDE. 
 
STORAGE: 
 
AVOID EXPOSURE TO MOISTURE AND DIRECT SUNLIGHT. STORE IN 
TIGHTLY CLOSED CONTAINERS AT ROOM TEMPERATURE. AVOID OXIDISING 
AGENTS AND ACIDS. 
 
FAILURE CONTROL METHODS: 
IF AFOS BENCHES AND FUME EXTRACTION ARE NOT AVAILABLE SUSPEND ACTIVITY UNTIL AVAILABLE. 
 
DECLARATION:  IF HANDLED CORRECTLY THE RISKS ARE SMALL AND THE CONTROLS ARE ADEQUATE. 
 
Name of assessor:   
 
Status:                        
 
Signed: 
 
Date: 
 
 
IMPORTANT ! 
 
THIS FORM AND THE PRODUCT SAFETY DATA SHEET MUST 
BE HELD IN THE DEPARTMENT/WARD C.O.S.H.H. FILE OR 
HEALTH & SAFETY FILE, AND A COPY SENT TO THE 
DIRECTORATE HEALTH & SAFETY CO-ORDINATOR. 
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Appendix S.  Research data for the non-neoadjuvant therapy group.  
 
Table S1.  General study data for the non-neoadjuvant therapy group. 
   
Factor (n=173) Variable Number  
(percentage / range) 
 
Sex Male 98/173 (56.6%) 
 Female 75/173 (43.4%) 
Age 21-30 1/173 (0.6%) 
 31-40 4/173 (2.3%) 
 41-50 7/173 (4.0%) 
 51-60 16/173 (9.2%) 
 61-70 50/173 (28.9%) 
 71-80 60/173 (34.7%) 
 81-90 31/173 (17.9%) 
 91-100 4/173 (2.3%) 
Mean age  70.7 years (25-97) 
Screening detected Yes - screening detected 19/173 (11.0%) 
 No - symptomatic 154/173 (89.0%) 
Clinical trial Entered 0/173 (0%) 
 Not entered 173/173 (100%) 
Site of tumour Caecum 38/173 (22.0%) 
 Ascending colon 18/173 (10.4%) 
 Hepatic flexure 7/173 (4.0%) 
 Transverse colon 11/173 (6.4%) 
 Splenic flexure 4/173 (2.3%) 
 Descending colon 9/173 (5.2%) 
 Sigmoid colon 49/173 (28.3%) 
 Rectum 37/173 (21.4%) 
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Table S2.  Pathological study data for the non-neoadjuvant therapy group. 
   
Factor (n=173) Variable Number  
(percentage / range) 
 
Mean time from surgery to primary 
dissection 
 3 days (1-5) 
Dissector group Consultant (n=5) 55/173 (31.8%)  
 AP (n=1) 51/173 (29.5%) 
 Senior trainee* (n=9) 46/173 (26.6%) 
 Junior trainee** (n=7) 21/173 (12.1%) 
Mean time for primary dissection*** (n=171) Overall 50 mins (14-150) 
 Consultant (n=5) 30 mins (14-92) 
 AP (n=1) 56 mins (25-105) 
 Senior trainee* (n=9) 51 mins (15-110) 
 Junior trainee** (n=7) 82 mins (30-150) 
Predicted intervention chemical**** Further fixation 83/168 (49.4%) 
 GEWF 85/168 (50.6%) 
Actual intervention chemical Further fixation 86/173 (49.7%) 
 GEWF 87/173 (50.3%) 
Accuracy of prediction**** Correct 166/168 (98.8%) 
 Incorrect 2/168 (1.2%) 
Mean time in intervention chemical   25 hours (24-32) 
Mean time for secondary dissection  15 mins (2-45) 
pT stage pT0 3/173 (1.7%) 
 pT1 14/173 (8.1%) 
 pT2 31/173 (17.9%) 
 pT3 82/173 (47.4%) 
 pT4 43/173 (24.9%) 
*In second year or more of histopathology training 
**In first year of histopathology training 
***Not measured in 2/173 cases 
****Not predicted in 5/173 cases 
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Appendix T.  Full statistical output for the independent samples T test – lymph node number. 
 
i. Whole group 
 
Group Statistics 
 ChemCode N Mean Std. Deviation Std. Error Mean 
LN2 
Further fixation 101 8.2772 5.34063 .53141 
GEWF 99 7.2525 6.17656 .62077 
 
 
 Levene’s Test for 
Equality of Variances 
t-test for Equality of Means 
F Sig.* t df Sig.** 
(2-tailed) 
Mean Difference Std. Error Difference 95% Confidence Interval of the Difference 
  
Lower Upper 
LN2 
Equal variances 
assumed 
1.831 .178 1.256 198 .211 1.02470 .81598 -.58442 2.63382 
Equal variances 
not assumed 
  1.254 192.796 .211 1.02470 .81716 -.58702 2.63643 
 
*As the p value of significance for Levene’s Test for Equality of Variance is > .05, there is equality of variance and the top row of results is taken. 
 
**As my research hypothesis is one-tailed, i.e. it “makes predictions regarding both the presence of an effect and also of the direction of this difference”, a 
one-tailed p-value of significance was taken (by halving the 2-tailed value generated by SPSS). 
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ii. Non-neoadjuvant therapy group 
 
Group Statistics 
 ChemCode N Mean Std. Deviation Std. Error Mean 
LN2 
Further fixation 86 8.5581 5.48067 .59100 
GEWF 87 7.4483 6.33880 .67959 
 
 
 Levene’s Test for 
Equality of Variances 
t-test for Equality of Means 
F Sig.* t df Sig.**  
(2-tailed) 
Mean Difference Std. Error Difference 95% Confidence Interval of the Difference 
  
Lower Upper 
LN2 
Equal variances 
assumed 
1.897 .170 1.231 171 .220 1.10986 .90138 -66940 2.88913 
Equal variances 
not assumed 
  1.232 168.031 .220 1.10986 .90062 -66813 2.88786 
 
*As the p value for Levene’s Test for Equality of Variance is > .05, there is equality of variance and the top row of results is taken. 
 
**As my research hypothesis is one-tailed, i.e. it “makes predictions regarding both the presence of an effect and also of the direction of this difference”, a 
one-tailed p-value of significance was taken (by halving the 2-tailed value generated by SPSS). 
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iii. Neoadjuvant therapy group 
 
Group Statistics 
 Chemcode N Mean Std. Deviation Std. Error Mean 
LN2 
Formalin 15 6.7333 4.31719 1.11469 
GEWF 12 5.8333 4.82104 1.39171 
 
 
 Levene’s Test for 
Equality of Variances 
t-test for Equality of Means 
F Sig.* t df Sig.**  
(2-tailed) 
Mean Difference Std. Error Difference 95% Confidence Interval of the Difference 
  
Lower Upper 
LN2 
Equal variances 
assumed 
.060 .809 .511 25 .614 .90000 1.76057 -2.72596 4.52596 
Equal variances 
not assumed 
  .505 22.398 .619 .90000 1.78309 -2.79410 4.59410 
 
*As the p value for Levene’s Test for Equality of Variance is > .05, there is equality of variance and the top row of results is taken. 
 
**As my research hypothesis is one-tailed, i.e. it “makes predictions regarding both the presence of an effect and also of the direction of this difference”, a 
one-tailed p-value of significance was taken (by halving the 2-tailed value generated by SPSS.
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Appendix U.  Full statistical output for the univariate ANOVA. 
 
i. Whole group 
Between-Subjects Factors 
 Value Label N 
ChemCode 
1 Further fixation 101 
2 GEWF 99 
 
Descriptive Statistics 
Dependent Variable:   LN2   
ChemCode Mean Std. Deviation N 
Further fixation 8.2772 5.34063 101 
GEWF 7.2525 6.17656 99 
Total 7.7700 5.77789 200 
 
Tests of Between-Subjects Effects 
Dependent Variable:   LN2   
Source Type III Sum of 
Squares 
df Mean Square F Sig. Partial Eta 
Squared 
Corrected Model 63.122a 2 31.561 .945 .390 .010 
Intercept 2095.528 1 2095.528 62.736 .000 .242 
LN1 10.627 1 10.627 .318 .573 .002 
ChemCode 51.033 1 51.033 1.528 .218 .008 
Error 6580.298 197 33.403    
Total 18718.000 200     
Corrected Total 6643.420 199     
a. R Squared = .010 (Adjusted R Squared = -.001) 
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ii. Non-neoadjuvant population 
 
Between-Subjects Factors 
 Value Label N 
ChemCode 
1 Further fixation 86 
2 GEWF 87 
 
Descriptive Statistics 
Dependent Variable:   LN2   
ChemCode Mean Std. Deviation N 
Further fixation 8.5581 5.48067 86 
GEWF 7.4483 6.33880 87 
Total 8.0000 5.93668 173 
 
Tests of Between-Subjects Effects 
Dependent Variable:   LN2   
Source Type III Sum of 
Squares 
df Mean Square F Sig. Partial Eta 
Squared 
Corrected Model 54.137a 2 27.068 .766 .466 .009 
Intercept 1998.680 1 1998.680 56.555 .000 .250 
LN1 .863 1 .863 .024 .876 .000 
ChemCode 52.214 1 52.214 1.477 .226 .009 
Error 6007.863 170 35.340    
Total 17134.000 173     
Corrected Total 6062.000 172     
a. R Squared = .009 (Adjusted R Squared = -.003) 
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iii. Neoadjuvant population 
Between-Subjects Factors 
 Value Label N 
Chemcode 
1 Formalin 15 
2 GEWF 12 
 
Descriptive Statistics 
Dependent Variable:   LN2   
Chemcode Mean Std. Deviation N 
Formalin 6.7333 4.31719 15 
GEWF 5.8333 4.82104 12 
Total 6.3333 4.48073 27 
 
Tests of Between-Subjects Effects 
Dependent Variable:   LN2   
Source Type III Sum of 
Squares 
df Mean Square F Sig. Partial Eta 
Squared 
Corrected Model 10.068a 2 5.034 .236 .792 .019 
Intercept 138.048 1 138.048 6.472 .018 .212 
LN1 4.668 1 4.668 .219 .644 .009 
Chemcode 7.098 1 7.098 .333 .569 .014 
Error 511.932 24 21.331    
Total 1605.000 27     
Corrected Total 522.000 26     
a. R Squared = .019 (Adjusted R Squared = -.062) 
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Appendix V.  Full statistical output for the independent samples t-test – lymph node size. 
 
i. Whole group 
 
Group Statistics 
 Code N Mean Std. Deviation Std. Error Mean 
LNsize 
Formalin 837 2.5560 1.52585 .05290 
GEWF 718 2.4293 1.44100 .05341 
 
 
 Levene’s Test for 
Equality of Variances 
t-test for Equality of Means 
F Sig.* t df Sig. 
(2-tailed) 
Mean 
Difference 
Std. Error Difference 95% Confidence Interval of the Difference 
  
Lower Upper 
LN2 
Equal variances 
assumed 
.255 .614 1.680 1558 .093 .12675 .07546 -.02126 .27476 
Equal variances 
not assumed 
  1.686 1548.941 .092 .12675 .07517 -.02070 .27420 
 
*As the p value for Levene’s Test for Equality of Variance is > .05, there is equality of variance and the top row of results is taken. 
 
338 
 
ii. Non-neoadjuvant group 
 
Group Statistics 
 Code N Mean Std. Deviation Std. Error Mean 
LNsize 
Formalin 736 2.6615 1.55697 .05771 
GEWF 648 2.5038 1.46394 .05716 
 
 
 Levene’s Test for 
Equality of Variances 
t-test for Equality of Means 
F Sig.* t df Sig. 
(2-tailed) 
Mean 
Difference 
Std. Error Difference 95% Confidence Interval of the Difference 
  
Lower Upper 
LN2 
Equal variances 
assumed 
.779 .378 1.936 1382 .053 .15773 .08148 -.00211 .31757 
Equal variances 
not assumed 
  1.942 1379.495 .052 .15773 .08122 -.00160 .31706 
 
*As the p value for Levene’s Test for Equality of Variance is > .05, there is equality of variance and the top row of results is taken. 
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iii. Neoadjuvant group 
 
Group Statistics 
 ChemCode N Mean Std. Deviation Std. Error Mean 
LNsize 
Formalin 101 1.8119 1.03646 .10313 
GEWF 70 1.7571 .99543 .11898 
 
 
 Levene’s Test for 
Equality of Variances 
t-test for Equality of Means 
F Sig.* t df Sig. 
(2-tailed) 
Mean 
Difference 
Std. Error Difference 95% Confidence Interval of the Difference 
  
Lower Upper 
LN2 
Equal variances 
assumed 
.436 .510 .345 169 .730 .05474 .15862 -.25839 .36787 
Equal variances 
not assumed 
  .348 152.312 .729 .05474 .15745 -.25634 .36581 
 
*As the p value for Levene’s Test for Equality of Variance is > .05, there is equality of variance and the top row of results is taken. 
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Division, Academic Registry, University House, with your thesis, prior to 
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